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3Abstract
On going research in our laboratory is focussed on the potential role of Insulin-like growth 
factor binding protein-5 (IGFBP-5) in apoptosis of mammary epithelial cells. In order to increase 
our understanding of IGFBP-5 functions, the work described below focussed on the relationship 
between the structure of the binding protein and its important molecular interactions.
Using site-directed mutagenesis, we have mutated two highly conserved amino acids, 
Gly203 and GIn209 (G203K and Q209A respectively) within the basic amino acid rich region (201- 
218) in the C-terminal domain of rat IGFBP-5. After analysis o f binding activity using three 
different methods -  IGF ligand blotting, IGF solution phase equilibrium binding and biosensor 
measurement -  we have shown that the mutation of either of these two residues results in a 
reduction in affinity of the binding protein for both IGF-I and IGF-II by approximately ten-fold. 
Furthermore, mutation of both amino acids (G203K/Q209A, termed the Double mutant) had a 
cumulative effect and results in the complete ablation of IGF-I binding and a several thousand-fold 
reduction in IGF-II binding. This reduction in IGF binding affinity was comparable to that observed 
for the C-terminally truncated mutant BP550 (residues 1-168), which suggests that Gly203 and 
Gln209 may be the major determinants for IGF binding in the C-terminal domain. In addition, 
using heparin ligand blots, we confirm that mutation of basic residues within the C-terminal 201- 
218 region (Hep- mutant: R201L, K202E, K206Q and R214A) results in major attenuation of 
heparin binding, whereas the G203K and Q209A single mutants and the Double mutant have no 
reduction in heparin binding. Therefore, our data suggests a potential overlap of heparin- and IGF- 
binding domains in the C-terminal region of IGFBP-5, and based on this, we discuss a potential 
model to explain the observed lower IGF binding affinity of ECM-bound IGFBP-5.
In an attempt to assess the separate contribution of the N- and C-terminal domains to IGF 
binding, we also made four chimeric IGFBP cDNAs, BP552, BP522, BP255 and BP225, by 
switching domains between rat IGFBP-5 and rat IGFBP-2. We were consistently unable to detect 
expression of BP225 protein in the baculovirus/insect cell system, so this chimera had to be 
excluded from further study. Recognition of BP552 and BP522 proteins by both anti-rat IGFBP-5 
and anti-rat IGFBP-2 antisera confirms their identity as chimeric proteins made up of domains from
4the native binding proteins, while BP255 was only recognised by the anti-rat IGFBP-5. The IGF 
binding properties of unpurified BP552, BP522 and BP255 proteins were assessed by IGF ligand 
blotting and IGF solution phase binding assays. These experiments demonstrated that BP552 and 
BP522 had comparable affinities with native IGFBP, whereas we were unable to detect any binding 
of BP255 to IGF-I by either technique, and only very weak interaction with IGF-II. Purified BP552 
and BP522 were also tested by biosensor analysis, and data confirmed the results from the previous 
experiments. From this we can conclude that the N-terminal domain of IGFBP-5 can co-operate 
with the C-terminal domain of IGFBP-2 to produce a high affinity IGF binding species, irrespective 
of which central domain is present, whereas preliminary evidence would suggest that this co­
operation may not occur between the N-terminal domain of IGFBP-2 and the C-terminal domain of 
IGFBP-5.
In addition to IGF binding, the IGFBP-5 protein contains consensus heparin binding 
motifs in both its C-terminal and central domains, although only the C-terminal site was previously 
shown to be functional. Using heparin ligand blotting, it was found that the ability of BP552 and 
BP550 to bind to heparin was equivalent to that of WTIGFBP-5, whereas WTIGFBP-2 and BP522 
failed to bind. These results demonstrate that an active heparin binding site in BP552 and BP550 is 
contained within the central domain of IGFBP-5, and that this site is only active in the absence of 
the carboxy-terminal domain. We subsequently mutated two basic amino acids (R136A:R137A) in 
the central consensus binding sites between residues 132-140. This resulted in the loss of heparin 
binding for BP550, confirming the importance of these two basic amino acids in the central domain 
heparin binding activity. In light of these findings, we suggest that C-terminally truncated 
fragments of IGFBP-5 generated in vivo by proteolysis could retain heparin/extracellular matrix 
(ECM) binding properties.
Finally, we propose that our various IGFBP-5 mutants described above provide an 
opportunity to test the structure-function relationships of this binding protein in an appropriate 
biological context.
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Chapter I. Introduction
1.1 Overview of the IGF axis
The insulin-like growth factors (IGFs), IGF-I and IGF-II, are small single chain peptides 
that share significant structural homology with insulin. They are involved in the regulation of cell 
growth, differentiation, and metabolism, eliciting diverse effects in multiple biological processes 
(reviewed by Stewart and Rotwein, 1996a). The biological effects of IGFs are mediated through 
binding to high-affinity receptors on the cell surface. The type I IGF receptor (IGF-I-R) is, like the 
insulin receptor, a heterotetrameric protein complex containing a tyrosine kinase domain that 
mediates signal transduction (De meyts et al, 1994). Ligand binding to this receptor results in 
growth and differentiative functions (Cheatham and Kahn, 1995; Le Roith et al, 1995), and its 
inactivation in receptor null mice leads invariably to severe neonatal growth deficiencies as a 
consequence of hypoplasia in several tissues (Liu et al, 1993a). The structurally distinct type II IGF 
receptor (IGF-II-R) is a monomeric protein lacking tyrosine kinase activity, and is also known as 
the cation dependent mannose-6-phosphate receptor. There is no known signal transduction 
mechanism initiated by this receptor, so that all proliferative effects of the IGFs are thought to be 
mediated through the IGF-I-R (Czech, 1989). However, the IGF-II-R appears to play an important 
role in the degradation of IGF-II, and inactivation of this receptor in mice by gene targeting results 
in foetal overgrowth, skeletal abnormalities, and perinatal death due to overexposure of the foetus 
to IGF-II (Wang et al, 1994; Lau et al, 1994; Ludwig et al, 1996).
Unlike insulin, the IGFs are bound in serum and other biological fluids to a family of six 
structurally and evolutionary related binding proteins, termed IGF-binding proteins (IGFBP-1 to 
IGFBP-6). In the circulation, -75-80% of the IGFs are present in a complex of molecular weight 
150kDa, which is composed of one molecule of IGF-I or IGF-II, an 85kDa ALS (termed the acid 
labile subunit - a liver derived glycoprotein) and either IGFBP-3 or -5. A smaller proportion (20- 
25%) of the IGFs are associated with other IGFBPs forming a 50kDa complex, and less than 1% is 
found in the free form of ~7.5kDa (Rajaram et al, 1997).
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The IGFBPs are expressed in a tissue-specific manner and have different affinities for the 
IGFs (reviewed in Clemmons, 1997). In addition to their role in preventing insulin-like side effects 
of the relatively large concentrations of IGFs in the circulation, the IGFBPs are also able to 
modulate different IGF actions positively or negatively by interruption of the IGF ligand-receptor 
interaction. Including at least four other low-affinity IGF binders, termed insulin-like growth factor 
binding protein-related proteins (IGFBP-rP) these proteins are part of a superfamily (Baxter et al, 
1998). The IGFBPs are able to modulate the action of IGFs due to the fact that they have at least 
50-fold higher affinity for binding IGFs than the IGF-I-R. However, at least three mechanisms have 
been shown to alter the affinity of the IGFBPs, making the network of regulatory components in the 
IGF system even more complex: IGFBP proteolysis, phosphorylation, and adherence to the cell 
surface or to the extracellular matrix (ECM) (Clemmons, 1997).
Most of the IGFBPs bind IGF-I and IGF-II with more or less equal affinity except for 
IGFBP-2 and -6, which have higher affinities for IGF-II (Kiefer et al, 1991). In plasma, the IGFs 
bind to IGFBPs, which control the bioavailability of circulating IGFs by prolonging their half-lives 
as well as delivering them to their target tissues. At the tissue or cellular level IGFBPs may exist in 
two compartments; either in the interstitial compartment or cell culture medium where the IGFBPs 
are in the soluble form, or bound to ECM and/or cell membranes. Soluble and immobilised IGF- 
IGFBP complexes could potentially prevent the IGFs from interacting with the receptor, thereby 
inhibiting the biological effects of the IGFs. This effect has been demonstrated for all six IGFBPs in 
diverse biological systems (Cohick and Clemmons, 1993; Rechler, 1993).
Binding of IGFs requires an intact binding protein, and proteolytic cleavage o f the IGFBPs 
generates fragments that have greatly reduced affinity for IGFs. Thus, proteases may function to 
release free IGFs, which are then able to bind to receptors. Furthermore, glycosaminoglycans such 
as heparin, heparan sulphate and dermatan sulphate regulate the interactions of IGFBP-3 and -5 
with IGF-I and inhibit proteolysis of the IGFBPs. Thus, these proteoglycans represent a further 
level of control of the IGF-IGFBP complexes and IGF action (Arai et al, 1994). Finally, the 
IGFBPs may have intrinsic cellular functions in the absence of IGFs, suggesting that they may act 
via their own receptor (Oh et al, 1993b, c). These relationships are summarised in Figure 1.1.
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1.2 Insulin-like growth factors (IGFs)
The term Insulin-like growth factor was proposed in 1976 (Rinderknecht and Humble, 
1976) to signify the relationship of these substances to insulin and to emphasise their growth 
promoting activities. IGF-I is a single-chain basic protein of 70 amino acids, whereas IGF-II is a 
slightly acidic single-chain peptide of 67 residues (Rinderknecht and Humble, 1976, 1978). Both 
IGF-I and -II show -70%  homology to each other, and their A and B domains show -50%  
homology to A and B chains of human insulin (Phillips et al, 1998). The B domain contains the N- 
terminus of the IGF protein and the D domain represents the C-terminus, whereas, domain C links 
the A and B domain.
1.2.1. IGF Receptors
IGFs interact with specific receptors designated type I (IGF-I-R) and type II (IGF-II-R) 
IGF receptors, as well as with the insulin receptor. Most of the mitogenic effects of the IGFs are 
considered to be mediated via IGF-I-R.
1.2.1.1 IGF-I-R
The IGF-I-R is a disulphide-linked heterotetrameric glycoprotein composed o f two ligand- 
binding a-subunits of 706 amino acid and two transmembrane 0-subunits of 627 residues. The 
human protein is produced by mRNAs derived from the single 21-exon IGF-I-R gene, located on 
chromosome 15q25-q26 (Abbot et al, 1992; Ullrich et al, 1986).
The a-subunits contain the ligand-binding region of the receptor. The IGF-I-R binds IGF-I 
with a dissociation constant (Kd) of -  InM in intact cells; IGF-II binds with several-fold lower 
affinity, and insulin with more than 100-fold lower affinity (Jones and Clemmons, 1995; Le Roith 
et al, 1995). The 0-subunits are composed of a short extracellular domain, a membrane-spanning 
segment, and a large intracytoplasmic region containing a tyrosine kinase domain and sites of 
tyrosine and serine phosphorylation (Le Roith et al, 1995; Ullrich et al, 1986). Ligand binding to 
the a-subunits triggers activation of the intracellular tyrosine kinase, leading to receptor 
autophosphorylation by an intramolecular trans-phosphorylation mechanism similar to that used by
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other receptor tyrosine kinases (Frattali and Pessin, 1993; Jones and Clemmons, 1995; LeRoith et 
al, 1995). The autophosphorylation activates the inherent tyrosine kinase activity o f the receptor, 
that leads to phosphorylation of other important tyrosines on the receptor as well as on endogenous 
substrates (Kato et al, 1992).
The IGF-I receptor is ubiquitously expressed, with highest levels seen during embryonic 
development and organogenesis. Mice homozygous for a null mutation of this receptor are small in 
size and die at birth. Their inability to develop properly is largely due to respiratory failure 
associated with underdeveloped respiratory muscles as well as poorly developed lungs and brains, 
and decreased bone ossification (Liu et al, 1993a; Baker et al, 1993).
I.2.1.2 IGF-Il/M annose-6-phosphate (M-6-P) receptor
The IGF-II-R is a single-chain membrane-spanning glycoprotein that also is known as the 
cation-independent mannose-6-phosphate receptor. The mature human receptor contains 2,451 
amino acids that can be divided into three regions, a large 2,264-residue extracellular domain, a 23- 
amino acid transmembrane region, and a 164-residue carboxyl-terminal cytoplasmic domain 
(Morgan et al, 1987; Oshima et al, 1988). The extracellular part of the IGF-II-R binds ligand, and 
the cytoplasmic region encodes segments responsible for sorting among different subcellular 
compartments (Rohrer et al, 1995; Lobel et al, 1988), for endocytosis (Lobel et al, 1988), and 
potentially for coupling to inhibitory GTP-binding proteins (Nishimoto et al, 1989; Okamoto et al,
1990). The IGF-II-R is highly conserved among different species, with -80%  homology being 
found among bovine, rat, mouse, and human receptors (Komfeld, 1992). The extracellular domain 
of each receptor is composed of 15 contiguous segments of 134-191 residues repeats that share 16- 
38% identity (Lobel et al, 1988; Macdonald et al, 1988; Morgan et al, 1987; Szebenyi and Rotwein, 
1994; Zhou and Sly, 1995). As mentioned before, no known IGF effects have been shown to be 
mediated by the IGF-II-R.
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1.2.2. Functions of IGFs
The in vivo effects o f IGFs are mainly anabolic insulin-like effects (stimulation of glucose 
uptake and glycogen synthesis) in fat and muscle cells (Froesch et al., 1985), and a growth 
promoting effect through mediation of GH (growth hormone) effects (Salmon and DuVall, 1970). 
Stimulation of cell proliferation in a variety of organs and tissues by IGFs has also been observed 
including nervous system development (Heidenreich, 1993), osteoblasts (Hock et al, 1988), bone 
endothelial cells (Fiorelli et al, 1994), chondrocytes (Ohlsson et al, 1992), hormone synthesis in 
ovary (Davoren et al, 1985; Talavera and Menon, 1991; Hernandez et al, 1988; Christman et al, 
1991; Erickson et al, 1991), spermatogonial cells in testes (Soder et al, 1992), and various cancer 
cells (reviewed by Le Roith, 1995).
In vitro, IGFs promote cell cycle progression from the Go\Gl to the S phase, resulting in 
DNA synthesis and cell proliferation (reviewed by Le Roith and Roberts, 1993). IGFs stimulate a 
mitogenic response in many cell types whereas in haematopoietic cells and in some carcinoma cell 
lines they can function as survival factors preventing apoptosis (reviewed by Le Roith and Roberts, 
1993). Proliferation and apoptosis signals may share some common pathways as they both induce 
similar changes in the morphology of the cells (chromatin condensation, loss of cell-cell contact 
inhibition, nuclear disintegration). This is supported by the observation that overexpression of 
proteins is normally associated with cell proliferation (Hartwell and Kastan, 1994; Steller, 1995; 
Askew et al., 1991; White et al., 1991). However, IGF-I has been shown to support viability in non 
proliferating cells in culture (Carlsson-Skwirut et al., 1989; Beck, 1994; Bozyczko-Coyne et al., 
1993; LeRoith et al., 1993; Svrzic and Schubert, 1990) suggesting that stimulation of cell 
proliferation and anti apoptotic action may be two distinct signals (Rubin and Baserga, 1995).
Secondly, IGFs stimulate cell differentiation in osteoblasts (Hall and Chambers, 1990), 
chondrocytes (Geduspan and Solursh, 1993), adipocytes and neural cells (Pahlman et al., 1991), 
and induce an acute insulin-like effect on protein and carbohydrate metabolism, especially in 
myoblasts (Dimitriadis et al., 1992). They also regulate the hormone secretion or induction of 
chemiotactic migration in specific cell types (Stracke et al. 1989; El-Badry et al, 1990).
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1.3 Insulin-like growth factor binding proteins (IGFBPs)
IGFBPs are produced by a variety of different tissues, and each tissue has specific patterns 
of IGFBP secretion. The six proteins also differ significantly in their biochemical characteristics, 
and this accounts for many of the differences that have been observed in their biological actions. In 
addition, proteolysis of IGFBPs by proteases plays a key role in modulating levels and actions of 
free IGFs and IGFBPs, and four IGFBP related proteins have been discovered recently which can 
also affect IGF action (Hwa et al, 1999).
1.3.1 General structure of IGFBPs
IGFBPs share at least 50% homology among themselves, and 80% homology between 
different species (Lamson et al, 1991; Shimasaki and Ling, 1991). Figure 1.2 shows the structure of 
IGFBP, where the molecule can be divided into three structurally distinct domains. Most of the 
homology is conserved in the N- and C- terminal domains, whereas the middle central domain has 
little similarity among the different IGFBPs (Hwa et al, 1999). Each protein contains a leader 
(signal) sequence with a hydrophobic domain, and all are known to be synthesized and secreted by 
at least one cell type. The proteins vary in length from 216 (IGFBP-6) to 289 amino acids (IGFBP- 
2). All six proteins contain 18 cysteines that are conserved (IGFBP-4 contains two additional 
cysteines in the central domain).
IGFBP-5 is produced as a 252 amino acid protein of ~29kDa. cDNA clones have been 
isolated and sequenced from human, rat, mouse, and chicken (Kiefer et al, 1991; Shimasaki et al, 
1991; Zhu et al, 1993; Allander et al, 1997). A 6.0 kb IGFBP-5 mRNA is expressed in a large 
variety of tissues and cell types, showing greatest abundance in the kidney. In some cell types 
smaller transcripts have been reported (Cohen et al, 1994).
The highly conserved amino- (N-) and carboxy- (C-) terminal domains are cysteine rich 
with 12 cysteines in the N-terminus and 6 in the C-terminus. The high number of cysteine residues 
in these domains suggest that these parts of the IGFBP proteins are highly structured, and therefore 
their three dimensional structure might be an important factor in their function. It is believed all of 
the cysteines are engaged in disulphide bridges, and disulphide linkages of cysteines are important
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for the correct folding and maintenance of the three-dimensional structure of many proteins. In 
addition it is believed that intradomain disulphide bond formation is more likely than interdomain 
disulphide linkages between cysteines in the N- and C-terminal domains.
Recently, the three C-terminal disulphide linkages of bovine IGFBP-2 were determined to 
be Cys13-Cys14, Cys15-Cys16, and Cysl7-Cys18 (Forbes et al, 1998). In addition, cyanogen bromide 
cleavage of this protein revealed that the N- and C-terminal domains were not linked by disulphide 
bonds (Forbes et al, 1998). The C-terminal disulphide linkages of human IGFBP-6 were also 
partially determined and are consistent with those of IGFBP-2 (Neuman et al, 1998). A structural 
study of IGFBP-5 has shown that the disulphide-linkages in N-terminal domain of human IGFBP-5 
are CysJ-Cys2, Cys3-Cys4, Cys5-Cys6, Cys7-Cys9, and Cys8-Cys10 (Neuman et al, 1999). Although, 
the disulphide linkages of cysteines 11 and 12 were not determined, inter-domain links with 
cysteines in the C-terminal domain of IGFBP-5 cannot be ruled out at present. This pattern of 
disulphide-linkages of the N-terminal domain of IGFBP-5 is identical to that of IGFBP-3 
(Hashimoto et al, 1997; Kalus et al, 1998). IGFBP-6 also showed the same pattern of disulphide- 
linkages in the N-terminal domain, although, partial determination of the N-terminal domain 
disulphide-linkages of IGFBP-1 showed a different pattern, where Cys1 is not linked to Cys2 and 
Cys3 is not linked to Cys4 (Neumann et al, 1999).
In contrast to the N- and C-terminal domains, the central domain has no sequence 
homology between IGFBPs and also no cysteines. However, this region contains phosphorylation, 
glycosylation, and many proteolytic cleavage sites suggesting that important biological functions of 
IGFBPs are regulated within this region (Conover, 1995).
The IGFBP superfamily also encompasses several IGFBP-related proteins (IGFBP-rPs) 
which bind IGFs with low affinity (Baxter et al, 1998). IGFBPs and IGFBP-rPs share the highly 
conserved and cysteine-rich N-terminal domain which appears to be crucial for several biological 
actions, including their binding to IGFs (Yamanaka et al, 1997; Vorwerk et al, 1997).
1.3.2 Evolution of IGFBP gene
While the six IGFBPs clearly have distinct amino acid sequences, they do share regions of 
strong homology and a similar genomic organisation (Allander et al, 1994; Binkert et al, 1992; Gao
23
et al, 1993; Kou et al, 1994a-b; Upton et al, 1993; Zhu et al, 1993), and the evolutionary 
conservation of IGFBPs supports their fundamental importance in regulatory processes. All human 
IGFBP genes lie in close proximity to homeobox (HOX) gene clusters on the different 
chromosomes, implying a genetic link between these two gene families. The vertebrate homeobox 
(HOX) genes are suggested to be true homologs to the insect homeotic gene complexes and to have 
arisen from duplications of a single ancestral gene cluster (Akam, 1989; Schugart et al, 1989; 
Pendleton et al, 1993). The human HOX gene family consists of four gene clusters, HOX A-D, 
localized to chromosomes 2, 7, 12, and 17 respectively (Scott, 1992; Cannizzaro et al, 1987; 
Acampora et al, 1989). As shown in Figure 1.3, the HOX and IGFBP genes/clusters are localized to 
the same chromosomal regions. Furthermore, the human IGFBP-2/-5 and IGFBP-1/-3 gene pairs 
are closely linked (Allander et al, 1994). Similarly, the two mouse IGFBP gene pairs (IGFBP-2/-5 
and IGFBP-1/-3) are also closely linked (Kou et al, 1994b).
In functional and structural aspects, IGFBP-3 and -5  are more closely related to each other 
than to other IGFBPs, and this is also true for IGFBP-1 and -2. It has been suggested that all 6 
IGFBP genes have evolved from a single ancestral IGFBP gene through a process o f gene 
duplication and chromosomal translocation and were dispersed to multiple chromosomal loci. In 
this model, IGFBP-3 and -5  were duplicated from a single gene, as were IGFBP-1 and -2 . Thus, 
the evolution of the HOX and IGFBP gene families appears to follow a similar pattern (Allander et 
al, 1995), and the association of the human genes at the same chromosomal loci suggests that 
ancesteral IGFBP and HOX genes were linked before the first duplication of chromosomal DNA 
containing the ancestral HOX cluster (Allander et al, 1994). Whether there is any functional 
significance to this linkage remains to be seen. It should be noted that the mouse IGFBP genes do 
not share the same chromosomal localization as mouse HOX A and D (Kou et al, 1994a), and this 
might reflect two different evolutionary pathways after the divergence of humans and mice 
(Allander et al, 1995).
1.3.3 IGF binding motifs
Although the structure of IGFBP proteins has not as yet been determined by X-ray 
crystallography, it is believed that the approximately 30kDa IGFBP proteins make contact with the
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Figure 1.3 Schematic diagram of IGFBP/Hox gene evolution
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much smaller IGF molecules (approximately 7.5kDa) with their N- and C-terminal domain 
simultaneously. Thus, the general structure of the IGFBP protein may be envisioned as two highly 
folded terminal domains in close contact, connected by a flexible central domain. Supporting this 
hypothesis, in vivo observations have initially shown that in biological fluids, IGFBPs can be 
proteolysed to fragments with diminished affinities for IGFs. To date, many researchers have 
performed experiments aimed at identifying the IGF binding motifs in N- and C-terminal domain of 
IGFBPs.
N-terminal domain Studies on human IGFBP-4 showed that the sequence Leu72-Ser91 
is important for IGF-II binding, as deletion of this region resulted in a protein which was 
undetectable by ligand blot (Qin et al, 1998). In support of this finding, it was shown that residues 
between Glu52-Ala92 in the N-terminal domain of rat IGFBP-3 are critical for binding IGF-II 
(Hashimoto et al, 1997). Recently, work from several laboratories has begun to identify the specific 
amino acids in the IGFBP molecule that contribute to IGF binding. At the N-terminus of bovine 
IGFBP-2, it was shown that Tyr60 was protected against iodination upon binding of IGFBP-2 to 
IGF-II (Hobba et al, 1996). Subsequently, the same group demonstrated that substitution of Tyr60 
with Ala or Phe leads to a 4.0- and 8.4-fold reduced affinity for IGF-I respectively, and a 3.5- and 
4.0-fold reduced affinity for IGF-II respectively (Hobba et al, 1998). These researchers suggested 
that the hydroxyl group of Tyr60 may participate in hydrogen bond formation and that this is 
important for the initial complex formation with IGF-I. They also suggested that this may be a 
common mechanism for all the IGFBPs, (with the exception of IGFBP-1 which has an alanine 
residue at the equivalent position). In support of this finding, Kalus et al. (1998) carried out nuclear 
magentic resonance spectroscopy (NMR) on a bacterially expressed N-terminal fragment of 
IGFBP-5 (residues 40-92). From this work it was proposed that the primary IGF binding sites 
comprise Val49, Tyr50 (equivalent to Tyr60 in IGFBP-2), Pro62 and Lys68 to Leu75, where the 
conserved Leu and Val residues localize in a hydrophobic patch on the surface o f the IGFBP-5 
protein (Kalus et al, 1998). Based on this study, Imai et al. (2000) mutated several amino acids 
within this hydrophobic patch between residues VaI49 and Leu74 in both IGFBP-3 and -5. They 
found that the substitutions Lys68Asn, Pro69Gln, Leu70Gln, Leu73Gln, and Leu74Gln in IGFBP-5 
(changing one charged residue, Lys68, to a neutral one and the four hydrophobic residues to
26
nonhydrophobic residues) resulted in an -1000-fold reduction in the affinity of IGFBP-5 for IGF-I. 
Substitutions for homologous residues in IGFBP-3 (Arg69Ser, Pro70Ala, Leu71Ser, Leu74Gln, and 
Leu75Gly) also resulted in a >1000-fold reduction in affinity. Furthermore, they demonstrated that 
the physiological consequence of this reduction in affinity was that the mutated IGFBP-3 and -5 
molecules became weak inhibitors of IGF-I-stimulated cell migration and DNA synthesis. 
Likewise, the ability of IGFBP-5 to inhibit IGF-I-stimulated receptor phosphorylation was 
attenuated. In conclusion, this study showed residues 68, 69, 70, 73, and 74 in IGFBP-5, as well as 
the homologous residues in IGFBP-3, appear to be critical for high affinity binding to IGF-I. 
Therefore, it was suggested that these residues form a binding pocket in both IGFBP proteins and 
were an important component of the core binding site (Imai et al, 2000). However, these 
researchers also demonstrated that the N-terminal fragments of IGFBP-5 have a 10- to 200-fold 
lower affinity for IGFs than the full length protein, which agrees well with the reported reduced 
affinities of other C-terminally truncated fragments of IGFBP-3 (Clemmons, 1993) and IGFBP-5 
(Andress et al, 1993). This indicates that other residues at the C-terminus of the IGF binding 
proteins may be involved in the additional stabilisation of the IGFBP/IGF complex that leads to 
high affinity IGF binding.
C-terminal domain Mutagenesis of the carboxy end of IGFBP-1 showed that deletion of 
the C-terminal 20 amino acids resulted in loss of IGF binding as measured by ligand blotting 
(Brinkman et al, 1991). In contrast to IGFBP-1, deletion of a similar region in human IGFBP-4 
(Lys215-Glu237) had no effect on IGF binding as determined by ligand blotting (Qin et al, 1998). 
Deletion of a further 10 amino acids (Cys205-Val214) reduced the binding to less than 15% of wild 
type IGFBP-4. However, it is conceivable that deletion of one of the very highly conserved 
cysteines in this region could have led to a major change in the secondary structure of the C- 
terminal domain, as the six cysteines at the C-terminus of bovine IGFBP-2 have been shown by 
Forbes et al. (1998) to form disulphide bonds between consecutive residues. In the Forbes study, 
the effects of four C-terminally truncated bovine IGFBP-2 mutants on IGF binding was also 
described (Figure 1.4). Interestingly, the truncation of 48 residues from the C-terminus of bovine 
IGFBP-2 had no effect on IGF binding (equivalent to residue 200 in human IGFBP-4), suggesting 
that residues which contribute to IGF binding differ between IGFBP-2 and -4. However, greater
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reduction in affinity for both IGFs was observed when 63 residues were deleted from the C- 
terminus of IGFBP-2 (mutant D in Figure 1.4), with a greater effect on IGF-II binding (up to 80- 
fold) as measured by charcoal binding solution phase assays. Therefore, this identified a critical 
region between amino acids 222-236 of bovine IGFBP-2 that is involved in binding IGFs (Forbes et 
al, 1998). These authors claimed that there was no real sequence conservation within this critical 
IGF binding region. Nevertheless, we decided to align the sequences from all six binding proteins 
from all species sequenced so far, and found two completely conserved amino acids in this region. 
Mutagenesis of these residues in IGFBP-5 and analysis of these effects on IGF and heparin binding 
forms the basis for Chapter III, and resulted in the publications Bramani et al, 1999 and Song et al, 
2000 .
The central domain of the IGFBPs has not been reported to contain any IGF binding 
properties. However, replacement of the IGFBP-3 central domain with that from IGFBP-2 resulted 
in an IGFBP chimera with reduced affinity for IGF-II (by at least 37%), which may suggest that the 
exact size of the central domain in each IGFBP may maximise high-affinity IGF binding by N-and 
C-terminal domains (Hashimoto et al, 1997).
1.3.4 Cell membrane and ECM binding motifs
Some IGFBPs not only bind IGFs, but also interact with cell surface molecules. IGFBP- 
land -2 bind to the <x5Pi integrin receptor in cell membranes via their RGD (Arg-Gly-Asn) sequence 
in the C-terminal domain, suggesting the possibility of an IGF-independent mechanism via these 
receptors (Jones et al, 1993a; Rauschnabel et al, 1999 abstract from Brighton meeting). Most of the 
IGFBPs have cell surface glycosaminoglycan, such as heparin and heparan sulphate, and 
extracellular matrix component binding properties (Hodgekinson et al, 1994). IGFBP-3 and -5  have 
the greatest potential to bind extracellular matrix via a stretch of basic amino acid in their C- 
terminal domain, and there is increasing evidence that IGFBP-3 and -5  have IGF-independent 
action through interaction of their heparin binding motifs and cell surface components (discussed 
later).
Adherence to cell surfaces, ECM proteoglycans, and glycosaminoglycans (GAGs) by 
various IGFBPs also has the potential to effect their affinity for binding IGFs. The ECM may serve
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to create a favourable microenvironment for cellular proliferation by stabilising or increasing local 
concentrations of peptide growth factors, by protecting such peptides from proteolysis or even 
regulating the interaction of growth factors with target receptors. Jones et al (1993b) found that 
adding an increasing concentration of salt resulted in decreased binding of IGFBP-5 to fibroblast 
ECM. This clearly demonstrated that the binding of GAGs and/or proteoglycans to IGFBPs is due 
to charge dependent ionic bonds and is not a hydrophobic event. Therefore, charged amino acids in 
the IGFBP-5 protein are important for ECM binding.
Consensus sequences for GAG binding have been formulated from known heparin binding 
proteins and used to identify potential heparin-binding regions in a range of proteins (Cardin and 
Weintraub, 1989). They identified two types of heparin binding sequences: XBBXBX (S: short 
type) and XBBBXXBX (L: long type), where B represents any basic amino acid (mainly Lys or 
Arg) and where X is an unspecified amino acid. Based on this work, Hodgkinson et al, (1994) 
looked for potential GAG binding sites in all six IGFBPs through human and rat sequences (Figure
1.5 and Table 1.1). They found five of the IGFBPs have at least one putative consensus heparin 
binding site in their central domain and/or C-terminal domain (IGFBP-4 has none). Interestingly, 
IGFBP-5 contains three consensus heparin-binding sites, where the central domain has two 
overlapping S-type sequences and the C-terminal domain has one L-type sequence (Figure 1.6). The 
GAG binding site in the C-terminal domain of IGFBP-3 (219-226) is conserved with that of 
IGFBP-5 (205-212). This region is part of a stretch of basic amino acids in the C-terminal domain 
of both IGFBP-3 and -5, suggesting a conserved biological function.
GAG and proteoglycan binding of IGFBP-3 and IGFBP-5 has been shown to play an 
important role in the ability of both of these IGFBPs to modify the cellular actions of IGF-I. 
However, the heparin binding capabilities of other IGFBPs has not as yet been reported, although 
the ability of IGFBP-2 to bind GAGs was shown to require that IGFBP-2 is already complexed 
with either IGF-I or -II  (Arai et al, 1996b). Generally, IGFBP binding to GAGs/ECM modulates 
the affinity of the IGFBP for IGFs. For example, IGFBP-3 binding to cell surfaces GAGs was 
shown to result in a ten-fold reduction in affinity of the binding protein for IGF-I (McCusker et al,
1991). Also, IGFBP-5 binding to ECM caused up to a 17-fold reduction in affinity for IGF-I and
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Table 1.1 GAG-binding consensus sequences of the IGFBP proteins
(Hodgekinson et al, 1994)
Sequence location 
(residue number) Sequence type
Protein
Human
IGFBP-1 144-149 S
IGFBP-2 179-184 S
IGFBP-3 219-226 L
IGFBP-4 - -
IGFBP-5 132-137 S
135-140 S
205-212 L
IGFBP- 6 172-179 L
Rat
IGFBP-1 157-162 S
IGFBP-2 160-165 S
IGFBP-3 220-227 L
IGFBP-4 - -
IGFBP-5 132-137 S
135-140 s
205-212 L
IGFBP- 6 - -
S and L refer to the short and long GAG-binding consensus sequences as originally described by 
Cardin & Weintrub (1989).
S = XBBXBX and L = XBBBXXBX where B represents Lys or Arg and X is undefined.
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was associated with stabilisation of the IGFBP-5/IGF complex such that it is resistant to proteolytic 
cleavage (Arai et al, 1994a).
The C -term inal dom ain 201-218 reeion o f  IG F B P -S  Association of IGFBP-5 with 
ECM results in an alteration in cell responsiveness to IGFs. The major binding site for ECM 
components (GAGs and proteoglycans) in the native IGFBP-5 protein is a stretch of basic amino 
acids (Arg20! to Arg218) in the C-terminal domain (Figure 1.6). Substitution of four basic amino 
acids within this region resulted in a major decrease in binding ECM components (Parker et al, 
1998; Song et al, 2000).
Furthermore, the binding of IGFBP-5 with GAGs was shown to cause an 8 -to 17-fold 
decrease in the affinity o f IGFBP-5 for IGF-I (Jones et al, 1993b; Arai et al, 1994a; Parker et al, 
1998). Arai et al. (1994a) suggested that GAGs did not directly compete with IGF-I for binding to 
IGFBP-5, but that GAG binding resulted in a conformational change in the IGFBP-5 protein 
structure, and that it was this that lowered its affinity for IGF-I. They also concluded that GAGs 
(and by inference the ECM) can lower IGF-I/IGFBP-5 interaction and this promotes IGF-I/receptor 
interaction. This may be crucial in obtaining the correct balance between a pool of ECM-bound 
IGFs that are protected from proteolysis and soluble IGFs able to interact with the cell surface 
receptor and bring about IGF effects.
More recently, Andress (1995) tested whether GAGs were also involved in the association 
of IGFBP-5 with the cell membrane. Both IGFBP-5 and its C-terminal-truncated variant 1169 
IGFBP-5 were shown to bind to osteoblast-like cell membranes and subsequently to become 
internalised. This binding was inhibited by a high salt concentration and could be competed with 
heparin> heparan sulphate> dermatan sulphate in decreasing order for both proteins (although 
higher salt and heparin concentration were required to displace 1-169 IGFBP-5 compared to the wild 
type protein). However, the conclusion that these results derive from a direct competition between 
the above molecules and cell membrane GAGs was called into question by the inability of 
heparinase or sodium chlorate treatment of the cell monolayers to affect IGFBP-5 binding to the 
cell membrane. The same group then went on to demonstrate that by cross-linking IGFBP-5 or 1-169 
IGFBP-5 to osteoblast monolayers, it was possible to detect labelled proteins in a complex with a
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420kDa Triton-extractable membrane protein. This protein was then purified from a cellular extract 
on an IGFBP-5 affinity chromatography column. The affinity labelling was greater for IGFBP-5 
than for its truncated variant and the formation of the complex was not affected by heparinase or 
chondroitinase pretreatment of the cell monolayer. In contrast, IGFBP-5 and ' ' 169IGFBP-5 failed to 
cross-link to any protein from an ECM preparation. The authors concluded that, while IGFBP-5 
association with the ECM might involve GAG interactions, the binding to osteoblast cell surfaces 
was mediated by a 420kDa protein, which could serve as an IGFBP-5 specific receptor. More 
recently, the functions of this putative receptor were further investigated (Andress, 1998). 
Treatment with IGFBP-5, or with the 201-218 peptide derived from IGFBP-5, was shown to cause 
increased serine phosphorylation of the 420kDa protein, which also appeared to display some 
kinase activity and be able to induce serine phosphorylation of casein in vitro.
It is well established that IGFBP-5 is the major bone IGFBP, and IGFBP-5 can bind to 
bone matrix, including the inorganic ECM component hydroxyapatite (HA). Campbell and Andress 
(1997b) showed that a synthetic IGFBP-5 (201-218) peptide was able to increase the binding of 
endogenous IGFBP-5 to HA as well as the binding of IGF-I to HA-bound IGFBP-5, and that this 
action was specific for the heparin binding domain. These results suggested that the 201-218 region 
of IGFBP-5 not only enhances binding of IGFBP-5 to HA, but that it also binds directly to IGFBP- 
5 in a certain way as to increase IGF-I binding to IGFBP-5. These data may indicate that IGFBP-5 
is able to bind to itself, and suggests the possibility of dimer formation (Campbell and Andress, 
1997b).
Domain switching to create chimeric IGFBP proteins has previously been adopted by other 
groups in order to ascertain which domains of IGFBP-3 and IGFBP-5 are involved in binding to a 
liver derived glycoprotein known as the ALS (Hashimoto et al. 1997, Twigg and Baxter, 1998). 
Using this approach, it was demonstrated that the stretch of basic amino acids that is common to the 
C-terminal domains of IGFBP-3 and IGFBP-5 is necessary for ternary complex formation with 
ALS and IGFs. In addition, it was shown that at high concentrations, the GAGs heparin and 
heparan sulphate inhibited ALS binding to IGFBP-5 when it was bound to IGF, suggesting overlap 
of heparin and ALS binding sites in the C-terminal domain (Twigg et al. 1998).
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In addition to the functions of the 201-218 region outlined above, a nuclear localisation 
sequence (NLS) was also identified within this region of IGFBP-5 (Schedlich et al., 1998; 
Schedlich et al, 2000), and an alternative route for IGFBP interaction with cells emerged (described 
in chapter 1.4.4). Finally, the 201-218 region has been shown to be involved in the interaction 
between IGFBP-5 and plasminogen activator inhibitor 1 (PAI-1), part of the plasminogen activation 
pathway (Campbell and Andress, 1997a; Campbell et al, 1998), and aS2-casein (Flint et al, 2000).
The C entral dom ain heparin binding resion  o f  IG F B P -S  Although a heparin 
binding consensus sequence has been identified in the central domain of IGFBP-5, its biological 
significance has not been explored fully. Parker et al (1996) synthesized central domain heparin 
binding peptides (Ala131-Thr141) and demonstrated that these could compete with C-terminal heparin 
binding peptides (Arg201-Arg218) for binding the ECM. However, they also noted that the central 
domain peptides were much less potent than the C-terminal domain peptides for binding ECM 
(Parker et al, 1996). Nevertheless, there is increasing evidence that the central domain heparin 
binding region of IGFBP-5 is activated upon removal of the C-terminal domain (Twigg et al, 2000; 
Song et al, 2001). Twigg et al (2000) generated a C-terminally truncated IGFBP-5, which is a 
mimic of a naturally occurring proteolytic fragment, and a domain switched chimeric mutant of 
IGFBP-5 and - 6 , termed 6-5-6. In both cases, mutant IGFBP-5 proteins formed ternary complexes 
with IGFs and ALS, suggesting that the central domain of IGFBP-5 contained the ALS binding 
activity. We have also shown that the central domain heparin binding region was activated after 
removal of C-terminal domain of IGFBP-5 (Song et al, 2001. This study will be discussed in more 
detail in chapter V). Furthermore, this suggests that proteolytic fragments of IGFBP-5 may retain 
significant ECM binding properties, and as a result may have differential effects to the native 
protein.
1.3.5 Post-translational modification
There is very little data on the effects of post-translational modification of IGFBPs on IGF 
binding. There is some evidence indicating that neither glycosylation nor phosphorylation appears 
to have a significant influence on the IGF binding affinities of IGFBPs (Hoeck and Mullu, 1994;
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Coverley and Baxter, 1995). So far, post-translational modifications of the IGFBPs have been found 
in the central-domain, but not in the N- or C- terminal domains (Hwa et al, 1998).
Glvcosvlation  of IGFBPs has been reported so far in IGFBP-3, -4, -5 and -6 . There is no 
clear evidence to date that IGFBP-1 and -2 are glycosylated (Table 1.2). Both N- and O-linked 
glycosylation has been reported; IGFBP-3 and -4 are N-glycosylated, whereas, IGFBP-5 and - 6  are
O-glycosylated. N-glycosylation appears only on an asparagine that is part of the consensus 
sequence Asn-X-Ser/Thr, where X is any amino acid except proline. Three N-glycosylation sites in 
the mature IGFBP-3 protein, Ans89, Asn109 and Asn172 have been characterized (Zapf et al, 1988), 
and one, Asn 104, in IGFBP-4 (Ceda et al, 1991). In contrast to the N-glycosylation sites, there are 
no consensus sequences for predicting O-glycosylation. Although, it has been reported that IGFBP- 
5 (Conover and Kiefer, 1993) and IGFBP- 6  (Bach et al, 1992; Neumann et al, 1998) are both O- 
glycosylated, glycosylation sites in IGFBP- 6  were determined to be within the central domain at 5 
amino acids, Thr126, Ser144, Thr145, Thr146, and Ser152 (Neumann et al, 1998). The ability to bind 
IGFs with high affinity appears not be influenced by N- or O-glycosylation, although there may be 
effects on other functions of IGFBPs, such as resistance to proteolysis (Neumann et al, 1998).
IGFBP-1, -3, and -5 are also post-translationally modified by phosphorylation  (Coverley 
and Baxter, 1997). Phosphorylation in all three IGFBPs is predominantly at serine residues found in 
the central domain (Table 1.2). Phosphorylation of proteins is an important and critical post- 
translational modification mechanism that is used by cells to stringently regulate the activities of 
numerous intracellular proteins, including proteins involved in the signal transduction pathways, in 
the cell cycle, and in gene expression. The purpose of phosphorylating secreted proteins like 
IGFBPs is unclear, but there is evidence that, at least for human IGFBP-1, phosphorylation 
enhances the affinity of this binding protein for IGFs 5-fold (Jones et al, 1991; Westwood et al,
1997). The phosphorylation of human IGFBP-1 occurs at three serine residues: SerlOl and Serl09 
in the central domain, and Ser 169 in the C-terminal domain. The phosphorylation of human IGFBP- 
3 was found at Seri 11 and Seri 13 (Hoeck and Mukku, 1994). Both of these serines are also in close 
proximity to one of the N-glycosylation sites, Asn 109. This work also demonstrated that 
phosphorylation of human IGFBP-3 did not appear to affect IGF binding (Hoeck and Mukku,
1994), although interestingly the phosphorylation of IGFBP-3 can be up-regulated by IGFs through
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Table 1.2 (based on Jones and Clemmons, 1995a; LeRoith, 1996; Hodgkinson et a l 1994 and 
Swiss-Prot sequence data base)
Characteristics IGFBP-1 IGFBP-2 IGFBP-3 IGFBP-4 IGFBP-5 IGFBP- 6
N residues
Human 234 289 264 237 252 249
Rat 247 270 265 233 252 252
Mr theoretical
Human 27903 35137 31660 27934 28553 30570
Rat 29628 32883 31680 27745 28428 30298
SDS-page 
(non reducing)«
30 32 39-41 24-28 30 30
Phosphorylation + - + - + -
Glycosylation - - N N O O
RGD sequence + + - - - -
Heparin-bind 
(S= short; L=Iong) 
Other basic aa seq.
S S S + L 
215-232
nd S+S+L
201-218
Nd
Heparin binding +/- + ++ + ++ Nd
Cell surf. Associat. + + + - + -
Proteolysis - + + + + Nd
IGF-I-IGF-II
preference ~ >IGF-I >IGF-II >IGF-I » IG F -II
Chromosomal
localiz. (human) 7p 2 q 7p 17q 2 q 1 2
HOX gene
association HOXA HOXD HOXA HOXB HOXD HOXC
Nd = not determined
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a mechanism involving IGF-I-R interaction (Coverley and Baxter, 1995). The importance of the 
phosphorylation of IGFBP-3, and the significance of IGF regulation of phosphorylation, is unclear 
but it may affect IGFBP-3 interactions with the ALS or with the cell surface (Coverley and Baxter,
1995).
The data for the phosphorylation of IGFBP-5 are very limited, although, like all the 
IGFBPs, there are several potential phosphorylation sites at serine and threonine residues in the 
central domain (Coverley and Baxter, 1995). The biological significance of IGFBP-5 
phosphorylation has not been elucidated.
1.3.6 Proteolysis of IGFBPs
Many studies have shown that proteolysis is an important mechanism for generating 
IGFBP fragments with a lower affinity for IGFs. Cleavage of IGFBPs results in release of free 
IGFs, which are then able to activate the IGF receptors (Figurel. 1). Prostate specific antigen (PSA) 
in seminal plasma was the first IGFBP protease to be biochemically identified (Cohen et al, 1992). 
To date, proteolysis of IGFBP-2 to - 6  has been described in multiple clinical states and cellular 
systems. Categories of IGFBP protease include kallikrein-like serine proteases (Cohen et al, 1992; 
Rajah et al, 1996), cathepsins (Conover et al, 1994; Conover et al, 1995b; Nunn et al, 1997; 
Claussen et al, 1997), and matrix metalloproteinases (MMPs) (Fowlkes et al, 1994a-b; Rajah et al,
1996). Kallikrein-like serine proteases include PSA, gamma-nerve growth factor and plasmin 
(Angelloz-Nicoud et al, 1996). PSA is present in high concentrations in patients with disseminated 
prostate cancer (Cohen et al, 1992), that is able to degrade IGFBP-3 and -5, but not IGFBP-1, -2, -4 
or - 6  (Collett-Solberg and Cohen, 1996). In addition, a serine protease specific to IGFBP-4 has 
been observed in smooth muscle and neuronal cell lines (Rees et al, 1998), and thrombin, another 
serine protease, cleaves IGFBP-5 at physiologically relevant concentrations (Zheng et al, 1998a). 
Cathepsins are proteases which are activated under acidic conditions, and this may be relevant to 
certain physiological and pathological processes (Conover and De Leon, 1994). Under such 
conditions, a high release of hydrogen ions may provide an acidic environment for extracellular 
cathepsin action, resulting in the cleavage of IGFBPs, which, in turn, may impact on cell growth
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rates through interaction with the IGF axis (Bereket et al, 1996). In vitro degradation experiments 
of IGFBPs by cathepsin D showed that IGFBP-1 to -5 were cleaved by cathepsin D in a 
concentration dependent manner to fragments of a defined size, (IGFBP- 6  was not degraded) 
(Claussen et al, 1997). MMPs comprise a family of peptide hydrolases responsible for the 
degradation of ECM components such as collagen and proteoglycans in processes involving tissue 
remodeling (Fowlkes et al, 1994a). MMPs have been identified in prostatic fluid and cells (Nunn et 
al, 1997). The fact that certain IGFBPs have been shown to be degraded by MMPs may imply a 
role for the binding proteins in these tissue remodeling events.
Proteolysis of IGFBP-5 has been the subject of study in many laboratories. IGFBP-5 
proteases belonging to the families of matrix metalloproteases and serine proteases have been 
described in fibroblast, osteoblast and chondrocyte culture (Kanzaki et al, 1994; Nam et al, 1994; 
Fowlkes et al, 1994a; Thraikill et al, 1995a; Matsumoto et al, 1996). Nam et al. (1994) identified an 
IGFBP-5 specific calcium-dependent serine protease in the culture medium from human fibroblasts, 
which cleaves intact IGFBP-5 to 17-22 kDa fragments. The proteolytic specificity for IGFBP-5 was 
confirmed by experiments in which IGFBP-1, -2, -3 and -4  were shown to remain intact after 
incubation with purified protease. The authors went on to show that the protease has properties 
similar to those of members of the kallikrein family. It is calcium and not zinc dependent, and its 
protease inhibitor activity profile shows that aprotinin is one of the most effective inhibitors. Most 
importantly, its activity is inhibited by a peptide containing the a r antichymotrypsin cleavage site 
(Yoon et al, 1987). (Xr Antichymotrypsin is a member of the serpin family of protease inhibitors, 
and it inhibits members of the kallikrein family (Huber and Carrel, 1989). However, the IGFBP-5 
protease does not appear to be a known kallikrein, because plasma kallikrein had minimal activity, 
and cleavage by this protease produced different fragment sizes. Likewise, IGFBP-5 protease 
activity was not inhibited by soybean trypsin inhibitor, a known kallikrein inhibitor. Furthermore, 
PSA cleaves IGFBP-3 (Watt et al, 1986), whereas the IGFBP-5 protease does not cleave this 
substrate. These finding suggest that the protease may be similar to human kallikreins, but two 
members of this family have been excluded as candidates.
Subsequently, Imai et al. (1997) identified the same protease in the culture medium from 
porcine smooth muscle cells (pSMC) and used site-directed mutagenesis to identify the primary
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proteolytic cleavage site at Argl38-Arg139, (which interestingly lies within the consensus heparin 
binding site in the central domain of IGFBP-5; previously discussed in chapter 1.3.4). By 
mutagenesis of these residues, (Arg138-Arg139 —► Asn138-Asn139), the authors were able to create a 
protease resistant mutant of IGFBP-5, which remained intact even after 24hr of incubation with the 
pSMC protease. Furthermore, the mutant IGFBP-5 was shown to inhibit several IGF-I actions when 
added to pSMC culture medium, including decreasing IGF-I stimulated cellular DNA synthesis by 
84%, protein synthesis by 77%, inhibition of IGF-I stimulated migration of pSMC by 77%, and 
inhibition of IGF-I stimulated phosphorylation of Insulin receptor substrate-1 (IRS-1). In contrast, 
the same amount of native IGFBP-5 did not have the same inhibitory effects on IGF-I actions. 
Therefore, these findings suggest that the proteolysis of IGFBP-5 is essential in order to potentiate 
several IGF-I actions, probably via the release of IGF-I to its receptor.
Interestingly, Nam et al (1994) also showed that the proteolysis of IGFBP-5 by its specific 
protease was inhibited by co-incubation with either heparin or a synthetic C-terminal domain basic 
amino acid region (201-218) peptide, and the authors concluded that heparin and the peptide may 
both bind directly to the protease through a charge based interaction. Initially, this conclusion 
appears surprising as heparin and the basic amino rich peptide have opposite charges (negative and 
positive respectively), which promotes their own interaction. In order for this to occur, it would be 
necessary for the protease to contain both positively and negatively charged regions to enable it to 
bind both of these molecules. We would consider the 201-218 peptide to be a likely binding partner 
for the protease, because the primary proteolytic cleavage site lies within a similar stretch of basic 
amino acids (the central heparin binding consensus site). Therefore, it is conceivable that the 201- 
218 peptide binds the protease directly and has an inhibitory effect. However, it is possible that 
heparin interferes with IGFBP-5 proteolytic activity by directly binding to either the IGFBP-5 or 
the protease. In support of the former, it has been shown that IGFBP-5 bound to ECM components 
through the 201-218 region is protected from subsequent proteolysis (Parker et al, 1998). Therefore, 
heparin binding to the 201-218 region of IGFBP-5 may have a conformational effect on the protein 
structure that prevents proteolysis in the central domain.
In addition to the IGFBP-5 specific protease, it has also been shown that the binding 
protein is cleaved by physiological relevant concentrations of thrombin (Zheng et al, 1998a). In
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addition, the authors were able to identify three thrombin cleavage sites in the IGFBP-5 protein 
(Lysl20-Hisl21, Argl56-Ilel57, and Argl92-Alal93), two o f which are C-terminal to the central 
heparin binding consensus sequence. Finally, the authors demonstrated that thrombin cleavage of 
IGFBP-5 was partially inhibited by IGF-I binding and they suggested that generation of active 
thrombin in vessel walls may be a physiologically relevant mechanism for controlling IGF-I 
bioactivity. Another group identified IGFBP-5 proteases of molecular weights 52-72 kDa in the 
culture medium of MC3T3-E1 osteoblasts, and subsequently were able to show that these proteases 
were MMPs (Thrailkill et al, 1995a). The cleavage sites for the MMPs in the IGFBP-5 protein have 
yet to be identified. Finally, screening of circulating 12 to 25kDa human IGFBP-5 fragments, 
which have very low affinity for IGFs as detected by ligand blots, in human hemofiltrate revealed 
further proteolysis sites in the IGFBP-5 sequence at Serl43, Lysl44, and A rgl8 8  (Standker et al, 
1998). Interestingly, only the 13.5kDa fragment was derived from the C-terminal domain, whereas 
most of the major fragments (Mr >20kDa) contained the central domain. These findings suggest 
that most of the primary cleavage sites are located in the central domain.
1.4 IGFBP Functions
IGFBPs have been shown to either inhibit or enhance IGF actions in different 
circumstances (reviewed in Hwa et al, 1999). The functions of IGFBPs and IGF actions have been 
studied in detail, but most of these studies have been conducted in vitro using cultured cells. 
Recently, in vivo studies of IGFBP action have also been carried out. These in vitro and in vivo 
studies have allowed a more comprehensive understanding of the role of IGFBPs in controlling IGF 
action. Although this section will discuss the individual actions of each protein, since they have 
usually been studied individually, it is important to remember that most cell types synthesize 
multiple IGFBP types as well as IGFBP proteases. Another fact that is often overlooked is that most 
in vitro experiments are conducted by removing the conditioned culture medium from the cell 
cultures at the time of initiation of the experiment, thereby reducing the soluble binding protein 
levels in the medium to zero before adding back IGFs. This is a nonphysiological situation since 
IGFBPs are present in all interstitial fluids in vivo. There is also increasing evidence for IGFBPs 
having IGF-independent activities mediated through their own receptors.
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1.4.1 In vivo functions
In plasma there are three general functions of IGFBPs; 1) The IGFBPs transport IGFs to 
their receptor sites in the body, 2) The binding of IGFBPs prolongs IGF half-life by as much as 
30min, or to 16hr when bound to IGFBP-3 in the 150kDa complex, compared to lOmin or less for 
free IGF alone (Jones and Clemmons, 1995), 3) Complexing with IGFBPs inhibits the insulin-like 
activity of IGFs and prevents hypoglycemia that would otherwise lead to death (Chan and Spencer,
1997). The IGFs are carried in the circulation predominantly in the ~150kDa complex with IGFBP- 
3 and the ALS, which does not bind IGFs directly. This complex sequesters more than 90% of the 
IGFs in the circulation (Lee and Rechler, 1996). Most of the rest of the IGFs are bound to other 
IGFBPs and approximately 0.4% remains in the free form (Clemmons, 1997). ALS is a 
glycoprotein with an apparent molecular weight of 84-86 kDa and a characteristic leucine-rich 
domain which is believed to facilitate protein-protein interaction (Leong et al., 1992). Liver is the 
main source of plasma IGF, IGFBP-3 and ALS. The proteins are released into the circulation where 
IGF initially combines with IGFBP-3 in a dimer complex and then subsequently binds to the ALS 
subunit to form a stable 150 kDa ternary complex (Jones and Clemmons, 1995). Recently, it was 
reported that a plasminogen and IGFBP-3 complex is also able to bind IGF-I with high affinity in 
normal plasma (Campbell, 1998). The theory that all IGFBP-3 present in the plasma is bound to 
ALS and IGF was based on gel filtration studies that simply showed that plasma IGFBP-3 is 
engaged in a 150 kDa complex. However, as plasminogen (97-92 kDa) has a similar molecular 
weight to ALS, it is possible that part of the 150 kDa is actually formed by IGFBP-3, IGF and 
plasminogen. Furthermore, an IGFBP-3-ALS-plasminogen trimeric complex could not form as both 
ALS and plasminogen interact with the 215-232 heparin binding sequence in the C-terminus of 
IGFBP-3, and therefore, their binding to IGFBP-3 is mutually exclusive.
It is believed that IGFBPs can also play a role in IGF transcapillary transport. Low 
molecular weight IGF-IGFBP complexes have been shown to cross capillary barriers (Jones and 
Clemmons, 1995) and a specific role for endothelium associated IGFBP-3 fragments has been 
proposed (Booth et al, 1996). IGFBP-1 has been identified in peritoneal fluid, the composition of 
which is believed to be similar to interstitial fluid. It is not known if the passage of IGFBP-1 to the
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extravascular compartment occurs by passive leakage from the blood or if it involves an 
active/regulated transport (Lee et al., 1997).
The deletion of IGF-I and -II mouse genes by homologous recombination produced 
animals of reduced in size (DeChiara et al., 1990; Powell-Braxton et al., 1993) indicating the 
involvement of the two peptides as cell survival factors in embryonic development. A role for 
IGFBPs in development was also postulated, acting either through the modulation of IGF action or 
in an IGF-independent fashion. IGFBP mRNA expression in rat and mouse embryos has been 
determined by in situ hybridization techniques and specific temporal-spatial expression patterns 
were observed (Baker et al, 1993; Powell-Braxton et al, 1993; Cerro et al, 1993; Green et al, 1994; 
Schuller et al, 1993; Streck et al, 1992; Wood et al, 1992). In particular, IGFBP-2 and-5 expression 
appears to be localized in the same or adjacent tissues (Green et al, 1994; Schuller et al, 1993) 
suggesting a complementary role for these two binding proteins in specific tissues during 
development (Allan et al, 2000). However, targeted disruption of the IGFBP-2 gene in mice did not 
produce any apparent phenotypical alteration (Wood et al, 1993). This result, while possibly 
suggesting functional redundancy between the 6  IGFPBs, does not exclude a specific role for each 
IGF-binding protein in the development of normal embryos.
1.4.2 Inhibition of IGFs action
The diverse activities of IGF-I and IGF-II in stimulating mitogenesis, increasing substrate 
uptake and metabolic activity, inhibiting apoptosis, and modulating a variety of specific functions 
in highly differentiated cell types are mediated through binding and activation of the type I IGF 
receptor. Although there are notable exceptions, the interaction of an IGFBP with IGF-I or IGF-II 
generally blocks receptor activation.
IG F BP-1. As reviewed in Clemmons (1997), many studies have demonstrated the 
inhibitory effects of IGFBP-1 on IGFs. Addition of molar excess of IGFBP-1 with IGF-I or IGF-II 
(at least 4:1) results in inhibition of IGF action, and excess IGFBP-1 has been shown to inhibit 
protein synthesis in muscle cells (McCusker et al, 1991; reviewed by Clemmons, 1997). One 
experiment has shown that IGFBP-1 blocks IGF-I interaction with receptors on human endometrial
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membranes, suggesting that this is the principal mechanism by which inhibition occurs (Rutanen et 
al, 1988). Prolonged incubation times of 24-36h with highly phoshorylated forms of IGFBP-1 have 
been shown to inhibit DNA synthesis in FRTL5 cells and chick embryo fibroblasts (Frauman et al,
1989). Also of interest was that while phosphorylated IGFBP-1 decreased IGF-I-stimulated DNA 
synthesis in human fibroblasts, dephosphorylated IGFBP-1 actually potentiated IGF action (Busby 
et al., 1988; Jones and Clemmons, 1995). These differential effects may be explained by the fact 
that phosphorylation of IGFBP-1 increases its affinity for binding IGFs 6 -fold, and this would also 
increase the difference in IGF-affinity between IGFBP-1 and the type-1 IGF receptor (Jones and 
Clemmons, 1995).
Recently, Gustafsson et al. (1999) demonstrated how IGFBP-1, -2 and -A  modulate IGF-I- 
induced DNA and protein synthesis in cultured rat vascular smooth muscle cells. DNA and protein 
synthesis were measured as incorporation of 3H-thymidine and 3H-leucine into DNA and protein 
respectively. IGFBP-1 and -4  acted in an inhibitory manner on IGF-I-induced DNA synthesis. 
While IGFBP-2 also inhibited the growth response to IGF-I, this effect was only obtained if the 
IGFBP-2 and IGF-I were pre-incubated together for 2hr prior to their addition to the cells. IGF-I- 
induced protein synthesis was also inhibited by all three IGFBPs. Similar results were reported by 
another group who showed that IGFBP-1 inhibits IGF-II stimulated DNA synthesis and the extent 
of glycogenesis in cultured rat hepatocytes (Menuelle et al, 1999).
Some in vivo and clinical studies have also shown inhibitory effects of IGFBP-1. Lewitt et 
al. (1991) injected a very large concentration of IGFBP-1 into rats, which resulted in at least a 10:1 
excess of IGFBP-1 to free IGF-I. This excess of IGFBP-1 resulted in a transient increase of blood 
glucose concentration, which suggests that molar excess of IGFBP-1 inhibits IGF-I mediated 
glucose uptake. In addition, increased IGFBP-1 levels were found in a patient who had displayed 
severe growth retardation since birth (Camacho-Hubner et al, 1999). It was found that in addition to 
inhibiting the biological activity of the IGFs, the increased IGFBP-1 levels were also associated 
with inhibition of circulating 150kDa ternary complex formation, which in turn would accelerate 
the rate of clearance of IGFs. Related to this, it has also been shown that increased IGFBP-1 levels 
inhibits the feedback action on GH leading to increased levels of this hormone (Barreca et al,
1998). This could lead to GH insensitivity syndrome, which also inhibits body growth.
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In several transgenic studies, overexpression of IGFBP-1 in the brain caused a retardation 
in brain growth (Dai et al, 1994). Interestingly, although the IGFBP-1 level in serum was ten times 
higher than in the wild type controls, the transgenic mice showed no growth retardation, suggesting 
that the molar excess of IGFBP-1 to IGF-I in the brain was relatively greater than in the serum. Lee 
et al. (1999) showed that IGF-I transgenic mice had enhanced growth even in undernourished 
conditions, whereas undernourished IGFBP-1 transgenic mice exhibited less growth than 
undernourished control mice. These in vivo experiments also illustrate that, as with in-vitro 
conditions, high levels of IGFBP-1 relative to IGF-I can result in growth attenuation.
IG F B P -2 . As reviewed in Clemmons (1997), IGFBP-2 is secreted by many cell lines and 
appears to be involved in cell proliferation. In most of the cell culture systems studied, IGFBP-2 
accumulates in the conditioned medium where it binds to IGFs with high affinity and potentially 
inhibits IGF action by preventing the interaction of the growth factors with the IGF-I receptor. In 
rat calvaria cells IGFBP-2 reduced both basal and IGF-I-stimulated 3[H]-thymidine uptake and 
collagen synthesis (Feyen et al, 1991). In porcine muscle satellite cells, multiple passaging culture 
caused reduced cell division and myotube formation accompanied by an increased secretion of 
IGFBP-2, which in turn may have reduced endogenous IGF-I activity (Fligger et al, 1998).
The addition of plasminogen to neuroblastoma cell cultures caused proteolysis of IGFBP-2 
which resulted in a 4-5 fold reduction in the affinity of the binding protein for IGF-II. In these cells, 
IGFBP-2 is the major regulator of IGF-II action as it is more abundant than IGFBP-4, which is also 
expressed and it has higher affinity for IGF-II. Plasminogen also induced a mitogenic effect in 
neuroblastoma cells, which was inhibited by blocking with an IGF-II specific antibody. This led to 
the conclusion that the plasminogen mitogenic effect derived from the increased bioavailability of 
IGF-II following the degradation of IGFBP-2 (Menouny et al, 1997).
Analogous experiments were undertaken in kidney fibroblasts stably transfected with an 
IGFBP-2 expression vector. The growth rate of cells transfected with IGFBP-2 was reduced 
compared to the control cells and the inhibition was reversed by IGF-I and II and even more 
potently by an IGF-I analogue, des[l-3]IGF-I, which has reduced affinity for IGFBPs. The anti- 
proliferating effect of IGFBP-2 was confirmed when the medium conditioned by IGFBP-2-
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transfected kidney fibroblasts was applied to choriocarcinoma cells, causing a reduction of cell 
proliferation (Hoflich et al, 1998)
A recently published study analyzed the correlation between the level of expression of 
IGFBP-2 and growth rate in C6  rat glioma cells transfected with an IGFBP-2 expression vector 
(Bradshaw et al, 1999). That IGFBP-2 might play a role in the regulation of cell proliferation was 
suggested by experiments in which primary cultures of glioma cells was transfected with IGFBP-2. 
Clones of cells with high levels of IGFBP-2 expression had decreased proliferation rates, whereas 
high rates of proliferation were associated with low levels o f IGFBP-2 expression. Moreover in a 
previous report the authors showed that the addition of IGFBP-2 to primary astroglial cells caused 
an inhibition of IGF stimulated 3[H]'thymidine uptake (Bradshaw and Han, 1993). Therefore, it was 
expected that the higher the expression of IGFBP-2 in C6  transfected clones, the lower was the rate 
of cell proliferation. Surprisingly the growth rate of cloned cells that expressed the highest level of 
IGFBP-2 did not differ from control cells, while an inhibition of cell proliferation became evident 
in clones expressing lower levels of the binding protein. Other parameters were also analyzed and 
interesting observations were recorded. First, the clones that expressed IGFBP-2 at the highest level 
displayed a concomitant upregulation of the endogenous IGF-I mRNA and it is possible that this 
cell compensation mechanism limited the effect of IGFBP-2 on cell proliferation. Second, the 
transfection of glioma cells with IGFBP-2 vector affected the expression pattern of other 
endogenously produced IGFBPs. For instance, in the clones with lower growth rate and moderate 
IGFBP-2 expression levels the appearance of a new 29kDa binding protein (possibly IGFBP-5) was 
noted both in the conditioned medium and associated to the cell membranes. Although transfected 
clones moderately expressing IGFBP-2 showed a decrease in cell proliferation it is possible that the 
effect was due to the induction of IGFBP-5 expression. It was concluded that factors other than the 
equilibrium between IGF-I and IGFBP-2 were involved in growth regulation (Bradshaw et al,
1999).
IG F B P S . As reviewed in Clemmons (1997), addition of excess purified IGFBP-3 with 
IGF-I inhibits the insulin-like actions of IGF-I in Balb/c 3T3 cells. In cultured fibroblasts, excess 
IGFBP-3 inhibits the DNA synthesis response to IGF-I with maximum inhibition noted at a 4:1 
molar ratio of IGFBP-3 to IGF-I (Blat et al, 1989). IGFBP-3 has been shown in chick fibroblasts to
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inhibit IGF-I stimulated DNA synthesis (Villaudy et al, 1991), and in rat granulosa cells 
steroidogenesis and cyclic AMP generation are inhibited by exogenous IGFBP-3 (Bicsak et al,
1990). In cultured rat or mouse osteoblasts, collagen synthesis has been shown to be inhibited by 
IGFBP-3 (Schmid et al, 1991), and it was proposed that the increased concentration of IGFBP-3 in 
the conditioned medium in mouse embryo fibroblasts could account for the observed density 
dependent inhibition of cell growth (Blat et al, 1994).
Exogenous IGFBP-3 in concentrations of 50ng/ml inhibited DNA synthesis induced by 
InM IGF-I in human vascular smooth muscle cells cultured from human renal arteries (Andersson 
et al, 1999). Moreover, the stimulatory effect of IGF-I through its receptor was shown to be 
inhibited significantly by addition of IGFBP-3 in human chondrocyte cells (Matsumoto, 2000). In a 
human glioblastoma cell line, the induction of p53 gene expression was shown to not only cause 
apoptosis, but also the stimulation of IGFBP-3 gene promoter and protein expression (Shen and 
Glazer, 1998). It had been shown previously that in this cell line the addition of recombinant 
IGFBP-3 caused apoptosis (possibly by inhibiting the cell survival action of the IGFs), but it 
remains to be demonstrated if the p53-induced apoptosis is mediated through the increase of 
endogenous IGFBP-3. Karas et al. (1997) showed that in endometrial cancer cells, membrane- 
associated IGFBP-3 inhibited IGF induced phosphorylation of IGF-I-R and IRS-1. Finally, TGF-P 
stimulates IGFBP-3 mRNA and peptide expression in several cell types, and TGF-P induced 
growth inhibition and apoptosis have been shown to be mediated through the induction of IGFBP-3 
(Cohen, 2000).
IG F B P -4 . To date, IGFBP-4 is the only IGFBP that has been shown to only inhibit IGFs. 
IGFBP-4 displays none of the properties associated with lowering of IGFBP affinity for IGFs, such 
as cell surface association or dephosphorylation. As reviewed in Clemmons (1997), however, 
inhibitory effects of IGFBP-4 are IGF-I-R dependent, including inhibition of IGF-I effects on DNA 
synthesis in cyclic AMP generation in osteoblasts (Mohan and Baylink, 1991), protein synthesis in 
B104 cells (Cheung et al, 1991), glycogen synthesis in osteosarcoma cells (Jones and Clemmons,
1995). Clinical observations have also reported that circulating levels of IGFBP-4 are increased in 
bone marrow with age, suggesting that IGFBP-4 has a negative effect on bone formation (Mohan et 
al, 1995).
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Damon et al (1998) overexpressed IGFBP-4 in the M l2 prostate epithelial cell line to 
determine the effects on tumor formation and apoptosis. IGF induced proliferation was reduced in 
the IGFBP-4 transfected cells compared with control cells. In addition, colony formation in soft 
agar was significantly inhibited in the IGFBP-4 transfected cells by up to 14 days after plating 
compared with the M12 controls, whereas, in the presence of des(l-3)IGF-I, which does not interact 
with IGFBPs but retains wild type potency at the IGF-I receptor, there was no significant difference 
between the control and IGFBP-4 transfectants in colony formation.
IGFBP-4 transgenic mice exhibited a significant reduction in wet weight of smooth muscle 
cell (SMC) rich tissues, including bladder, intestine, aorta, uterus, and stomach, with no change in 
total body or carcass weight (Wang et al, 1998). In situ hybridization showed that transgene 
expression was targeted exclusively to the muscular layers of the arteries, veins, bladder, stomach, 
intestine, and uterus. Overexpression of IGFBP-4 was associated with SMC hypoplasia, a 
reciprocal phenotype to that of transgenic mice overexpressing IGF-I under the control of the same 
promoter. Double transgenic mice derived from mating IGFBP-4 with IGF-1 transgenic animals 
show a modest decrease in wet weight at selected SMC tissues. These data suggest that IGFBP-4 is 
a functional antagonist of IGF-I action on SMC in vivo. In support of this, others have shown that 
IGFBP-4 can inhibit IGF-I induced DNA synthesis in human vascular smooth muscle cells 
(Andersson et al, 1999).
IG F BP-6. Due to its low affinity for IGF-I, any IGFBP- 6  inhibitory effects are mainly 
restricted to IGF-II action. IGFBP- 6  is an O-linked glycoprotein, and Marinaro, et al (2000) 
reported that O-glycosylation stimulates the inhibitory effects of IGFBP-6 . The half-life of O- 
glycosylated IGFBP- 6  was 2.3 fold greater than that of non-giycosylated IGFBP-6 , however this O- 
glycosylation did not inhibit intravascular proteolysis of IGFBP-6 , suggesting that O-glycosylation 
delays the clearance of IGFBP- 6  from the circulation and therefore contribute to its role as an 
inhibitor of IGF-II actions. In the ovary, follicle-stimulating hormone (FSH) and luteinizing 
hormone (LH) stimulate IGFBP- 6  secretion which in turn inhibits IGF-I stimulated steroidogenesis, 
although less potently then IGFBP-2 or 4 (Jones and Clemmons, 1995). IGFBP- 6  also inhibits IGF- 
II, but not IGF-I, induced differentiation of myoblasts (Bach et al, 1994). As described for other
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IGFBPs, IGFBP- 6  expression can be subjected to TGF-P regulation which has been shown to 
decrease IGFBP- 6  mRNA in osteoblasts (Gabbitas and Canalis, 1997).
IGFBP- 6  secretion in keratinocytes, myoblasts and neuroblastoma cells increases when 
cells undergo growth arrest (Chambery et al, 1998). These authors were also able to show that 
differentiation of neuroblastoma cells induced by retinoic acid caused a reduction in IGFBP-2 and -
4 expression, but increased IGFBP- 6  expression. They postulated that the function of IGFBP- 6  in 
these cells might be to sequester endogenous IGF-II from interacting with the IGF-I-R. Overall, 
from both in vitro and in vivo studies, there is an indication that IGFBP- 6  might play a growth 
inhibition role in a wide range of cell tumours (breast carcinoma, prostate carcinoma, endometrial 
carcinoma, neuroblastoma) (Sheikh et al, 1993; Bach and Rechler, 1996; Drivdahl et al, 1995; 
Gong et al, 1992; Babajko and Binoux, 1996).
IG F BP-S, As reviewed in Clemmons (1997), IGFBP-5 was shown to inhibit IGF-I and 
II-stimulated DNA and glycogen synthesis in human osteosarcoma cells (Kiefer et al, 1992), and 
decrease the IGF-I stimulated steroidogenesis in Leydig cells (Liu et al, 1993b). In addition, when 
IGFBP-5 was added in the presence of IGF-II, it inhibited both proliferation and differentiation in 
L6A1 muscle cells, whereas interestingly, in the presence of IGF-I, it stimulated all aspects of the 
myogenic response to the growth factor (Ewton et al, 1998).
In some of the experiments designed to investigate the biology of this binding protein it 
was noted that a correlation existed between the occurrence of apoptosis and the increased 
expression of IGFBP-5. Guennette and Tenniswood (1994) reported that IGFBP-5 expression 
increases in involuting prostate concomitant with apoptosis in this tissue. In addition, a correlation 
between IGFBP-5 expression and apoptosis was also noted in finasteride or castration-induced 
prostate involution (Thomas et al, 1998), in ovarian atretic follicles (Erickson et al., 1992), in rat 
involuting mammary gland (Tonner et al, 1995, 1997) and in the involuting thyroid (Phillips et al, 
1994). Guennette and Tenniswood (1994) proposed a model to explain the specific role played by 
different IGFBPs during the involution of the prostate gland, and this is discussed below.
Pro-apoptotic m odel fo r IG F B P S  action. In this model it was postulated that IGFBP-
5 could exert a pro-apoptotic effect by sequestering the IGFs to the ECM and thereby preventing 
the interaction of the growth factors with IGF-I-R on the cell surface. In turn, this would inhibit the
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cell survival signalling action of the IGFs and allow apoptosis to proceed. (Figure 1.7). To 
exemplify this model, we will use the association of IGFBP-5 expression with apoptosis of 
mammary epithelial cells in the involuting mammary gland, as this is part of the ongoing research 
programme within our laboratory.
First, it has been established IGF-I can act as a survival factor for many different cell types 
including mammary epithelium (O’Conner, 1998). Several transgenic models have confirmed this 
survival effect of IGF-I, where overexpression of this growth factor within the mammary gland was 
shown to retard mammary gland involution after removal of the suckling young (Hadsell et al, 
1996; Neuenschwander et al, 1996). Interestingly, IGFBP-5 expression in the lactating mammary 
gland has been shown to occur at very low level, comparable to that found in normal serum (Tonner 
et al, 1997). However, these authors demonstrated that there was a very large increase in both 
IGFBP-5 mRNA and protein expression within the involuting mammary gland, concomitant with 
apoptosis of mammary epithelial cells. Therefore, they hypothesized that one of the early events 
associated with mammary gland involution is the secretion of IGFBP-5, which in turn serves to 
inhibit IGF-I-mediated cell survival. In support of these findings, others have also shown that 
prolactin, which suppresses IGFBP-5 expression, can inhibit apoptosis (Travers et al, 1996), 
whereas teat sealing, which should increase IGFBP-5 expression, is associated with increased levels 
of apoptosis (Quarrie et al, 1996). However, Lund et al (1996) demonstrated that glucocorticoids, 
which do not have a demonstrated relationship with IGFBP-5 expression, only effect the later, 
second phase of involution occurring 3-4 days after litter removal, and this is consistent with the 
hypothesis that IGFBP-5 is involved in the initial stages of apoptosis.
A high affinity interaction has also been demonstrated between IGFBP-5 and the casein 
micelle fraction of milk (Tonner et al, 1997). Indeed, IGFBP-5 binds with high affinity to 
hydroxyapatite (a crystalline form of calcium phosphate) in bone (Mohan, 1993), and casein 
micelles also possess calcium phosphate nanoclusters (Holt, 1985). Therefore, as an alternative to 
IGFBP-5 sequestering IGFs to the ECM, it has been suggested that the binding protein may induce 
apoptosis of mammary epithelial cells by sequestering IGF-I to casein micelles, thereby inhibiting 
its survival function. However, the interaction of IGFBP-5 with the mammary epithelial cell surface 
cannot be ruled out, as has been proposed for endothelial cells (Booth et al, 1995), or the possibility
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Figure 1.7 Pro-apoptotic model of IGFBP-5
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that apoptosis of these cells involves IGFBP-5 mediated cell signalling (Andress, 1995). In the 
involuting mammary gland, the majority of IGFBP-5 is found in the intact form, although a number 
of active proteolytic enzymes have been identified there (Tonner et al, 1997).
Finally, the plasminogen activation system is also involved in tissue remodelling and 
apoptosis, and this provided a further route for IGFBP-5 action. IGFBP-5 has been shown to bind 
plasminogen-activating inhibitor-I (PAI-I), through the basic amino acid region in the C-terminus 
of the binding protein (201-218) (Nam et al, 1997). More recently, it was shown that IGFBP-5 also 
binds to the milk protein aS2-casein and, in particular, to its dimeric form (Tonner et al, 2000). 
Dimeric aS2-casein has also been shown to bind to both plasminogen and t-PA (tissue-type 
plasminogen activator), and this binding results in the enhanced activity of t-PA, thereby enhancing 
the conversion of plasminogen to plasmin (Heegaard et al, 1997). Plasmin plays a central role in 
cleaving a number of pro-enzymes, such as procollagenases, and thereby initiating the degradation 
of the ECM at the end of lactation when extensive tissue remodelling occurs (Matrisian, 1990). 
Therefore, the close physical proximity of IGFBP-5 and components of the plasminogen system on 
the casein micelle suggest a possible functional interaction, supported by the observation that 
IGFBP-5 binds to PAI-I (Nam et al, 1996). As PAI-I binds to t-PA and inhibits its actions, it is 
conceivable that IGFBP-5 plays a dual role in tissue remodelling/apoptosis of the mammary gland: 
1) IGFBP-5 activates cell death by sequestration of IGF-I, and 2) IGFBP-5 activates plasminogen 
cleavage by sequestering PAI-1 (Tonner et al, 2000). In support of this, both prolactin and GH 
inhibit t-PA activity and plasminogen activation in the involuting mammary gland (Tonner et al,
2000). In conclusion, IGFBP-5 may have a central role in co-ordinating cell death and tissue 
remodelling processes.
1.4.3 Stimulation of IGFs action
IG F B P -1 . As reviewed in Clemmons (1997), potentiation of IGF effects by IGFBP-1 is 
generally observed when the non-phosphorylated isoform of the binding protein is used, or when it 
is added at low concentrations (Elgin et al, 1987; Busby et al, 1988). IGFBP-1 enhanced IGF-I, but 
not IGF-H, stimulated proliferation in human keratinocytes and skin fibroblasts (Kratz et al, 1992)
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and increased DNA synthesis in human, mouse embryo fibroblasts (Schuller et al, 1993). In 
contrast to the aforementioned inhibitory effect o f IGFBP-1 in pSMC, this binding protein was 
reported to increase the IGF-I-stimulated 3[H]'thymidine uptake 4.8-fold, while IGFBP-2 increased 
this IGF action 2.2-fold under the same conditions (Bouraer et al, 1992).
IG F B P S .  As reviewed in Clemmons (1997), stimulation of IGF action by IGFBP-3 is 
mainly thought to involve sequestering IGFs to cell surfaces (Baxter, 1988; Conover et al, 1992). 
When either recombinant human glycosylated or non glycosylated IGFBP-3 was incubated with 
bovine fibroblasts, it associated to the cell monolayer, and provided an additional low affinity 
binding site for 125I-IGF-I (Conover, 1992). After 72h pre-incubation of the cells with IGFBP-3, 
aminoisobutyric acid (AIB) and thymidine uptake stimulated by IGF-I, insulin and [QAYLJIGF-I 
(which has full affinity for IGF-I-R and reduced affinity for IGFBP-3) were potentiated. Cell 
responsiveness to the growth factors correlated with their affinity for IGF-I-R, but not their affinity 
for IGFBP-3. It could be hypothesized that IGFBP-3 localizes IGF-I on the cell membrane and 
slowly releases it to the receptor, thus preventing the down regulation of IGF-I-R activity that is 
induced by an excess of IGF.
The human colon cancer cell lines COLO205, HT29 and SW620 are known to secrete 
IGF-II and IGFBPs. Michell et al (1997) characterized the sensitivity of these cell lines to 
exogenous IGF-I and examined the effects of their autocrine IGFBPs on these responses. Cells 
cultured in serum-free medium were treated with l-100ng/ml IGF-I, or des[l-3]IGF-I (a truncated 
IGF-I which does not appreciably bind IGFBPs), and DNA synthesis was determined by 24h 
incorporation of 3 [H]-thymidine. Experiments were repeated in the presence of 24h cell-conditioned 
media containing endogenous IGFBPs. In all three cell lines, cell-conditioned media reduced the 
sensitivity to IGF-I but not to des[l-3]IGF-I suggesting that IGFBPs in the cell-conditioned media 
of colon cells inhibit IGF-I action. IGFBP-4 was identified in all cell lines and IGFBP-2 from the 
COLO205 and SW620 cell lines, but not the HT29 cells. No IGFBP-3 was identified in the 24h 
cultured conditioned media, but IGFBP-3 was found in the cell membrane of all three cell lines. 
Interestingly, when endogenous secreted IGFBPs were removed, the cell lines were consistently 
less sensitive to des[l-3]IGF-I suggesting that IGFBP-3 associated with the cell layer enhances 
responses to IGF-I. In addition, Giannini et al (1999) showed that IGFBP-3 is involved in growth
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regulation of human glomerular endothelial cells (GENC). When they added IGFBP-3 antibody to 
the culture media, cell proliferation was significantly reduced, whereas recombinant human IGFBP- 
3 alone had no effect on these cells. However, after 48h pre-incubation with IGFBP-3 the IGF-I 
stimulated GENC growth was increased, suggesting that IGFBP-3 could potentiate the IGF-I 
induced GENC proliferation.
Both IGFBP-3 and transforming growth factor-beta (TGF-0) have been separately shown 
to have cell-specific growth-inhibiting or growth-potentiating effects (Oh et al, 1995). TGF-P 
stimulates IGFBP-3 mRNA and peptide expression in several cell types, and TGF-P-induced 
growth inhibition and apoptosis have been shown to be mediated through the induction of IGFBP-3 
(Oh et al, 1995). Cohen et al. (2000) reported that TGF-P treatment of airway smooth muscle 
(ASM) cells resulted in a 10- to 20-fold increase in IGFBP-3 mRNA and protein expression. 
Addition of either IGFBP-3 or TGF-P to the culture medium also resulted in an approximately two­
fold increase in cell proliferation. Coincubation of ASM cells with IGFBP-3 antisense oligomers as 
well as with an IGFBP-3 neutralising antibody blocked the growth induced by TGF-p. These 
findings suggest that IGFBP-3 is capable of mediating the growth stimulatory effect of TGF-P in 
ASM cells.
IG F BP-S. As reviewed in Clemmons (1997), stimulatory effects of IGFBP-5 have been 
reported in various cell lines. These effects may be dependent upon the form of IGFBP-5 present. 
For example, ECM-associated IGFBP-5 enhanced human fibroblast growth in response to IGF-I 
treatment, while the binding protein in the conditioned medium was degraded to a 21kDa fragment 
that lacked any potentiating effects (Jones et al, 1993b). In bone cells, as with smooth muscle cells, 
IGFBP-5 has been reported to have both cell proliferation and differentiation promoting effects 
(reviewed by Clemmons, 1997). In human osteoblast-like cells both IGFBP-5 and its carboxy- 
truncated 23kDa fragment enhanced IGF-I and IGF-II stimulated mitogenesis (Andress el al, 1993). 
IGFBP-5 also appears to stimulate proliferation of these cells by both IGF-dependent and 
independent pathways (Andress and Bimbaum, 1992). During the differentiation process in 
MC3T3-E1 mouse osteoblasts, IGFBP-5 secretion increases in the initial cell proliferation period 
and it reaches its peak at the start of differentiation, after which it declines (Thraikill et al, 1995b). 
In contrast, it has been noticed that in rat osteoblasts, growth factors which stimulated cell
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proliferation, such as FGF, TGF-P and PDGF, decreased the expression of IGFBP-5, IGF-I and 
IGF-II (Canalis and Gabbitas, 1995), while factors that stimulated cell differentiation, (namely IGFs 
and retinoic acid), increased IGFBP-5 expression (Conover and Kiefer, 1993; Dong and Canalis, 
1995; Gabbitas and Canalis, 1998). Cortisol, which is an inhibitor of multiple parameters of bone 
formation, including cell proliferation, reduced IGFBP-5 expression and its deposition onto the 
ECM (Gabbitas et al, 1996).
Recently Kanatani et al. (2000) reported the effects o f IGFBP-5 on osteoclastic activity 
and osteoclast formation. These observations demonstrated both IGF-dependent and IGF- 
independent regulation of IGFBP-5. IGFBP-5 significantly stimulated pit formation by pre-existent 
osteoclasts in mouse bone cell cultures and its stimulatory effect was completely blocked by an 
IGF-I antibody (Ab). However, IGFBP-5 did not affect the bone-resorbing activity of isolated 
rabbit osteoclasts. A direct effect of IGFBP-5 on osteoclast precursors was also examined and it 
was shown that IGFBP-5 stimulated osteoclast-like cell formation from osteoclast precursors in a 
dose dependent manner, irrespective o f the presence of IGF-I Ab. The present data indicate that 
IGFBP-5 stimulates bone resorption both by stimulation of osteoclast formation in an IGF-I- 
independent fashion and by IGF-I-dependent activation of mature osteoclasts, possibly via 
osteoblasts.
As with bone cells, there are contrasting results published suggesting that IGFBP-5 
potentiates either the proliferating or the differentiating effect o f IGF peptides on smooth muscle 
cells (SMC). In porcine SMC transfected with IGFBP-5 cDNA the expressed protein accumulated 
in the ECM more abundantly than in the control cells and it potentiated the IGF-I stimulation of 
DNA synthesis. Conversely, the transfection of pSMC cells with IGFBP-5 mutants which have 
reduced ECM binding affinity, resulted in an inhibition of IGF-I stimulated DNA synthesis (Parker 
et al, 1998).
Similar results in terms of potentiation of IGF stimulated 3[H]-thymidine uptake were 
obtained in SMC when monolayers were incubated for 48h with IGFBP-5. (Clemmons, 1998). It 
was suggested that, in order to achieve an IGF enhancing effect, IGFBP-5 had to be proteolyzed 
into a 21kDa fragment, which retained the ability to associate to the ECM but had greatly reduced 
affinity for IGFs. This theory is further strengthened by the observation that a proteolysis resistant
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IGFBP-5 mutant had an IGF inhibitory effect in the same culture conditions (Duan and Clemmons,
1998). In this latter study it was shown that IGFBP-5 and IGF expression is high in proliferating 
cells and declines when cells reach confluence. In contrast, other authors report that in L6A1 
muscle cells (Ewton et al, 1998) and in C2 mouse myoblasts (Rousse et al, 1998) IGFBP-5 
expression increases during cell differentiation. In L6A1 cells IGFBP-5 expression was higher in 
differentiating cells and the binding protein showed an inhibitory effect on IGF stimulated 
proliferation and a potentiating effect on cell differentiation stimulated by IGF-I but not IGF-II 
(Ewton et al, 1998).
1.4.4 IGF-independent functions
The discovery of IGF-independent modulation of growth by IGFBPs provided evidence 
for the presence of specific cell-surface IGFBP receptors and added a further layer of complexity to 
the IGF axis. These actions are more accurately described as IGF-I-R independent, because they 
may be modulated by IGF binding without requiring the presence of the IGF-I-R. Such actions are 
likely to involve structural domains of IGFBPs that are distinct from the IGF-binding determinants.
IG F B P -1  The first characterized of these domains is the Arg-Gly-Asp (RGD) integrin- 
binding motif present in the carboxy-terminu
s of IGFBP-1 and -2 , but not in any other IGFBP. The interaction of the C-terminal RGD 
sequence of IGFBP-1 with the cellular a 5Pi integrin (fibronectin receptor) on the cell surface has 
been described (Jones et al, 1993a). Post-translational modifications might influence this binding as 
it has been reported that only the phosphorylated form of IGFBP-1 can associate with the cell 
surface (Chan and Spencer, 1997). Integrins that have been considered principally as adhesion 
molecules are now increasingly reported to be involved in cellular signaling events (reviewed by 
Baxter, 2000). The integrin a  subunit is responsible for ligand specificity, while the P subunit 
determines the signal specificity, which means that the stimulation by different ligand molecules 
can lead to the same cellular response.
Cell migration is a complex phenomenon resulting from the interaction between several 
growth factors, the cells and the extracellular matrix (Gockerman et al, 1995). Therefore a
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combination of factors, including the integrin type expressed on the cell surface and the cellular 
substratum, can affect the ability of a molecule to stimulate cell migration. IGFBP-1 stimulates cell 
migration in CHO cells (Jones et al, 1993a) and in pSMC cells seeded on fibronectin coated plates 
(Gockerman et al, 1995). The RGD sequence appears to be essential for this stimulation to occur as 
demonstrated by the inhibition of the IGFBP-1-stimulated cell migration by a competitive RGD 
peptide or by the inability of a WGD-IGFBP-1 mutant to stimulate cell migration. It has been 
shown that fibronectin inhibits cell migration in CHO cells overexpressing a 5Pi integrin (Giancotti 
and Ruoslahti, 1990) and although it is involved in cell adhesion, it does not facilitate cell migration 
in pSMC cells (Clark, 1993). Therefore IGFBP-1 stimulation of cell migration could result from its 
competition with fibronectin to bind (X5P1 integrin. (Gockerman et al, 1995).
IGF-I and II alone are also potent stimulators of pSMC cell migration on fibronectin 
coated plates (Gockerman et al, 1995). In this case, IGFBP-1 was shown to exert an inhibitory 
effect on IGF-stimulated migration by antagonizing the binding of the growth factors to IGF-I-R. 
IGF-I also promotes pSMC cell migration on vitronectin coated plates, but in this case both the 
stimulation of the IGF-I-R by IGF-I and the ligand occupancy of 0 ^ 3  integrin (vitronectin receptor) 
appear to be necessary (Jones et al, 1995). The addition of either IGFBP-1 to antagonize IGF/IGF-
I-R interaction or OvP3 integrin competitors (such as echistatin and kistrin) inhibits this IGF-I- 
stimulated cell migration (Jones et al, 1995).
IG F B P -3 and -5. Apart from IGFBP-1, the only other proteins for which IGF-I-R 
independent functions have been demonstrated are IGFBP-3 and -5.
Study o f Hs578T human breast cancer cells has demonstrated that IGFBP-3 is the major 
IGFBP species secreted and that it associates with cell surface membranes (Oh et al, 1992). This 
work suggested that IGFs may specifically regulate the concentration of IGFBP-3 in Hs578T 
conditioned medium (CM) through non-receptor mediated dissociation of cell surface-associated 
IGFBP-3. The same group presented work which suggested the existence of a specific IGFBP-3 
receptor in Hs578T cells (Oh et al, 1993a-c). They demonstrated that both exogenous and 
endogenous IGFBP-3 binds to the Hs578T cell surface and inhibits cell proliferation stimulated by 
IGF-I, but not that by IGF analogs with reduced affinity for IGFBP-3. By cross-linking l25I-IGFBP- 
3 to the cell monolayer and subsequently immune precipitating the cell lysate with antibodies raised
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against IGFBP-3, three cell surface proteins (20, 26 and 50 kDa) were identified with IGFBP-3 
binding properties. Therefore, the authors proposed that the IGFBP-3 inhibitory effect on cell 
proliferation could be mediated through a specific IGFBP-3 receptor.
In addition, it was shown that substances that inhibited Hs578T cell growth, such as TGF- 
p2 (transforming growth factor), anti-estrogens and retinoic acid, induced an increase of IGFBP-3 
expression (Oh et al, 1995). TGF-P-induced growth arrest was also significantly reversed by 
transfecting the cells with antisense IGFBP-3. Furthermore, IGF-II and Leu27 IGF-II (which has 
wild-type affinity for IGFBP-3, but reduced affinity for IGF-I-R) were able to reverse TGF-P 
stimulated growth suppression, whereas treatment with an IGF-II analogue (which has reduced 
affinity for IGFBP, but wild type affinity for IGF-I-R) could not. These data indicate that the 
mechanism by which transforming growth factor-P (TGF-P) supresses cell growth cannot simply be 
explained by an increase in IGFBP-3 and subsequent sequestration of IGFs from IGF-I-R, and 
suggests that IGFBP-3 acts in an IGF-independent fashion (Oh et al, 1995). Related to this, Leal et 
al. (1997) suggested that the type V TGF-P receptor is a putative cell surface associated IGFBP-3 
receptor in mink lung epithelial cells. They also found IGFBP-4 and -5  (less potent than IGFBP-3) 
are additional ligands for the type V TGF-P receptor, which mediates the growth inhibitory 
response through signaling pathways distinct from that mediated by the TGF-P heterocomplex 
(Leal et al, 1999). Further support for a specific IGFBP-3 receptor came from a study where it was 
shown that IGF-I-R-negative mouse fibroblasts displayed lower growth rate compared to the 
controls when transfected with human IGFBP-3 (Valentinis et al, 1995). Moreover, several reports 
have shown that IGFBP-3 fragments derived by limited plasmin proteolysis were able to inhibit 
IGF-stimulated mitogenesis and even the mitogenic effect of insulin, despite their reduced affinity 
for IGF (Oh, 1997).
In the prostate cell line, PC-3, IGFBP-3 fragments derived by plasmin digestion displayed 
the opposite biological effect to those described above (Oh, 1997). Intact IGFBP-3 was able to 
increase cell proliferation and a fragment of IGFBP-3 containing residues 1-169 (1169IGFBP-3) was 
almost three times more effective than the wild type molecule. This effect is probably due to a 
modulation of endogenous IGF-II-induced cell proliferation as it is markedly reversed by an anti- 
IGF-I-R monoclonal antibody (aIR-3). In contrast, a 195IGFBP-3 fragment, derived from further
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digestion of the 1-169 peptide, reduced cell proliferation to 50% of basal levels. This fragment 
which does not bind IGF-II, was able to reverse IGF-II induced cell proliferation even when the 
accessibility o f IGF-I-R was blocked with the addition of aIR-3 (Angelloz-Nicoud et al, 1998). This 
data confirms previous work which described the growth inhibitory effect of the 1_95IGFBP-3 
fragment in mouse fibroblasts with targeted disruption of IGF-I-R gene (Mohseni-Zadeh and 
Binoux, 1997). Therefore, these data suggest that M69IGFBP-3 has IGF-I-R dependent effects on 
cell proliferation, whereas l_95IGFBP-3 has an inhibitory effect on cell proliferation through an IGF- 
I-R independent manner.
Yamanaka et al. (1999) evaluated IGFBP-3 binding sites on breast cancer cell membranes 
by competitive binding studies with IGFBP-1 through - 6  and various forms of IGFBP-3, including 
synthetic IGFBP-3 fragments. Among the IGFBPs, only IGFBP-5 showed weak competition, 
indicating that IGFBP-3 binding to breast cancer cell surfaces is specific. This was confirmed by 
showing that synthetic IGFBP-3 peptides containing IGFBP-3 glycosaminoglycan-binding domains 
competed only weakly for IGFBP-3 binding to the cell surface. Rat IGFBP-3 was 20-fold less 
potent in its ability to compete with human IGFBP-3, as well as 10- to 20-fold less potent for cell 
growth inhibition than human IGFBP-3. When various IGFBP-3 fragments were evaluated for 
affinity for the IGFBP-3 receptor, only those fragments that contain the midregion of the IGFBP-3 
molecule were able to inhibit IGFBP-3 binding, indicating that the midregion of the IGFBP-3 
molecule is responsible for binding to its receptor (Yamanaka et al, 1999).
An alternative method of interaction between the cells and IGFBPs has recently been 
described for IGFBP-3 and -5 when they were shown to translocate to the cell nucleus. Using 
immunofluorescence, IGFBP-3 was detected in the nucleus of proliferating human keratinocytes 
and laser scanning confocal microscopy confirmed that the binding protein was present in the 
nucleus and not in the perinuclear spaces (Wraight et al, 1998). Nuclear uptake of fluorescently 
labeled IGFBP-3 and 5 was demonstrated in proliferating human breast cancer cells after 90 
minutes, whereas no nuclear uptake was observed after the addition of an equivalent amount of 
labeled IGFBP-1 and 2, although all labeled proteins were shown to associate to the cell membrane 
(Schedlich et al, 1998). Both IGFBP-3 and 5 contain a NLS sequence (nuclear localization signal) 
inside the C-terminal 18 residue sequence (215-232 for IGFBP-3 and 201-218 for IGFBP-5) that is
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also involved in heparin/GAGs and ALS binding (Radulescu, 1994). Based on this structural study 
of IGFBP-3, the same group used immunocytochemistry to identify the nuclear localization of 
IGFBP-3 in a lung cancer cell line where IGFBP-3 antibodies specifically stained the nuclei (Jaques 
et al, 1997). This finding suggests the possibility that nuclear IGFBP-3 is functional and involved in 
the pathogenesis of lung cancer.
The NLS motif is a bipartite nuclear targeting sequence found in many nuclear proteins 
and consists of 2 basic residues followed by an interval of 10-11 amino acids and then at least 3 
basic residues within the next 5 positions. Schedlich et al. (1998) reported that substitution of the 
(228KGRKR) IGFBP-3 sequence with the corresponding (MDGEA) IGFBP-1-derived sequence 
abolishes nuclear uptake (Schedlich et al, 1998). IGFBP-3 nuclear localization does not seem to be 
affected by lysosomotropic inhibiting agents nor by microtubule disrupting agents, suggesting the 
internalization and translocation occurs through an alternative pathway (Schedlich et al, 1998). 
Furthermore, Schedlich et al. (2000) describes the mechanism for nuclear import of IGFBP-3 and 
IGFBP-5. In digitonin-permeabilised cells where the nuclear envelope remains intact, nuclear 
translocation of wild type IGFBP-3 appears to occur by a nuclear localisation sequence (NLS)- 
dependent pathway mediated principally by the importin-p, nuclear transport factor, and requiring 
both ATP and GTP hydrolysis. In cells where both the plasma membrane and nuclear envelope 
were permeabilized, wild-type IGFBP-3, but not the mutant form (MDGEA), accumulated in the 
nucleus, implying that the NLS was also involved in mediating binding to nuclear components. By 
fusing wild type and mutant forms of NLS sequences (IGFBP-3 [215-232] and IGFBP-5 [201-218]) 
to the green fluorescent protein, they identified the critical residues of the NLS necessary and 
sufficient for nuclear accumulation. Using westem-ligand binding assays, wild-type IGFBP-3 and 
IGFBP-5, but not an NLS mutant form of IGFBP-3, were shown to be recognised by importin-P 
and the alpha/beta heterodimer, but only poorly by importin alpha. These results suggest that the 
NLS within the C-terminal domain of IGFBP-3 and IGFBP-5 are required for importin-P-dependent 
nuclear uptake, and probably also accumulation through mediating binding to nuclear components 
(Schedlich et al, 2000). Finally, although IGFBP-3 preferentially binds to the cell surface, it can 
also associate to ECM, although less potently in comparison with IGFBP-5 (Jones et al, 1993b; 
Imai et al, 1997).
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Andress and Bimbaum (1992) reported that a purified 23kDa fragment of IGFBP-5 from 
cultured human osteoblast-like cells enhanced mitogenesis. This effect was unique from other 
binding proteins in not requiring a preincubation period or serum co-factors, and furthermore, the 
mitogenesis was stimulated by endogenous IGFBP-5 without exogenous or endogenous IGFs. 
Therefore, the authors suggested that this was an IGF-independent action of IGFBP-5 (Andress and 
Bimbaum, 1992). Similar results reported that IGFBP-5 potentiated bone cell proliferation even in 
the absence of IGFs, suggesting an IGF-independent mechanism involving IGFBP-5-specific cell 
surface binding sites (Mohan et al, 1995). Moreover, in cultured mouse osteoblast cells, 
recombinant carboxyl-truncated IGFBP-51' 169 has been demonstrated to be able to bind to osteoblast 
monolayers and stimulate mitogenesis without exogenous IGF-I (Andress et al, 1993). While it was 
proposed that this intrinsic mitogenic action of truncated IGFBP-5 was mediated by cell surface 
binding, the exact mechanism of IGFBP-5 binding to osteoblasts was not determined. 
Subsequently, the same author has presented evidence for the existence of a 420kDa osteoblast cell 
membarane protein that acts as an “IGFBP-5 receptor” (Andress, 1995). This work described the 
purification of the putative receptor using IGFBP-5 affinity chromatography and also demonstrated 
that IGFBP-5 binding to the receptor was not competed by solubilized heparan sulfate 
proteoglycan. In conclusion, the author suggests that this 420 kDa membrane protein may be 
involoved in receptor-mediated signal transduction, since earlier studies demonstrated that IGFBP- 
51-169 directly stimulates mitogenesis in mouse osteoblasts (Andress et al, 1993). In support of this, 
the same author has more recently presented evidence for serine phosphorylation of the 420 kDa 
protein as a result of binding by intact IGFBP-5, IGFBP-51' 169 or IGFBP-5201' 218 peptides (Andress, 
1998).
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1.5 Aims of study
Recent work from our laboratory has addressed the role of IGFBP-5 in the developing 
mammary gland. First, we have observed up-regulation of IGFBP-5 expression during apoptosis of 
mammary epithelial cells in the involuting mammary gland (Tonner et al, 1995 and 1997). As 
discussed above, a pro-apoptotic model has been proposed to account for this effect of IGFBP-5. In 
this model, IGFBP-5 sequesters IGFs to casein micelles, prevents growth factors/receptor 
interaction, and thereby initiates apoptosis. Second, an IGF-independent role of IGFBP-5 has been 
suggested in remodelling of ECM in the mammary gland via up-regulation of the plasminogen 
system. Here IGFBP-5 is proposed to sequester PAI-I to casein micelles, thereby enhancing tissue t- 
PA levels, which, in turn, results in production of the ECM degrading enzyme, plasmin. In order to 
increase our understanding of these potential IGFBP-5 functions, the work described in this thesis 
was focussed on the relationship between the binding protein's structure and its important molecular 
interactions.
The aims of this study were:
1) To assess the separate contributions of the N- and C-terminal domains of IGFBP-5 with 
respect to IGF binding.
2) To identify specific amino acids within the IGFBP-5 protein sequence that are 
important IGF binding determinants, with the aim of producing a mutant that cannot bind IGFs.
3) Based on the pro-apoptotic model of IGFBP-5 action, to further investigate sequences in 
the binding protein involved in ECM binding, using the ECM glycosaminoglycan heparin as a 
model. Furthermore, to produce an IGFBP-5 mutant which cannot bind heparin/ECM.
4) To produce a variety of IGFBP-5 mutants that are defective in important molecular 
interactions, which can then be used to test the biological functions of the binding protein in 
appropriate cell systems.
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Chapter II. Materials and Methods
General laboratory chem icals and  reagents were supplied by BDH (Poole, Dorset, 
UK) and by Fisher Scientific (Loughborough, Leicestershire, UK). Unless specified otherwise, 
most of the other chemicals were from Sigma (Poole, Dorset, UK). Cell culture media and 
supplements were supplied by Gibco BRL, Life Technologies (Paisley, UK) or Sigma, and 
molecular biology reagents were from Boehringer Mannheim (East Sussex, UK), Promega 
(Southampton, UK) or New England Biolabs (Hertfordshire, UK). Cell culture plasticware was 
supplied by Costar (Bucks, UK) or Greiner Labortechnik (Stonehouse, Glos, UK). Water (tissue 
culture grade) was from Life Technologies, otherwise double distilled tap water was used. Unless 
otherwise stated, all centrifugations of Eppendorf tubes were carried out with bench top microfuge 
(MSE microcentaur), while centrifugations necessary for cell culture routine mantainance and 
experimental work were conducted in a MSE mistral 2000 centrifuge (MSE Loughborough, 
Leicestershire, UK).
11.1 Solutions/Buffers and basic methodologies
11.1.1 Solutions and buffers
A. Nucleic acid work
10 X  TBE (Tris Borate EDTA)
1M Tris-HCl, 0.9M Boric acid, 0.01M EDTA, pH 8.4.
10 X  TAE (Tris Acetate EDTA)
0.4M Tris, 0.2M Na acetate, 0.01M EDTA, pH7.2 with glacial acetic acid.
5 X  Orange G (electrophoresis loading DNA sample buffer) 
lOOmM EDTA, 20% (w/v) Ficoll, 0.1% (w/v) Orange G.
TE buffer
lOmM Tris-HCl, pH8.0, ImM EDTA, Autoclaved.
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LB (Luria-Bertaini) medium
1% (w/v) Tryptone (Oxoid, Hampshire, UK), 0.5% (w/v) Yeast extract, 0.5% (w/v) Sodium 
Chloride, pH 7.5, Autoclaved.
LB aaar plate
LB medium, 1.5% (w/v) Agar (Oxoid, Hampshire, UK), pH 7.0. Autoclaved and with 
addition of appropriate antibiotics.
Antibiotic stock solutions
Ampicillin 125mg/ml in H20 , Tetracycline 12.5mg/ml in 80% (v/v) ethanol, Kanamycin 
lOmg/ml in H20 , Gentamycin 7mg/ml in H20 .
B. Baculovirus expression system
Formvl buffered Acetone (4ml)
1.2ml Phosphate buffered saline, 1ml 37% (v/v) formaldehyde solution, 1.8ml Acetone. 
Bacmid selection LB plates
Autoclaved LB agar, 50pg/ml Kanamycin 7pg/ml, Gentamycin lOpg/ml, Tetracycline 
40pg/ml, IPTG 200pg/ml, 5-bromo-3-indolyl-P-D-galactopyranoside.
C. Protein purification
Equilibrium buffer
0.5M Sodium Chloride, 50mM Tris-HCl, pH 6.5.
Basic washing buffer
0.1M Tris-HCl, 0.5M Sodium chloride, pH 8.5.
Acidic washing buffer
0.1M Sodium Acetate, 0.5M Sodium Chloride, pH 4.5.
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Elution buffer
0.5% (v/v) Acetic acid, pH 3.0.
Concentrated Tris buffer 
2M Tris base. 
Column stroraae buffer
50mM Tris-HCl, 0.5M Sodium Chloride, pH 7.4, 0.01% (w/v) Sodium azide.
D. lodination
Radio Immuno Assay (RIA) buffer per litre
30mM Sodium Chloride, 60mM Sodium Phosphate, 0.25mM Thimerosal, 0.5% (w/v) 
BSA, pH 7.4.
Sodium Phosphate solution (Pi)
0.5M Sodium Phosphate, pH 7.0.
E. Protein electrophoresis and blotting
1 X  Sample buffer (SDS-paae protein ael loading buffer)
0.8M Tris-HCl, 2% (w/v) SDS, 10% (v/v) Glycerol, 1.2% (w/v) Bromophenol blue, pH 6 .8 , 
Adding 5% (v/v) |3-mercaptoethanol for the reducing gel.
10% SDS
10% (w/v) Sodium dodecyl sulfate in distilled H20 .
10 X  Running buffer (protein ael electrophoresis buffer)
0.25M Tris base, 2M Glycine, 1% (w/v) SDS.
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10 X  Blotting buffer (Gel to membrane transfer buffer)
0.25M Tris base, 2M Glycine, 20% (v/v) methanol.
10 X  TBS (Tris buffered saline)
0.1M Tris-HCl, 530mM Sodium Chloride, pH 7.6, + 0.5% (v/v) Tween-20 for TBS-
Tween.
10 X  PBS (Phosphate buffered saline) per litre
0.1M Sodium Chloride, lOmM di-Sodium hydrogen orthophosphate, lOmM Sodium 
dihydrogen orthophospate, pH 7.0, + 0.5% (v/v) Tween-20 for PBS-Tween.
F. Charcoal binding solution phase assay
1 X  Charcoal binding solution assay buffer 
50mM Tris-HCl, 0.5% (w/v) BSA, pH 7.4. 
1 X  Charcoal binding solution
1% (w/v) activated charcoal (Sigma), 50mM Tris-HCl, 0.5% (w/v) BSA,pH 7.4, 0.2% 
(w/v) Protamine sulfate.
11.1.2 Preparation of Gels
A. DNA Gels
Agarose gels
1% (w/v) high gelling temperature agarose (Promega) in lxTBE buffer and 0.5pg/ml of 
ethidium- bromide (Biorad, Hertfordshire,UK ). Size markers were purchased from Promega; these 
were m in d lll (23130, 9416, 6557,4361,2322, 2027, 564 and 125 base pairs) and <J>xl74 (1353, 
1078, 872, 603, 310, 281, 271, 234, 194,118 and 72 base pairs).
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B. Protein Gels
4% Stacking ael
0.25M Tris-HCl, 4% (w/v) total acrylamide (ratio 37.5:1 -  bisacrylamide), 0.1% (w/v) 
SDS, 5mM AMPS, 0.1% (v/v) tetramethylethylenediamine (TEMED).
12.5% Running ael
0.375M Tris-HCl, 12.5% (w/v) total accrylamide (ratio 37.5:1 -  bisaccrylamide), 0.1% 
(w/v) SDS, 5mM AMPS, 0.05% (v/v) TEMED.
16% Running ael
0.375M Tris-HCl, 16% (w/v) total accrylamide (ratio 37.5:1 -  bisaccrylamide), 0.1% (w/v) 
SDS, 5mM AMPS, 0.05% (v/v) TEMED.
11.1.3 Cell lines
A. Bacterial Cell lines
The Escherichia coli (E. coli) strains JM109 (Yanisch-Perron et al, 1985) and JM110 
(Yanisch-Perron et al, 1985) were used for basic DNA manipulation.
ES1301/wm/A cells (Promega), a mismatch repair minus strain of E. coli (Siegel et al, 
1982), were used for the site-directed mutagenesis. MutS strain prevents repair of the newly 
synthesized unmethylated strand (Siegel et al, 1982; Kramer et al, 1984), leading to high mutation 
efficiencies.
DHlOBac (Gibco BRL) strain was used to produce recombinant baculovirus molecules 
for the expression of eukaryotic proteins (Luckow et al, 1993). This cell contains the parent bacmid 
pMON14272 and the helper plasmid pMON7124. The parent bacmid contains a mini-F replicon, 
the kanamycin resistance gene, an attTn7 site and the lacZa complementation factor. The helper 
plasmid contains the tnsABCD region which supplies the transposition proteins required for 
insertion of the mini-Tn7 from the donor plasmid into its target site on the parent bacimd.
B.lnsect Cell line
Sf9 A clonal isolate of the Spodoptera frugiperda cell line IPLB-s£21-AE, was used for 
expressing recombinant baculovirus and proteins. Sf9 has been originally established from ovarian 
tissue of the fall armyworm (Vaughn et al, 1977), and selected for its high susceptibility to 
baculovirus infection.
Insect cell culture. We received as a gift from Life Technologies a frozen vial of cells 
already adapted to serum free conditions. Both wt and mutant IGFBPs were expressed in Sf9 cells 
with serum free medium (SFM), protein free (SF900-II Gibco) conditions for several reasons. 
Firstly, as IGFBPs are secreted proteins, we intended to recover the expressed protein directly from 
the supernatant of cultures insect cells grown in suspension. The manufacturing company (Life 
Technologies) that commercialises the Bac-to-Bac expression system claims that, in serum free 
conditions, the recombinant secreted protein represents the major protein species in the insect cell 
supernatant, so that further purification might not be required. Secondly, serum bovine IGFBPs 
would contaminate the recombinant protein preparation and the separation between rat and bovine 
IGFBPs would require a laborious reverse-phase chromatography step. Finally, protease activity 
contained in the serum could potentially degrade the expressed protein.
Sf9 insect cell culture was initiated directly in suspension, thawing 1.7xl07 cells in 40ml 
of SF900-II medium (without addition of antibiotics or antimycotics) in a 50ml spinner flask 
(Techne, Cambridge, UK). Cells were routinely grown at 27°C, with stirring at 75rpm using a 
Techne MCS-104S biological stirrer placed inside the incubator. Cell viability was checked every 
day with Trypan blue staining (0.5% w/v Trypan in PBS, mixed at 1:2 with the cells). Cell viability 
was consistently over 99%, with the larger cell clusters depositing on the bottom of the flask. These 
were routinely removed by aspiration. Cell density was maintained between 0.5 and 2 x 1 0 6cells/ml.
It is recommended to use SFM-adapted cells only for a low number of passages (12-15), as 
culture of insect cells in SFM in suspension has been reported to decrease cell viability and foreign 
protein expression (Clemm, 1994). For this reason we made frozen stocks of early passage cells. 
Cells were harvested in mid log phase with a viability >97%. After 5min of centrifugation at 
lOOOrpm, the cells were resuspended at a density of 1-2 x l0 7cells/ml in medium containing 7.5% 
v/v DMSO and 92.5% of a 1:1 mix of fresh and cell-conditioned SF900-II medium. Vials were
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wrapped in cotton wool, placed in a polystyrene box, stored at -70°C overnight and then transferred 
to liquid nitrogen.
C. Mammalian Cell lines
C2 myoblast cell line was derived from thigh muscle of C3H mice (Yaffe and Saxel, 
1997). This cell line is used as a biochemical parameter of differentiation by monitering activity of 
creatine kinase (Yaffe and Saxel, 1997). The cell line was kindly donated by Dr. Claire Stewart 
(University of Bristol, Bristol, UK) and used to test the biological function of IGFBP-5. This cell 
line expresses IGFBP-5 mRNA and protein during its terminal differentiation. Furthermore, 
IGFBP-5 appears to be the only IGFBP produced by C2 cells and by another rapidly fusing muscle 
cell line, F3 azamyoblast clone b (James et al, 1993; Rotwein et al, 1995; Roussse et al, 1998). 
Cells were cultured at 37°C on 0.2% w/v gelatin (type A: from porcine skin, Sigma) coated T75 
flasks (Coming) with DMEM L-glutamax medium (Gibco) containing 10% v/v foetal bovine serum 
(Gibco) and 10% v/v new bom calf seurm (Gibco). At confluence cells were washed with PBS and 
detached from the plastic surface by a few minutes incubation at 37°C in the presence of 3-7ml of 
XI Trypsin-EDTA solution (0.5mg/ml Trypsin and 0.2mg/ml EDTA, obtained by diluting xlO 
concentrated solution with HBSS). 15-20ml of 10% FBS F12 medium were added to inactivate 
trypsin, then cells were harvested in 50ml centrifuge tubes and centrifuged at lOOOrpm for 5min. 
Supernatant was discarded and cell pellets resuspended in complete medium.
Prim ary goat mammary epithelial cells are derived from‘British Sannen’ goat mammary 
glands. Cells were obtained from Dr. C. Wilde in this institute. Cells were routinely cultured at 
37°C in 10 % foetal calf serum (FCS) DMEM(41965-039 Life Technologies) supplemented with 
penicillin and streptomycin, and used to express green fluorescent protein (GFP) to test the 
mammalian expression baculovirus system.
D. Antisera
Anti-rat IGFBP-5 antisera was made in house by immunizing sheep with recombinant 
rat IGFBP-5 protein. Antiserum was by kindly donated by Dr. David Flint, and was first reported in
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Bramani et al. (1999). This antiserum was routinely used at a dilution of 1:2000 for Western 
immuno blotting.
Anti-rat IGFBP-2 antisera raised in rabbit was purchased from TCS Bilogicals (Bucks, 
UK), and used at a dilution 1:5000 for Western blot.
Antisera to sheep or rabbit Imunoglobulin (IgG) conjugated to horse radish peroxidase 
(HRP) were purchased from Sigma and used at a dilution 1:10000 and 1:20000, respectively.
11.1.4 General techniques for DNA sub-cloning
cDNA clones for rat IGFBP-5 and rat IGFBP-2 were kindly provided by Dr Sean Gunette 
(John Wayne Cancer Research Institute, Los Angeles, USA) cloned into the EcoRI site of 
pGEM7Zf (Promega). The full-length IGFBP-5 cDNA contains 869 base pairs (bp) of coding 
sequence and 95 bp of 5’ and 3’ untranslated sequences, making the excised EcoRI fragment 964 
bp in total. The full-length IGFBP-2 cDNA contains 912 bp of coding sequence and 65 bp of 5’ and 
3’ untranslated sequences, making the excised EcoRI fragment 977 bp in total.
Restriction enzyme digestion. Restriction digests were typically performed in excess of 
enzyme: 20|il reaction volume containing lpgDNA, 2pl xlObuffer (containing 0.5mg/ml BSA), 
lOunits enzyme. Endonuclease enzymes and appropriate lOx buffers were supplied by Boehringer, 
Promega or New England biolab. Digestion mixes were incubated at the recommended temperature 
for l- 2 h.
Agarose gel electrophoresis. 1% (w/v) low melting point agarose (Sigma) was dissolved 
in lxTBE buffer and 0.5pg/ml ethidium bromide was added. Gels were electrophoresed in IX TBE 
buffer as described above. Low melting point agarose gels were used for DNA inserts, that were to 
be excised from the gel and extracted with QIAquick Gel extraction kit (QIAGEN, West Sussex, 
UK) following the instructions described by the manufacture. Electrophoresed DNA was visualised 
on a Herolab transilluminator (Mididoc, gel documentation analysis system and EASI store 
software Herolab Molekulare Trenntechnik,)
Ligation. Leinarization of plasmid DNA with a single restriction enzyme was followed by 
alkaline phosphatase (Promega) treatment to prevent self-ligation (2pg DNA, 2 units enzyme, 37°C
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for 30min, inactivated 65°C for lOmin). A typical ligation reaction would be performed in 15pi 
volume containing: 1.5pl X 10 ligation buffer (500mM Tris-HCl (pH7.5), lOOmM MgCl2, lOOmM 
DTT, lOmM ATP, 250pg/ml BSA); 100-200ng of linearized, plasmid DNA, 100-200ng of DNA 
insert with compatible restriction enzyme ends and 15U T4DNA ligase (0.5 pi of high concentration 
T4DNA ligase from New England Biolab, Hertfordshire, UK). Reactions were incubated at 16°C 
overnight.
Transformation. For a typical transformation, aliquots of JM109 competent cells would 
be thawed on ice for approximately lOmin. lOOpl of cell suspension would be placed in 
polypropylene tubes on ice and after the addition of 50ng of plasmid DNA, tubes would be mixed 
and incubated on ice for 30min. Tubes were incubated at 42°C for 45 seconds and immediately 
chilled on ice for 2min. After the addition of 900pl LB medium to each tube, cells were incubated 
at 37°C for lh with shaking to allow them time to express the antibiotic resistance gene on the 
plasmid which they have just taken up before being exposed to this antibiotic. lOOpl of cell 
suspension would be plated onto LB-agar plates in the presence or absence of appropriate drug 
selection and plates incubated at 37°C for 18-24h.
Minipreps were performed by using Ultraclean™ mini plasmid prep kit (MoBio 
Laboratories, Solana Beach, CA) to obtain purified DNA that could be subsequently used for most 
molecular biological techniques. The procedure used was that recommended by manufacture.
Maxipreps were performed using QIAGEN tips 500 (QIAGEN, West Sussex, UK) 
following the method recommended by the manufacturer.
II.2 Site-directed mutagenesis
In order to introduce the mutations necessary for creating our various IGFBP-5 mutants, 
we carried out site-directed mutagenesis of the rat IGFBP-5 cDNA (pGEM7Zf rat IGFBP-5 was 
kindly gifted by Dr Sean Guenette, John Wayne Cancer Institute Los Angeles) using the Promega 
“Altered sitesR II” in vitro mutagenesis system. This technique exploits the hybridization between 
the wild type gene and a single stranded oligonucleotide which has a sequence complementary to 
the wt gene, but which carries an alteration of a few base pairs at the site of mutagenesis. First, the
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IGFBP-5 gene was cloned in pALTERexl plasmid which contains an inactivated ampicillin 
resistance gene and an active tetracycline resistance gene. In each mutagenesis reaction, 2 or 3 
different oligonucleotides were used: i) one oligo to introduce the desired mutation (various 
IGFBP-5 mutants), ii) one oligo to repair the ampicillin resistance gene, and iii) one oligo to knock 
out the tetracycline resistance gene. Subsequent rounds of mutagensis would then employ a 
tetracyline repair oligonucleotide, and an ampicillin knock out oligonucleotide if  required.
T4DNA polymerase was used to synthesis nascent DNA between the oligonucleotides, 
using plasmid single strand DNA as template, and DNA ligase was used to ligate the newly 
synthesised DNA fragments. As a result, a wt-mutant hybrid DNA duplex was obtained. In order to 
avoid the host-directed mismatch repair system which would repair the unmethylated newly 
synthesised DNA strand, the hybrid duplex was amplified in the E. coli mutS strain (ES1301muts). 
Due to the semi-conservative mode of DNA replication, wt and mutated plasmids would 
theoretically be amplified at the same ratio. The introduction of ampicillin selection allows an 
increase in the yield of mutated DNA over the wt.
11.2.1 Construction of G203K, Q209A, and BP550 mutants
IGFBP-5 cloning into pALTER exl. The rat IGFBP-5 cDNA was excised from the 
pGEM vector as an EcoRI fragment, separated in an agarose gel and extracted using QIAquick Gel 
extraction kit. EcoRI digested pALTERex-1 plasmid was separated by the same procedure as 
mentioned above. pAlter-IGFBP-5 resulting from this ligation was transformed into JM109 cells, 
and grown on tetracycline plates for 48h at 37°C. Single colonies were picked and grown in LB-tet 
medium. Mini and maxi preps were prepared (pALTERexl-IGFBP-5 stock solution was present at 
43 6 fig/m 1 in TE buffer)
Mutagenetic primers. For the construction of G203K, Q209A, and BP550, which has a 
premature stop codon between the junction of exon 2 and exon 3 of IGFBP-5, mutagenic primers 
were designed as follows. First, according to the number of nucleotide substituted, the size of the 
mutagenic primers were adjusted. If  one or two nucleotides were substituted, mutagenic primers 
containing at least 11 or 15 base pairs respectively of flanking sequence at either side of the
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mutated nucleotide(s) were designed. This would allow sufficient hybridization to the IGFBP-5 
sequence. Second, where possible the mutagenic primers were designed in such a way as to create 
unique restriction endonuclease sites to make it easy for screening purposes. G203K, Q209A, and 
BP550 mutagenic primers created unique Apol, SphI, and Apal restriction sites, respectively. For 
G203K and Q209A mutations, the mutagenic primers used were 5’- 
CCAACTGTGACCGCAAAAATTCA CAAGAGA AAGC-3’ and 5 ’-GATTCTACAAG
Apol
AGAAAGGCATGCAAGCCTTCTCGTGG-3 respectively. To create the Double mutant, Q209A 
SphI
DNA was used as the template and the mutagenic primer used was 5’-CCAACTGTGACCGCAA 
A A AA IICT AC A AG AG A A AGG-3 ’.
Apol
To create BP550, the mutagenic primer used was 5’-TGAGACAGGAATCTGACTA 
GGGCCCCT GCCGCAGACA-3’. All the mutagenic primers were supplied and lyophilised either 
Apal
from Cruachem Ltd (Glasgow, UK) or MWG biotec (Milton Keynes, UK). Each oligonucleotide 
was resuspended in H20  at lpg/ml.
5’phosphorylation of oligonucleotides, lpg  (lp l) of each oligonucleotide was incubated 
at 37°C for 30min in the presence of 2.5pl of kinase buffer xlO (Promega, Southampton, UK), 0.5U 
(0.5pl) T4 polynucleotide kinase (Promega), 2.5|il of lOmM ATP (in a final volume of 25pl). 
Kinase was then heat inactivated at 70°C for 10min and the reactions stored at -20°C.
Alkaline denaturation reaction. 6 fj.l of pALTER ex 1-IGFBP-5 template (2.5p.gDNA) 
was incubated for 30min at 37°C with lpl of 4M NaOH and lp l of 2mM EDTA (in a final volume 
of 20pl). 2pl of 3M Na acetate (pH4.8) was added and DNA was precipitated at -70°C for 30min 
with the addition of 75pl of 100% ethanol. After centrifugation at 13000rpm for 15min and 
washing the pellet with 200pl of prechilled 70% ethanol, samples were recentrifuged at 13000rpm 
for 15min. The supernatants were discarded, pellets were vacuum dried and resuspended in lOOpl
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TE. DNA denaturation was confirmed on a 1% (w/v) agarose gel, where single stranded DNA runs 
as a separate lower band.
Annealing reaction. lOjil of alkaline denatured ds DNA template, lp l Amp-repair Oligo, 
l|il Tet-knockout Oligo, ljfi of phosphorylated mutagenic primers diluted 1:3, 2pi of 
manufacturer’s xlO annealing buffer and H20  to a final volume of 20pl, were incubated for 5min in 
a 75°C water bath. The water bath was then switched off until the temperature reached 45°C 
(approximately 30min) and finally tubes were put on ice until room temperature (RT) was reached. 
The following were added on ice (in this order): 3pl synthesis xlO buffer, lp l (5-10units) T4 DNA 
polymerase, lpl (l-3units) T4 DNA ligase and finally H20  to 30 pi. Tubes were then incubated for 
90min at 37°C.
Transformation of ES1301 mutant competent cells. For transformation 1.5pl of 
mutagenesis reaction (approximately lOng of template DNA) was used and the general protocol 
described earlier (page 71) was followed, except that after the addition of DNA, the cells were 
incubated on ice for only lOmin. The cells were then incubated at 37°C for 30min with shaking, and 
500pl of each culture was then transferred to a fresh tube containing 4.5ml LB-Amp medium and 
grown overnight at 37°C with shaking.
Plasmid mini prep. Miniprep preparations, of DNA were undertaken following the 
protocol described above.
Transforming m utant DNAs into competent cells. The yield of mutated DNAs obtained 
from ES1301muts by the mini prep preparations was estimated on a 1% (w/v) agarose gel. 5-1 Ong 
of DNA was transformed into JM109 competent cells. However, the BP550 mutant was 
transformed into JM110, which does not contain dcm (DNA cytosine methylation) methylase. This 
is because the created restriction endonuclease site in BP550, Apal, is dcm sensitive. The cells were 
then grown overnight on LB-Amp plates at 37°C. Mini-preps and maxi-preps were prepared and the 
presence of mutant DNA was verified by restriction digestion with the diagnostic restriction 
enzymes. The resulting fragments were separated by electrophoresis on a 1% (w/v) agarose gel and 
the result is shown in chapter III (page 98).
Sequencing analysis of mutant DNA was carried out to verify that the correct mutations 
were present. 7-10pg of DNA was sent to MWG biotec (Milton Keynes, UK) for automated
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sequencing. Either T7 or SP6 primers were used for sequencing, as they flank the multiple cloning 
site in pAlter-exl.
11.2.2 Construction of Hep- and Double
For the Hep- (R201L, K202E, K206Q, R214A) and Double (G203K, Q209A) mutations, 
two rounds of mutagenesis were performed. For the Hep- mutation, R201L, K202E, and K206Q 
mutations were initially created with the mutagenic primer, 5’-CCTGCCCAACTGTGACCTCGA
Xhol
GGGATTCTACCAGAGAAAGCAGTGCAAG-3’, which created unique Xhol restriction site. 
Using this modified cDNA as a template, a second round of mutagenesis was carried out to mutate 
R214A with the mutagenic primer, 5’-AGCAGTGCAAGCCTTCTGCAGGCCGCAAACGTGG
PstI
CAT-3’, which created a unique PstI restriction site. For the Double mutations, the Q209A mutant 
cDNA was used as a template DNA. The mutagenic primer used was 5’-CCAACTGTGACCGCAA 
AAAATTCT ACAAGAGA AAGG-3’, which created a unique Apol site.
Apol
11.2.3 Construction of BP255, BP225, BP522, and BP552
To construct the chimeric mutant IGFBPs, unique Xhol restriction endonuclease sites were 
inserted at the junction of exons 1 and 2 in the full-length cDNAs for IGFBP-2 and -5  using the 
mutagenic primers 5’-TCCGAGTGGTCATCCTCGAGGTCTGCAACCTGCTGTG-3’ and 5’-TC
Xhol
CCGAGAGTCTCTCTCGAGCTTGGTTTGCTCGCCGT-3’ for IGFBP-2 and -5  respectively.
Xhol
Xhol sites were also introduced at the junction between exons 2 and 3 using the mutagenic primers 
5’-TGGCAAGGGGTCCTGGCCTCGAGTGGGCGCAGCTTCTTGG-3’ and 5’-TGTCTGCGGC
Xhol
AGGGGCCCTCGAGAGATTCCTGTCTCATCT-3’ for IGFBP-2 and-5  respectively. The N- and 
Xhol
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C-terminal domains were then “cut and pasted” by digesting with Xhol and ligating to create 
BP255, BP225, BP522 and BP552 chimeras. A further round of mutagenesis was required to 
remove the Xhol sites and restore the wild type sequence at the junction between IGFBP-2 and -5  
exons in the chimeric cDNAs, using mutagenic primers 5’-TCCCGAGAGTCTCTCTCACTGTCT 
GCAACCTGCTGTG-3’ for BP255, 5’-TGTCTGCGGCAGGGGCCAGGAGGTGGGCGCAGCT 
TCTTG-3’ for BP225, 5’-TCCG AGTGGTCATCCTCTATCTTGGTTTGCTCGCCGT-3’ for 
BP522, and 5’-TGGCAAGGGGTCCTG GCTTGGTCAGATTCCTGTCTCATCT-3> for BP552.
11.2.4. Construction of Hep-2, Hep-3, and BP550Hep-
In order to disrupt the heparin binding sites in the central domain of IGFBPs, R136A and 
R137A mutations were created using WTIGFBP-5, Hep- and BP550 as templates. The 
oligonucleotide used was 5'-GGCTGTGAAGAAGGATGCAGCAAAGAAGCTGACCCAGTC-3'.
Tsel
This oligonucleotide introduced an additional Tsel site.
II.3 Protein expression using Baculovirus expression system
Both wild type (wt) IGFBP-2 and -5 , and all other mutant proteins were expressed with 
the Bac-to-Bac™ baculovirus expression system (Life Technologies). In this system the gene to be 
expressed is cloned into baculovirus and the recombinant virus is used to infect insect cells which 
express the recombinant protein.
11.3.1 Overview of the system (Figure 11.1)
Wt and all the mutant genes were cloned into the donor plasmid, pFastBac, down stream 
of the polyhedrin promoter of AcNPV (Autographica californica nuclear polyhedrosis virus) 
baculovirus. In nature, the polyhedrin promoter is activated in the very late phase of baculovirus 
infection of insect cells. In this phase virus DNA particles are packaged in polyhedrin protein and
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stored as occlusion bodies. However, the expression of polyhedrin protein is not essential under in 
vitro conditions where the virus can replicate and infect neighbouring cells even if the polyhedrin 
gene is substituted with a heterologous gene. In pFastBac donor plasmid, the polyhedrin promoter 
and the gene of interest are located in an expression cassette flanked by the right and left arm of 
bacterial transposon gene, Tn7.
When pFastBac is transformed into E. coli DHlOBac cells, a helper plasmid (pMON7124) 
provides the functions necessary to transpose the gene of interest from pFastBac to a baculovirus 
shuttle vector, (the bacmid, pMON14272), contained in the cells. Routinely bacmid can be 
propagated in E.coli DHlOBac cells as a large, low copy number plasmid which confers on the cells 
kanamycin resistance and the ability to ferment lactose. The bacmid possesses a gene encoding 
lacZa peptide which compensates the for lacZ deletion in the bacterial chromosome. Therefore, on 
BluoGal (5-bromo-3-indolyl-P-D-galactopyranoside)-IPTG plates, DHlOBac colonies appear blue. 
Moreover the bacmid has inserted inside the lacZa gene, a mini-a//Tn7attachment site for Tn7 
bacterial transposon. Inside DHlOBac cells the mini-Tn7 element of pFastBac (including the gene 
of interest and the protein expression cassette) is transposed at the bacmid mini-at/Tn7 site. The 
insertion of the mini-Tn7 element into the bacmid causes the disruption of the reading frame of 
lacZa peptide. Therefore on BluoGal-IPTG plates, colonies containing recombinant bacmid will 
appear white, allowing an easy selection from the background of blue colonies containing non 
recombinant bacmid.
Finally, recombinant bacmid is purified and used to transfect a monolayer of Sf9 insect 
cells. Viral stock is harvested from the supernatant of transfected cells and is utilised to infect fresh 
insect cells in order to obtain the expression of the protein of interest.
Cloning WT1GFBP-5 and -2, and other mutants into pFastB acl. Both WTIGFBPs and 
all the other mutants inserts were obtained by digesting approximately 20fig of pALTER 
recombinant vectors with 4(j.l (=40units) of appropriate restriction enzymes at 37°C for 2h in a final 
volume of 60|il with appropriate lx  diluted buffer. DNA inserts were separated in a 1% (w/v) 
agarose gel and extracted with the QIAquick Gel extraction kit.
Analogously, 20jig of pFastBac plasmid were prepared for the ligation reaction by 
digestion with appropriate restriction enzymes with separation and purification by 1% (w/v) agarose
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gel loading and QIAquick Gel extraction kit respectively. Relative amounts of pFastBac, 
WTIGFBPs and all the other mutant DNAs were estimated on a 1% agarose gel by comparison with 
the intensity of known amounts of DNA in size marker bands. Approximately, 2fig of pFastBacl 
were ligated to 2p,g of either wt or mutated IGFBP-5 fragments following the general protocol 
described above. Ligation products were transformed into JM109 cells under ampicillin (100ng/ml) 
selection. Minipreps of DNA were prepared and a restriction enzyme digestion was performed to 
detect the recombinant clones. Orientation of the recombinant inserts was verified by multi­
restriction enzyme digest. Maxi prep DNA was then prepared for each one of the mutants or wt 
IGFBP-5 proteins.
Transposition. DHlOBac cells were transformed with lng of wt IGFBPs and all the other 
mutant genes. The general protocol was followed, with the exception that after transformation 
900jil of LB medium was added and that the cells were incubated for 4 h at 37°C with shaking to 
allow them time to express the antibiotic resistance gene on the plasmid which they have just taken 
up before being exposed to these antibiotics. Each culture of transformed cells was serially diluted 
with LB (1 0 1, 10'2, 10'3) and lOOpl of each dilution was plated onto appropriate LB agar plates to 
select for recombinant bacmid DNA (Chapter II; page 64). After 24h incubation at 37°C, 10 large 
white colonies within a background of small blue colonies were picked, and to confirm the white 
phenotype, they were re-plated on fresh plates.
High M r plasmid (Bacmid) mini preps. From each of the wt IGFBPs and all the other 
mutants DHlOBac plates a single colony with confirmed white phenotype was picked and cultured 
at 37°C for 24 h in 2ml of LB medium supplemented with kanamycin, gentamycin and tetracycline 
(at the same concentration reported above for the plates). High Mr bacmid mini preps were 
prepared by Ultraclean™ mini plasmid prep kit.
Transfection of Sf9 cells with recombinant Bacmid DNA. Sf9 insect cells (>97% 
viable) were grown in suspension to mid log phase. Cells were then resuspended at 4.5x10s cells/ml 
in SF900B medium containing 50U/ml penicillin and 50fig/ml streptomycin. 2ml of cell suspension 
was placed in each well of a 6well plate and cells were left to attach for lhr at room temperature. In 
a tube, 100|nl of SF900II medium without antibiotics was mixed with 5|il of each recombinant 
Bacmid. At the same time lOOpl of SF900II medium without antibiotics was mixed with 6jxl of
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Celfectin (Life Technologies) and then added to recombinant bacmid and incubated at ROOM 
TEMPERATURE for 25min. Wells containing cell monolayers were washed with 2 ml of SF900II 
without antibiotics. Transfection was performed in the following order: i) 0.8ml of SF900 II was 
added to each tube containing 200^ of lipid-DNA complexes and the contents mixed, ii) Following 
complete removal of wash medium from one well, the cell monolayer was overlaid with 1ml of 
transfection mixture and incubated for 5h at 27°C. The transfection mixture was then removed and 
2ml of SF900II medium with antibiotics was added, and the plate was incubated for 72h at 27°C. 
After this incubation period, the supernatants containing recombinant viruses were harvested. 
Supernatants from 2 wells were pooled, centrifuged at lOOOrpm for 5min, transferred to a 15ml tube 
wrapped with foil and stored at 4°C. lOOpl of this sample was assayed for protein expression by 
Western blot.
Virus amplification . In order to obtain a large volume of high titre viral suspension 
necessary to innoculate 50-100ml of insect cell cultures, the supernatants harvested after 48h from 
insect cells transfected with recombinant bacmids underwent several rounds of amplification. Insect 
cells were seeded at confluent density on 6 well plates or flasks. The viral innoculum was diluted in 
a volume of SF900II just sufficient to cover the cell monolayer, which was then incubated for lh at 
room temperature. The innoculum was discarded and replaced with fresh SF900II medium, and 
cells were incubated for 48hr at 27°C. Supernatants were harvested, centrifuged at lOOOrpm for 
5min to eliminate residual cells, transferred to bottles wrapped with foil and stored at 4°C.
Virus titration Titration of virus was performed with the BacPAK™ baculovirus rapid 
titer kit (Clontech, CA USA, supplied by Cambridge Bioscience, Cambridge, UK) following 
procedures recommended by the manufacturer.
Protein harvesting For protein production, a 50ml suspension culture of SF900II medium 
containing 2 xlO6 cells/ml of Sf9 cells in log phase was infected with a variable volume of virus 
innoculum. Virus infection was performed at a multiplicity of infection (MOI) of 5 using the 
following formula:
innoculum required (ml): desired MOI(pfu/ml) x (total number of cells)
titre of viral innoculum (pfu/ml)
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During the infection, samples were taken at 8hr intervals to check the cell viability and 
cultures were harvested when the viability dropped below 80%. The samples were also analysed on 
Western blots for the expression and possible degradation of the protein, in an attempt to optimise 
the harvesting time.
Insect cells were separated from the media by centrifugation at 3000rpm for 2min, 
supernatants were concentrated on Millipore tubes (Ultrafree-20) by centrifugation at 1700xg for 
2hr at 4°C, and stored at -20°C.
II.4 IGF-II affinity chromatography purification
11.4.1 Affinity column preparation
Columns were prepared and run following the recommendations described in “Affinity 
chromatography. Principle and methods” hand book (Pharmacia LKB biotechonology Cat.N 18- 
1022-29). 500ug of activated CM Sepharose 4B (Cat N. 17-0490— 01 Pharmacia Biotech, Uppsala 
Sweden) was washed in a sintered glass filter with 150ml of ImM HC1. 0.9mg of rhIGF-II (media 
grade GroPep) was dissolved in coupling buffer (0.1M NaHC03, pH 8.0) and mixed with the gel 
end over end for lhr at room temperature. Sepharose gel coupled with IGF-II was poured into a 
Biorad plastic column and, after discarding the excess coupling buffer, was washed first with 100ml 
of 0.05M Tris-HCl, 0.5M NaCl pH 8.0, then with 100 ml of 0.05M formate, 0.5M NaCl, pH 4.0. 
Excess activated CM groups were blocked with 0.1M Tris-HCl pH 8.0 and the column re­
equilibrated in 50mM Tris-HCl, 0.5M NaCl, 0.01% sodium azide pH 7.4. The column volume was 
lml.
11.4.2 Purification of wt IGFBPs and mutant proteins and lodination of IGFs
Protein purification was performed following the method described by Carr et al. (1994). 
800pl IGF-II-coupled Sepharose gel, prepared as described above, was equilibrated with 10ml 
equilibration buffer (0.5M NaCl, 50mM Tris-HCl pH 6.5). 2- 4ml of concentrated insect cell culture
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supernatant containing wt IGFBPs and mutant proteins were applied to the column. The gel was 
mixed gently with the sample several times and incubated overnight at 4°C. Unbound protein 
solution was run through the column, reapplied twice and finally harvested and kept at -20°C to be 
analysed for the residual presence of IGFBPs. The column was washed with 10 ml equilibration 
buffer (0.5M NaCl, 50mM Tris-HCl pH 6.5) (the first 1ml of the flow through was retained for 
analysis). 6 ml of elution buffer (0.5M acetic acid pH3) was incubated with column gel for lOmin 
before starting the elution. 6x 1ml fractions were collected in Eppendorf tubes already containing 
275 pi 2M Tris base necessary for immediate pH buffering to pH 7.0. Fractions were kept on ice and 
the column washed with 10ml equilibrium buffer (0.5NaCl, 50mM Tris-HCl pH 6.5). Subsequently, 
alternate washes with 5ml of basic washing buffer (0.1M Tris-HCl, 0.5 NaCl, pH 8.5) and 5 ml of 
acidic washing buffer (0.1M Na acetate, 0.5M NaCl, pH 4.5) were repeated twice. For storage the 
column was equilibrated in column storage buffer (50mM Tris-HCl, 0.5 M NaCl, 0.01% (w/v) 
sodium azide, pH 7.4) and kept at 4°C.
WTIGFBPs and all the other mutants fractions eluted from the affinity column were 
analysed for their relative protein content by Coomassie blue gels and the presence of purified 
proteins was confirmed by anti IGFBP-5 and -2  antisera. Western immunoblots and 125I-IGF-I/-II 
ligand blots. Measurement of protein concentration was by Bradford assay (see below).
Iodination of IGFs. IGF-I and -II were iodinated with Nal25I (ICN, Hampshire, UK) to a 
specific radioactivity of 130 MBq/umol by the iodogen-coated tube method (Fraker and Speck, 
1978)
II.5 Protein analysis using Bradford assay
Proteins were quantified using the Bio-Rad protein assay system (Pierce, Chester, UK) 
which is adapted from Bardford et al. 1976. Five dilutions of a BSA standard in elution buffer to 
pH 7.0 with concentrated Tris buffer (page 65), 2M Tris (pH 7.0), which was an appropriate blank 
for the protein solutions to be tested were prepared as a standard solution. The linear range of the 
assay was 5.0 pg/ml to approximately 100 pg /ml. Standard and protein sample solutions were 
normally assayed in triplicate. 160 pi of each standard and sample solution were pipetted into
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separate microtitre plate wells, and then 40 |il of diluted dye reagent concentrate was added to each 
well and mixed thoroughly using a multi-channel pipette. Samples were incubated for lOmin at 
room temperature, and loaded into a TitreTeck® multi-scan and absorbance measured at 600nm.
II.6 Immobilized protein assay
11.6.1 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)
SDS-PAGE was carried out following the method described by Laemmli (1970). Protein
gels contained 12.5% or 16% total acrylamide (page 67). Polymerisation was initiated with 
ammonium persulphate (Biorad) and TEMED. Stacking gels were as described on page 67. 
Samples for analysis were mixed 1:1 with sample buffer (page 65). Electrophoresis was performed 
at constant voltage (150V) on a Biorad mini protean II apparatus in runnig buffer (page 65).
Coomassie blue staining. This technique was employed to visualise protein bands after 
electrophoretic separation and to estimate their relative concentration. Gels were stained in 5% (v/v) 
methanol, 7.5% (v/v) acetic acid, 0.3% (w/v) Comassie blue R250 by shaking gently for 
approximately lhr at room temperature. To enable the detection of protein bands from the stained 
background, gels were washed for lOmin in 5% (v/v) methanol, 7.5% (v/v) acetic acid, then fresh 
solution was replaced and gels destained overnight. For further analysis, gels were dried between 
cellophane sheets with Hoefer Easy breeze gel dryer equipment. Alternatively, if direct 
autoradiograhy was to follow, gels were placed on filter paper (Biorad), covered by Saran film and 
dried on a Hoefer (Hoefer scientific instruments, S.Francisco, CA) dual temperature slab gel drier at 
80°C for 2h and then at room temperature until completion.
Electrotransfer. As an alternative to direct gel staining, proteins separated by 
electrophoresis were transferred from the gel to either Hybond-C extra or Hybond-PVDF 
(Amersham) membranes. In the latter case membranes required lOsec pre-wetting in methanol and 
subsequent 5min rinsing in H20  before use. Gel sandwiches (fibre pad, filter paper, gel, membrane, 
filter paper, fibre pad) were assembled under transfer buffer (25mM Tris, 192mM glycine, 20% 
(v/v) methanol) in a bath and then located in the Biorad mini transblot apparatus equipped with an 
ice pack. Protein electrotransfer was performed at a fixed voltage (100V) for lh, unless otherwise
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indicated. Blotted proteins were usually visualised by Ponceau S staining, as described below. 
Membranes were then either blocked for ligand or Western blotting for immediate analysis or dried 
and stored between filter paper in a plastic bag at 4°C, for later analysis. Dried PVDF membranes 
were moistened for lOsec in methanol before being further processed.
Ponceau S staining. Sigma Ponceau S concentrated solution (Ponceau S, 2% w/v, in TCA, 
30% w/v, and sulphosalicylic acid, 30% w/v), diluted 1:10 with water, was applied to the 
membranes for lOmin for visualisation of protein bands. After washing with water, the membranes 
were dried and stored or directly incubated in blocking buffer for further analysis by ligand or 
Western blotting.
11.6.2 125I-IGF-I/-II ligand blot
125I-IGF-I/-II ligand blotting was performed essentially as described by Hossenlopp et al. 
(1986). After transfer, membranes were washed with 50ml 3% (v/v) NP40 Tris-saline solution 
(lOmM Tris-HCl, 60mM NaCl 0.05% (w/v) sodium azide, pH 7.6) for 30min, with 50 ml 1% (w/v) 
BSA Tris-saline solution for 2h and finally with 50ml 0.1% (v/v) Tween 20 Tris-saline solution for 
lOmin. Approximately 1.5-2 x 106cpm 125I-IGF-I/-II in 1.5ml of 1% (w/v) BSA, 0.1% (v/v) Tween 
20 Tris-saline solution was added to a plastic bag containing each blot and incubation was 
continued overnight at 4°C. Blots were then washed twice for 15min in 50ml 0.1% (v/v) Tween20 
Tris-saline solution and three times for 15min in 50ml Tris-saline solution. After drying, 
membranes were exposed to autorad films (Hyperfilm Pmax, Amersham) in an 18x24 radiographic 
cassette (Genetic Research Instrumentation Ltd. Essex, UK) at -70°C for 4-10 days. The films were 
bathed in GBX Kodak developer for approximately 3min followed by a quick rinse in water, moved 
to fixer solution for 5min and then extensively washed in tap water.
As an alternative to autoradiographs, dried blots were exposed to a Molecular Dynamics 
Phospho-imager screen for 2 days at room temperature and the resulting image was visualized with 
the Phospholmager 445SI software (Molecular Dynamics) and Image Quant™ software.
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11.6.3 Western immunoblot
Typically, blotted membranes were blocked in 3% BSA TBS-T (20mMTris- HC1, 137mM 
NaCl, pH 7.6 supplemented with 0.1% v/v Tween) for lhr at room temperature or overnight at 4°C. 
After rinsing in TBS-T, membranes were incubated with the first antibody for lhr at room 
temperature in a plastic bag containing approximately 1.5ml of 1-3% (w/v) BSA TBS-T. The 
dilution and the exact nature of first antibody varied as specified in each experiment. Blots were 
washed x2 quickly, xl for 15min and x2 for 5min with TBS-T, with shaking. HRP-conjugated 
second antibody, was added to 50ml of 5% (w/v) skimmed dried milk TBS-T in which each 
membrane was incubated for lh at room temperature, with gentle agitation. After washing in TBS- 
T, as described above, protein detection would be performed with Enhanced Chemi-Luminescence 
technique (ECL™ Amersham, Buckinghamshire, UK) by exposing blots for various lengths of time 
to Hyperfilm™ ECL™ (Amersham). Finally the films would be processed as described above in 
developer and fixer.
11.6.4 Heparin ligand blot
The method used was adapted from that described previously by others (Grulich-Henn et 
al. 1998) for detection of serum IGFBPs by blotting with biotinylated IGF-I. 200ng of each protein 
was subjected to electrophoresis on 12.5% or 16% SDS-PAGE under non-reducing conditions and 
subsequently transferred onto Hybond™-C Extra membranes (Amersham). After transfer, the filters 
were dried at 37°C for 5min. The membranes were then washed with 3% (v/v) NP40 Tris-saline 
(lOmM Tris-HCl, 0.15M NaCl pH 7.4) for 30min and blocked with 3% (w/v) BSA- Tris-saline for 
2hrs at room temperature with shaking. They were then incubated overnight with a 1:2000 dilution 
of Heparin-Albumin-Biotin (Sigma, USA) in 1% (w/v) BSA/0.1% (v/v) Tween-20- Tris-saline at 
room temperature. The membranes were washed (3 x 15min) with 1% (w/v) BSA/0.1% (v/v) 
Tween-20- Tris-saline and then incubated with a 1:2,000 dilution of streptavidin-HRP conjugate 
(Boehringer Mannheim) in 1% (w/v) BSA/0.1% (v/v) Tween-20- Tris-saline for lhr. Finally, the 
membranes were washed (3 x 15min) with Tris-saline, and bound heparin was detected using the 
Enhanced Chemi-Luminescence technique (ECL™ Amersham, Buckinghamshire, UK) by
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exposing blots for various lengths of time to Hyperfilm™ ECL™ (Amersham). Protein loading was 
monitored by blotting duplicate membranes with antiserum to WTIGFBP-5.
11.7 Solution phase assay
Competition studies were established to determine the affinity of wt IGFBP-2/-5, and the 
other mutants for IGF-I or IGF-II. Both wild type and mutant preparations were diluted 1:2500 with 
assay buffer and lOOpl were added to radio immuno assay (RIA) tubes. lOOfil of assay buffer +/- 
increasing amount of cold IGF-I or IGF-II were added. 1 mg/ml IGF-I and II stock solutions in 
lOmM acetic acid were appropriately diluted to obtain a final concentration of 0.25, 0.5, 1, 2.5, 5, 
10, 25, 50ng/ml. Subsequently, approximately 25000cpm of I25I-IGF-I or IGF-II in lOOpl of assay 
buffer were added so that wild type proteins and mutants were each tested for all combinations of 
competitive binding (IGF-I v 125I IGF-I and IGF-II v ,25I IGF-II). After overnight incubation at 4°C, 
600pl of 1% (w/v) activated charcoal solution containing 0.2% (w/v) protamine sulfate was added 
and centrifuged (3000rpm X 30min) to separate unbound tracer. Blank value for each of l25I-IGF-I 
and l25I-IGF-II tracers was determined and the radioactivity measured in all other charcoal pellets 
was subtracted from the appropriate blank as described above. 125 I IGF-I/II binding of wt or 
mutated IGFBP-5 proteins in the absence of cold IGFs was designated the control value. The 
residual tracer binding in the presence of cold IGF competitors was expressed as either a percentage 
of control value (100%) or a linear regression curve by Scatchard analysis (Scatchard, 1949)
11.8 BIACORE analysis
Kinetics of wt IGFBPs and mutants binding to both IGF-I and IGF-II was investigated 
using a BIACore 2000 system (BiaCore, Herts, UK).
BIACORE 2000 system is for real-time biomolecular interaction analysis (BIA) using 
surface plasmon resonance (SPR) technology. This system monitors the formation and dissociation 
of biomolecular complexes on a sensor surface as the interaction occurs. By covalently attaching 
one molecule (the ligand) to the surface, the binding of another molecule in solution (the analyte) 
with the ligand is followed. Measurements are made under condition of continuous flow, where the
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sensor surface forms one wall of the flow cell. For the majority o f applications, the biospecific 
surface can be regenerated and reused for an extended series of analyses.
SPR is a non-invasive optical measuring technique which measures the mass concentration 
of biomolecules in close proximity to a specially prepared surface. The technique does not require 
any labeling of the interacting components. The response is largely independent of the nature of the 
biomolecule, so that all steps in an interaction analysis may be followed with the same detection 
technique.
This system measures surface protein concentrations from a few pg/mm2, and can monitor 
changes in the surface concentration on a time scale down to 0.1 second. The technology allows 
determination of binding specificity, kinetics and concentration with analytes ranging in size from 
about 150 to 106 g/mole (dalton) or more. Flow-through technology with integrated microfluidics 
gives reproducible sample handling and simplifies kinetic calculations. Finally, this system can be 
used for studying the interactions of proteins, protein conjugates, nucleic acids, lipid micelles and 
even larger particles such as viruses and whole cells.
Sensor chip (CM5) is a general purpose chip coated with carboxy-methylated dextran to 
which biomolecules can be linked with a variety of established chemical methods. CM5 is glass 
slide coated with a thin gold film to which the carboxy-methylated dextran surface matrix is 
covalently bonded (Figure 11.2). This chip is mounted on a plastic support frame in a protective 
cassette.
Integrated n-Fluidic Cartridge (IFC) The IFC consists of a series of channels and 
pneumatic valves encased in a plastic housing, and serves to control delivery of liquid to the sensor 
chip surface. Protein samples are injected from the autosampler (automatic sample injection pump) 
into the IFC, which connects directly with the detector flow cells. The detector flow cells are 
formed directly on the IFC by docking the sensor chip on to the IFC flow cell block. This consists 
of four grooves, rectangular in cross section, moulded into the surface of the IFC. Each groove has 
its own liquid delivery channel and control valve in the IFC. The block is pressed against the sensor 
chip, forming four separate flow cells with sensor chip surface as one wall. Effluent from the flow 
cells is collected in an outlet channel and directed either to waste or the recovery cup. The IFC 
allows single or multichannel analysis in up to four flow cells (Figure II.3). Sample injection
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Surface matrix 
Linker layer —  
Gold film 
Glass support '
Figure II.2 Sensor Chip CM5 is a glass slide coated with a thin gold film to 
which the carboxymethyl dextran surface matrix is covalently bonded. The 
matrix surface forms one wall of the detector flow cell.
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] l N
FC 3
V FC 4
J
Figure II.3 Simplified diagrammatic illustration of sample flow through 
two flow cells. The symbols O and □ represent open and closed valves 
respectively.
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commands activate a sequence of operations covering aspiration of sample from the autosampler 
vial, delivering the required amount of sample to the flow cells, and flushing the IFC with buffer 
ready for the next injection.
Immobilizing IGF-I and IGF-II onto CM5 and protein analysis. IGF-I and IGF-II were 
immobilized to flow cell number 2 and 3 respectively in the CM5 chip via NHS/EDC, which are 
coupling reagents to the flow cell surface, according to the manufacturer’s instructions. In the 
control flow cell, insulin (which does not bind IGFBP-5) was similarly immobilized on flow cell 
number 1. Each polypeptide was immobilized to a level of 1000 reponse units (Rus).
Both wild types and mutant proteins were applied simultaneously to the sensor chip 
containing IGF-I, IGF-II or insulin at a flow rate of 30 ul/min. Five different concentrations (1.09, 
2.18, 4.37, 8.75 and 17.5 nM) of proteins were applied. The regeneration of biosensor chip surface 
following association and dissociation of binding protein was achieved with sequential 2 x 2  min 
pulses of 20mM HC1. Under these conditions the biosensor surface was regenerated without any 
time-dependant increases in background RU signal. Kinetic values (Kon and Koff) were calculated 
assuming a 1:1 stoichiometry of binding between IGFs and proteins and using BIA evaluation 3.0 
software provided by the manufacturer.
II.9 Construction of mammalian cell line expression Baculovirus vector
The baculovirus system is being used increasingly to express proteins in mammalian cells. 
The receptor for baculovirus on mammalian cells is not known, but it is likely to be a 
glycosaminoglycan or other ubiquitous cellular component, given the wide range of cell types 
susceptible to infection. As AcNPV (Autographa californica nuclear polyhedrosis virus) is only 
able to replicate in cells derived from lepidoptera (moths and butterflies), growth of AcNPV in the 
laboratory usually requires less extensive biosafety precautions than animal viruses. We have 
constructed a hybrid mammalian-baculovirus expressing vector (Figure VI. 1) containing two 
expression cassettes controlled by constitutive mammalian promoters: the cytomegalovirus 
immediate early (CMV-IE) promoter and the simian virus 40 (SV40) early promoter controlling 
neomycin phosphotransferase II. The virus is prepared and amplified using normal insect cell 
culture procedure (as shown in chapterll.3), although the virus does not contain the insect cell
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specific polyhedrin promoter. Using this virus, we have expressed green fluorescence protein (GFP) 
as a reporter gene in several mammalian cell lines, and both wt IGFBPs and other mutants in mouse 
C2 myoblast cell lines.
11.9.1 Construction of recombinant Baculoviruses
pBacM aml was constructed by using shuttle vectors derived from pFastBac 1 (Life 
Technologeis). Plasmid DNA was digested with SnaBI and Hpal to remove the baculovirus 
polyhedrin gene promoter sequences. A 3.1~kbp Nrul-Bstl 1071 fragment from pcDNA3 
(Invitrogen), which contains the cytomegalo virus -  immediate early (CMV-IE) promoter/enhancer 
with a multiple cloning site and polyadenylation signal followed by the simian virus 40 promoter -  
neomycin phosphotransferase II expression cassette, was inserted into the pFastBacl backbone.
pBacMam GFP. Green fluorescence protein gene was initially inserted into pBacMaml 
as an EcoRI -  Xbal fragment to construct pFastBacMaml GFP reporter gene construct.
pBacMam wt IGFBP-5/Hep-/Double. Wt-IGFBP-5, Hep-, and Double gene were cloned 
from pFastBacl to pBacMaml as BamHI -  Xhol fragments.
Recombinant viruses were generated by using the Bac-to-Bac system (Life technologies) 
as explained above in chapter II.3. Harvested stock viruses were concentrated by centrifugation at 
35,000 X g for 60min, and pelleted virus was resuspended in Dulbeco’s PBS (Life technology) 
without serum. Virus titres were determined by the BacPAK™ baculovirus rapid titer kit (Clontech) 
following procedures recommended by the manufacturer.
11.10 Expression GFP in C2 myoblast cell line and primary goat mammary 
epithelial cells
Virus infection and expression of GFP. C2 myoblast cells were seeded on gelatin coated 
6-well culture dishes (cellstar) at 2 X 106 cells/well and incubated for 3 hours at 37°C. Culture 
medium was removed and cells were washed with three times with 2ml PBS to eliminate traces of 
serum. After removal of PBS, cells were treated with 1ml volume of virus innoculum (MOI 200 -  
400) for 12 -24 hrs at 37°C. lOmM Sodium butyrate was immediately added after virus treatment
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to increase the infection rates following the method of Condreay et al, 1999. After incubation with 
virus, the virus innoculum was removed from the cells, and the cells were washed three times with 
2m 1 PBS and trypsinised. Cells were transferred into gelatin coated T75 flasks, and infected cells 
were then selected with 10 ml of fresh media containing 500ug/ml G-418 (Sigma).
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Chapter III. Overlap of IGF- and heparin-binding sites in rat IGFBP-5
111.1 Introduction
As discussed above in chapter 1.3.3, several laboratories have begun to identify the specific 
amino acids in the IGFBP molecule that contribute to IGF binding, and in the study by Forbes et 
al., (1998) they identified a critical region for binding IGFs in the C-terminus of bovine IGFBP-2 
(Figurel.4, Page 26 ). This critical region of bIGFBP-2 corresponds to amino acids 201-216 in the 
rat IGFBP-5 (rIGFBP-5) sequence, which lies within the basic heparin binding region of the 
protein, which we already discussed in chapter 1.3.4. We carried out an alignment of sequeneces 
from all six IGFBPs from all species sequenced so far and found two completely conserved amino 
acids (Gly 203 and Gln209 in the rIGFBP-5 sequence) (Figure III.l), which, in turn, suggests an 
important conserved function for these two amino acids. Therefore, we decided to mutate these 
residues to assess whether they could be involved in IGF binding and/or heparin binding. These two 
individual mutants of rIGFBP-5 are called G203K and Q209A (Figure III.2). Subsequently, we 
made a third mutant in which both of these residues were mutated (G203K/Q209A), and we have 
called this the Double mutant. In addition, in order to assess the overall contribution of the C- 
terminus of IGFBP-5 to IGF binding, we introduced a premature stop codon at the junction between 
the central and C-terminal domains of rIGFBP-5 to make a truncated mutant named BP550. Finally, 
we have made a fifth mutant named Hep-, in which mutations were made in four of the flanking 
basic amino acids, previously shown by others (Parker et al, 1998) to be involved in heparin 
binding (R201L, K202E, K206Q, and R214A) (Figure ffl.2).
111.2 Results
III.2.1 Construction of G203K, Q209A, Hep-, Double, and BP550
To create G203K and Q209A, site-directed mutagenesis was performed at two separate 
sites on the rat IGFBP-5 cDNA using the ‘Altered sites’ system (Promega) as described in chapter
II. The oligonucleotides for creating both G203K and Q209A also generate unique restriction
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Cysteine-Rich Non-Conserved
Cysteine-Rich
N-Terminal Domain Central Domain
C-Terminal
Domain
BP5 rat (197) PNCDRKGF YKRKQCKP(212)
BP1 human (179) PNCNKNGFYHSRQCET( 194)
BP1 bovine (183) PNCNKNGFYHSKQCET(183)
BP1 rat (192) PNCNKNGFYHSKQCET (207)
BP2 human (224) PNCDKHGL YNLKQCKM(239)
BP2 rat (205) PNCDKHGL YNLKQCKM(220)
BP3 human (211) PNCDKKGFYKKKQCRP(225)
BP3 bovine (211) PNCDKKGFYKKKQCRP(225)
BP3 pig (207) PNCDKKGF YKKKQCRS (222)
BP3 rat (212) PNCDKKGF YKKKQCRP(226)
BP4 human (182) PNCDRNGNFHPKQCHP( 197)
PB4 bovine (182) PNCDRNGNFHPKQCHP( 197)
BP4 rat (178) PNCDRN GNFHPKQCHP( 193)
BP5 human (197) PNCDRKGF YKRKQCKP(212)
BP6 human (166) PNCDHRGF YRKRQCRS( 181)
BP6 rat (149) PNCDLRGF YRKQQCRS( 164)n
Figure III.l Alignment of sequences for IGFBPs corresponding to rat IGFBP- 
5 residues 197-212 The 15 sequences are aligned according to the location of 
conserved cysteine residues (underlined) at residues 199 and 210 for rat IGFBP-5. 
This alignment clearly indicates the conservation of residues corresponding to 
glycine 203 and glutamine 209 in rat IGFBP-5, and these residues are shown in 
bold and indicated by arrows
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G203K
Arg-Lys-Gly-Phe-Tyr-Lys-Arg-Lys-Gln-Cys-Lys-Pro-Ser-Arg-Gly-Arg-Lys-Arg
II
Lys
Q209A
Arg-Lys-Gly-Phe-Tyr-Lys-Arg-Lys-GIn-Cys-Lys-Pro-Ser-Arg-Gly-Arg-Lys-Arg
u
Ala 
Hep-
Arg-Lys-Gly-Phe-Tyr-Lys-Arg-Lys-Gln-Cys-Lys-Pro-Ser-Arg-Gly-Arg-Lys-Arg
II II I) U
Leu Glu Gin Ala
Double
Arg-Lys-Gly-Phe-Tyr-Lys-Arg-Lys-Gln-Cys-Lys-Pro-Ser-Arg-Gly-Arg-Lys-Arg
u
Lys Ala
BP550 (168 a.a) N-terminal domain
168
Central domain
Stop
Figure III.2 Site directed mutagenesis of 201-218 region of 
IGFBP-5 and BP550
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endonuclease cleavage sites that are Apol and SphI, respectively. Figure III.4 shows the results of 
Apol and SphI restriction analyses of WTIGFBP-5, G203K, and Q209A cDNAs, inserted in the 
pFastBacl plasmid. Although there are no Apol or SphI sites within the wild type rIGFBP-5 cDNA 
sequence, there are five Apol and one SphI restriction sites within the pFastBacl plasmid (Figure 
III.3). The BP5 cDNA is cloned into the unique EcoRI site (GAATTC), which also corresponds to 
an Apol site (PuAATTPy). Therefore, the expected size of fragments generated from Apol 
digestion of pFastBacl WTIGFBP-5 are 3628, 964 (corresponding to the BP5 cDNA), 495, 379, 
262 and 11 (undetected) base pairs (bp) (Figure III.4A). After successful mutagenesis to create 
G203K, the new Apol restriction site within the IGFBP-5 sequence cuts within the 964 fragment to 
generate new 721 bp and 243bp fragments, the latter of which is not resolved from the 262 bp 
pFastBacl fragment (Figure III.4A). pFastBacl WTIGFBP-5 is linearised following digestion with 
SphI to create a single 5739 bp fragment (Figure III.4B). After successful mutagenesis to create 
Q209A, the new SphI restriction site within the IGFBP-5 sequence results in the release of a 300 bp 
fragment (229 bp from the Bp5 sequence and 71 bp from pFastBacl) (Figure III.4B).
To create the Double mutant, Q209A was used as the template DNA for site-directed 
mutagenesis and the mutagenic primer was that described in chapter II. After mutation, restiction 
enzyme digestion analysis indicated the prescence of both Apol and SphI sites (data not shown). 
The Hep- mutant (R201L, K202E, K206Q, and R214A) was created following two rounds of 
mutagenesis. Firstly, R201L, K202E, and K206Q were produced, creating a unique Xhol restriction 
site in the IGFBP-5 cDNA. Using this mutated cDNA as a template, a second round of mutagenesis 
was performed to create R214A, which introduced a unique PstI site within the IGFBP-5 cDNA. 
Figure III.5 A shows the results of both Xhol and PstI restriction digestion analyses of WTIGFBP-5 
and Hep- DNA, inserted in the pFastBacl plasmid. Although there are no Xhol or PstI sites within 
the wild type rIGFBP-5 cDNA sequence, there is a single Xhol and PstI restriction site within the 
polylinker of the pFastBacl plasmid. Therefore, digestion with either Xhol or PstI of 
pFastbacl WTIGFBP-5 results in the linearisation of the plasmid (Figure III.5A). However, after 
succesful mutagenesis to create Hep-, the new Xhol restriction site within the IGFBP-5 sequence 
results in the release of a 317 bp fragment (252bp from the IGFBP-5 sequence and 65 bp from 
pFastBac 1), whereas the new PstI restriction site results in the release of a 270 bp fragment (212bp
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5’-untranslated sequence 3’-untranslated sequence
IGFBP-2: 53bp IGFBP-2: 12bp
IGFBP-5: 15bp Inserted IGFBPs IGFBP-5: 80bp
EcoRl/ApoI: 4054bp
PstI: 4112bp
Xhol: 4119bp
EcoRl/ApoI: 4054bp
SphI: 4125bp
pFastBac 1 
4775bp
Apol: 4316bp
Apol: 4695bp
Apol: 426bp
Apol: 415bp
Fig III.3 pFastBac 1 restriction map. Multiple cloning site contains EcoRI, Apol, 
PstI, Xhol, and SphI restriction sites. Four other Apol restriction sites are found in 
Dther region of vector.
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SM WT Q209ASM WT G203K
23130
9416
6557
23130
Figure III.4 1% agarose gels stained with ethidium bromide (EtBr) 
showing the results of (A) Apol digest of pFastBac 1 wtIGFBP-5 and 
G203K cDNAs (B) SphI digest of pFastBac 1 wtIGFBP-5 and Q209A 
cDNAs. SM represents DNA size markers (X-Hindlll and (|>xl74 in A; X-  
Hindlll alone in B), and fragment size is indicated. Arrows indicate newly 
created restriction fragments in the mutants.
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A.
23130
9416
6557
2322
2027
Xhol PstI
SM WT Hep- SM WT Hep-
564
B.
23130
9416
6557
Apal
WT BP550
Figure III.5 Restriction enzyme analyses of wild type (WT) IGFBP-5, Hep-, 
and BP550 inserted in pFastBacl plasmid (A) Xhol digests of wtIGFBP-5 and 
Hep- and PstI digests of wtIGFBP-5 and Hep-. (B) Apal digest of the pFastbacl 
wtIGFBP-5 and BP550. SM represents DNA size markers (A.-HindIII alone in A 
and; X-Hindlll and (j)xl74 in B), and fragment size is indicated. Arrows indicate 
newly created restriction fragments in the mutants.
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from the IGFBP-5 sequence and 58bp from pFastBacl) (Figure III.5A). The BP550 mutation 
introduces a unique Apal restriction site, as there are no Apal restriction sites in either the IGFBP-5 
or pFastBacl plasmid sequence (note that this restriction site is dcm methylation sensetive, so that 
the mutant DNA had to be amplified in the JM110 bacterial cell line, which is dcm free). As 
expected, Apal does not cut pFastbaclWTIGFBP-5, whereas pFastBaclBP550 is linearised (Figure 
III.5B).
111.2.2 Expression of mutant proteins
The baculovirus expression system was chosen to express wt IGFBP-5, G203K, Q209A, 
Hep-, Double and BP550 in insect cells. The baculovirus expression system offers the advantage of 
being able to directly harvest the recombinant protein in a soluble form from the insect cell 
conditioned medium, as these cells are able to utilize mammalian signal peptide sequences and 
secrete the protein.
Following the construction of recombinant baculoviruses carrying either wt IGFBP-5 or 
other mutant DNAs, the expression of the encoded proteins was obtained by infecting Sf9 insect 
cells, as described in chapter II. To detect the presence of WTIGFBP-5 or other mutant proteins in 
the insect cell supernatants, equal volumes of the concentrated conditioned media were collected 
following a time-course and electrophoresed on a 12% (or 16% for BP550) gel under non-reducing 
conditions. Figure III.6 shows the results of IGFBP-5 western blots with these samples. From this 
work, it became apparent that the virus infection time required for achieving optimal yield of 
recombinant protein varied between the different clones. WTIGFBP-5 and the other mutant proteins 
appeared as a major band of approximately 34kDa, with the exception of BP550 at 24kDa (Figure 
III.6). Others have reported an IGFBP species expressed from sI9 insect cells, which had IGF 
binding affinities similar to mammalian IGFBP-1 (Doverskog et al, 1999). However, we have tested 
our sf9 cells, which were obtained directly form Gibco-Life technology, and two independent 
researchers in our group were un able to detect any IGF binding activity in culture medium from 
uninfected cells (Figure III.7; pers. Comm. S. Bramani). We consider it unlikely that different 
strains of sI9 insect cells would differentially express an IGFBP species, and believe that our results 
question the validity of the data of Doverskog et al, 1999.
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Following concentration, the harvested proteins were purified on an IGF-II affinity column 
(described in chapter II). The purity of the proteins were assessed on IGFBP-5 westerns, and the 
results for WTIGFBP-5 are shown in Figure III.8. All the recombinant proteins described in this 
thesis were subject to the same purification procedure and showed immunogenic reactivity with 
either anti-rat IGFBP-5, or anti-rat IGFBP-2 (as described in chapter IV). Although there was some 
non-specific loss of protein during the washing stages, we were able to obtain protein 
concentrations of 40, 46, 45, 25, 22 and 24ug/ml for WTIGFBP-5, G203K, Q209A, Hep-, Double, 
and BP550 respectively, as measured by Bradford assay. The in vitro analyses o f these purified 
proteins forms the remainder of the results in this chapter.
111.2.3 Analysis of G203K and Q209A
Western lisand and immunoblotine. Approximately 200ng of WTIGFBP-5, Hep- and the 
two single mutants, G203K and Q209A, were loaded on a 12% polyacrylamide gel under non­
reducing conditions to examine the binding to both 125I-IGF-I and -II by ligand blot analysis. 
Following ligand blot analysis, the membrane was re-probed with anti-rat IGFBP-5 antisera to 
monitor protein loading. Figure III.9A shows that, although both G203K and Q209A are slightly 
overloaded with respect to WTIGFBP-5 and Hep-, the binding of both G203K and Q209A to IGFs 
is dearly compromised compared with WTIGFBP-5. Scanning densitometry of these blots indicates 
that binding of G203K and Q209A was reduced to approximately 15-25% of that seen for the 
WTIGFBP-5 for both IGF-I and IGF-II binding (Figure III.9B). Conversely, the binding of the 
Hep- mutant to either 125I-IGF-I or -II was not affected, giving a signal on ligand blots equivalent to 
that seen for WTIGFBP-5. This experiment was repeated six times with similar results in each 
instance.
Solution phase analysis was performed to examine the affinity of these four proteins for 
IGFs (FigureIII.10). Data were analysed by Scatchard transformation (Scatchard, 1949) which 
generated a linear regression binding curve. Scatchard analysis of the binding curves for 
WTIGFBP-5, Hep-, G203K and Q209A proteins gave Kd values of 0.061, 0.058, 0.283 and 
0.173nM respectively for binding to IGF-I (Figure III.10A) and 0.024, 0.41, 0.077 and 0.12nM
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respectively for binding to IGF-II (Figure III.10B). These data for WTIGFBP-5 indicate a 2.5-fold 
greater affinity for IGF-II than for IGF-I, which agrees with the ligand preference reported for 
human IGFBP-5 (Kiefer et al, 1992). These data also indicate that the compromised binding of 
IGF-I and -II to G203K and Q209A detected by ligand blot was also apparent in solution phase, 
with a 4.6- and 3.2-fold reduction in binding of G203K to IGF-I and -II, respectively and a 2.8- and 
5-fold reduction in Q209A binding to IGF-I and -II, respectively. We did not detect any significant 
differences in binding IGFs between WTIGFBP-5 and the Hep- mutant by either ligand blotting or 
solution phase assay. These experiments were repeated four times with similar results obtained in 
each instance.
111.2.4 Analysis of Double mutant and BP550
Although the G203K and Q209A mutantions caused a significant reduction in binding to 
both IGF-I and -II, this was not comparable with the previous C-terminally truncated IGFBP-2 
mutant of Forbes et al. (1998) where they had observed an 80-fold reduction in binding IGF-II 
following the deletion of both of these amino acids. Consequently, we decided to mutate both 
amino acids to establish whether there might be a cumulative effect of G203 and Q209 on IGF 
binding. Figure III. 11 shows the results of an ,25I-IGF-I and -II ligand blot and an anti-IGFBP-5 
immuno blot for WTIGFBP-5, Hep- and Double mutant. Our ligand blots demonstrate that binding 
of Double mutant to 125I-IGF-I is completely ablated , where 125I-IGF-H binding is minimal (Figure
III. 11). This experiment was repeated five times with similar results in each instance. For further 
confirmation of the IGF-binding properties of the Double mutant, solution phase analysis was 
performed with both Double mutant and BP550. Data were again analysed by Scatchard. Kd values 
of Double and BP550 were 5.01 and 3.86nM for binding to IGF-I (Figure III. 12A), and 4.8 and 
4.1nM for binding to IGF-II respectively (Figure III.12B). Comparing this to the affinity of 
WTIGFBP-5 (Figure III. 10) shows that the Double mutant has a 82- and 200-fold lower affinity for 
IGF-I and -II, respectively, whereas BP550 has a 63- and 170-fold lower affinity for IGF-I and -II 
respectively. This experiment was repeated four times, with similar results obtained each time.
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111.2.5 BIA-core analysis
As a further confirmation of the IGF-binding properties of these IGFBP-5 mutant proteins, 
biosensor analysis of binding kinetics of the proteins were undertaken to both immobilised IGF-I 
and -II biosensor surface (Table III. 1). This type o f analysis gives details of on- and off-rate kinetic 
constants from which association and dissociation constants can be derived, whereas solution phase 
assay only represents equilibrium binding events. The qualitative differences in the affinity of the 
four IGFBP-5 proteins for both IGF-I and -II  were maintained (Table III. 1 and Figure III. 13). 
Closer inspection of the Biacore data revealed that the reduction in the affinity of the mutants for 
IGF-I and IGF-II was due largely to a reduction in association rates, with much smaller effects on 
the dissociation rates for these complexes. Therefore the overall equilibrium constant (KD) of 
G203K showed a 6.5-and 15-fold lower affinity than that of WTIGFBP-5 in binding IGF-I and -II 
respectively. For the Q209A mutant, there was a 12- and 51-fold reduction compared to WTIGFBP- 
5 in binding IGF-I and IGF-II respectively. For the Double mutant, no real association could be 
measured in this system. However note that both ligand and western immuno blot showed a doublet 
band of the same size at WTIGFBP-5, which bound l25I-IGF-II weakly. The C-terminally truncated 
BP550 also showed large reductions in binding to IGF-I and IGF-II, although the effect for IGF-I 
was less than that for IGF-II.
Also o f interest was the observation that, although the overall affinity (KD) o f the Hep- 
mutant for IGF-I and -II  was similar to that of wild-type IGFBP-5 at the level of rate constants 
there were apparent differences for the interaction of Hep- with either IGF-I or IGF-II. However, 
the 8- and 26-fold decreases in Kon values for Hep- binding to IGF-I and -II, respectively, were 
partly compensated by the 15- and 67-fold decreases in Koff values obtained for the same binding 
events. This results in a similar affinity for WTIGFBP-5 and Hep- binding to IGF-I and -II. In 
addition, the absolute values for equilibrium constants (KD) derived by biosensor were two to three 
orders of magnitude lower than that obtained with the charcoal-based solution phase assays (see 
Discussion). The BiaCore experiments were carried out on two separate occasions, with extremely 
similar data produced on both occasions.
Table IIL1 Bia-core analysis o f kinetic constants for WTIGFBP-5, hep-, G203K, 
Q209A, Double and BP550 binding to immobilised IGF-I and —II. For further 
details, see chapter II.
Protein
IGF-I IGF-II
Kqn (Ms'1) Koff (s ') k d (m ") Kqn (Ms") Koff (s *) Kd (M-1)
WTIGFBP-5 4.9 X 104 1.6 X IO'3 3.2 X 10" 2.5 X 105 3.3 X 10" 1.3 X 10‘9
Hep- 6.3 X 103 1.1 X 10" 1.8 X 10"8 9.7 X 103 4.9 X 10" 5.0 X IO’9
G203K 9.4 X 103 2.0 X IO'3 2.1 X 10‘7 2.8 X 104 5.7 X 10" 2.0 X 10"
Q209A 1.7 X 104 6.8 X IO’3 3.9 X IO 7 6.3 X 103 5.2 X 10" 6.5 X IO'7
Double 0.0735 3.7 X 10'3 0.0504 759 5.7 X IO'3 7.5 X 10"
BP550 1.6 X 103 0.0173 1.1 X 10‘5 2.1 X 103 3.6 X IO 3 1.7 X 10"
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III.2.6 Heparin binding assay
Experiments were also carried out to investigate the heparin-binding properties of 
WTIGFBP-5 and other mutant proteins. Using a blotting methodology with a heparin-biotin 
conjugate and streptavidin-HRP/ECL detection system, we were able to confirm that the Hep- 
mutant containing mutations at four basic residues important for heparin binding (R201L, K202E, 
K206Q and R214A) showed greatly reduced heparin binding (Figure III. 14). However, the G203K, 
Q209A and Double mutant displayed a binding activity for the heparin-biotin conjugate similar to 
that displayed by the WTIGFBP-5. This experiment was repeated seven times, with similar results 
in each instance.
III.3 Discussion
The IGFBP-5 doublet produced by expression in the baculovirus system is a common 
feature from several laboratories (personal communications Dr. D. Andress, Dr. S. Guenette), 
including commercially available hIGFBP-5 (Austral biologicals), and this may be the result of 
inefficient cleavage of the mammalian signal peptide during secretion. In addition, others have 
observed an IGFBP-5 doublet expressed from human fibroblast cells (Arai et al. 1994b), 
demonstrating that this is not specifically a result of expression of IGFBP-5 in insect cells. 
Nevertheless, Biacore analysis of the wild type rIGFBP-5/hIGFs interaction recorded a single 
association and dissociation event suggesting that the IGFBP-5 doublet represents a single species 
with respect to IGF binding. Also, the strong recognition of the mutant proteins with our in house 
IGFBP-5 antibody demonstrates their immunological integrity.
Ligand blot analysis with 125I-IGF-II followed by densitometry indicated binding of 
G203K and Q209A at 15-25% of that seen for wt IGFBP-5, which agreed with the data obtained 
following ligand blot analysis with 125I-IGF-I. However, solution phase assay with IGF-II indicated 
a somewhat smaller decrease in affinity - reduced 3-fold and 5-fold for G203K and Q209A 
respectively. Although we did not conduct a systematic analysis of the differences in ligand binding 
between these two methodologies such differences have been reported previously (Hobba et al, 
1998). In a similar vein, ligand blot analysis suggested equivalent binding of labeled IGF-I and -II
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by WTIGFBP-5 and Hep- proteins. This was paralleled by only a small difference in affinity 
between the two proteins on solution phase analysis of binding (Hep- has same and 1.7-fold lower 
affinity for both IGF-I and -II). Interestingly, BiaCore analysis of Hep- indicated a much reduced 
value for Kon compared to WTIGFBP-5. However this was balanced by the fact that Hep- also 
displayed a lower Koff when compared to WTIGFBP-5. It has been suggested by Hobba et al 
(1998) that ligand blot analysis may rank IGF binding to IGFBPs in order of the K o f f  values for 
complex formation. Although this is still open to some debate our ligand blot data show equivalent 
signals for WTIGFBP-5 and Hep- proteins. It is important to note that the Kd of our WTIGFBP-5, 
as determined by solution phase assay is in agreement with the work of others using mammalian 
IGFBP-5 and the yeast expressed protein (Kiefer et al. 1992).
In a qualitative sense our biosensor data support the findings of both the ligand and 
solution phase assays o f IGF affinity with major effects of G203K and Q209A binding to IGF-I and 
-II and a much smaller effect of Hep- interaction with either of the IGFs, although there are specific 
effects on K 0 n and K o f f  fo r  this latter protein (see Results). The absolute Kd values obtained by 
Biosensor are 10-100 fold lower than those seen in solution phase and are also lower by the same 
order of magnitude than the affinity constants reported for the human IGFBP-5 interaction with 
hIGF-I by BiaCore (Kalus et al, 1998). However, these researchers used biotinylated IGF-I or -II 
immobilised to streptavidin coated biosensor chips together with different conditions for monitoring 
on and off rates. In addition the homologous interaction system reported by these authors (human 
IGFs and human IGFBP-5) is different from the current study where rat IGFBP-5 proteins were 
exposed to sensor chips containing directly immobilised human IGF-I or -II. Together, these 
experimental differences may account for the different results obtained. Interestingly, and 
supportive of this argument, are the findings of Hobba et al, 1998, who examined the heterologous 
interaction of bovine IGFBP-2 with immobilised human IGF-I and -II. In this study conditions of 
ligand immobilization and binding analysis were similar to those described in the current work and 
accordingly these authors reported kinetic constants of the same order as reported here. 
Notwithstanding these arguments, our Biosensor data fully supports our ligand blotting and solution 
phase data indicating compromised binding of G203K and Q209A to both IGF-I and IGF-II with 
only a relatively minor affect on IGF binding of Hep-. In conclusion, we have demonstrated that
Gly203 and Gln209 in rIGFBP-5 are important determinants in binding IGFs as measured by three 
independent techniques, ligand blotting, solution phase assay and Biacore analysis.
Others have found a far greater reduction (upto 80-fold) in IGF-II affinity when the 
equivalent amino acids (222-236) were deleted from bovine IGFBP-2 (Forbes et al. 1998). This 
may reflect differences in the C-terminus between IGFBP-5 and -2  with respect to binding IGF-II, 
or alternatively, the loss of both of these residues, as is the case with the IGFBP-2 truncation, may 
have a cumulative effect which results in a greater reduction in binding. In order to test this 
hypothesis, we subsequently made both the Double (G203K/Q209A) and C-terminally truncated 
BP550 mutants. As the C-terminal domain of IGFBP-5 has been previously shown to be required 
for IGF binding, (Andress et al, 1993), BP550 serves as a negative control which cannot bind 
ligand effectively. As expected, ligand blotting could not detect any binding of BP550 to IGF-I and 
only very weak binding activity to IGF-II. Interestingly, this was also the case for the Double 
mutant. In support of this, our solution phase experiments demonstrated that BP550 had a 63- and 
170-fold reduced Kd for IGF-I and -II  respectively, compared to WTIGFBP-5 (Figure III. 12), 
whereas the Double mutant had a 82- and 200-fold reduction in binding affinity for IGF-I and -II 
respectively. Furthermore, in the Biacore assay, the Double mutant showed a large reduction in 
binding both IGF-I and IGF-II and again this was manifested as a major decrease in the association 
rate for the proteins, whereas the dissociation rate was relatively less affected. Therfore, we have 
clearly shown that there is a cumulative effect o f Gly203 and Gln209 on IGF binding, where loss of 
both leads to a far greater reduction in IGF binding affinity, and this may explain the previous 
discrepancy with the data of Forbes et al (1998) for IGFBP-2. In addition, as the Double mutant has 
a reduction in IGF binding that is comparable to that for BP550, which lacks the entire C-terminal 
domain, this may indicate that Gly203 and Gln209 are the major determinants in this domain with 
respect to IGF binding.
The fact that Gly203 and Gln209 in the C-terminus of IGFBP-5 are completely conserved 
between all six binding proteins from all species sequenced to date suggests that they may have a 
conserved function in IGFBP biology. From this work it would appear that for IGFBP-5 at least, 
one of the functions of these residues involves IGF binding. This is of major significance when one 
considers that in IGFBP-5 and -3  these two residues lie in the middle of a stretch of basic amino
acids that have previously been shown to be involved in binding to heparin and to components of 
the ECM (Arai et al. 1996a; Parker et al. 1996). Other functions ascribed to this region in IGFBP-5 
include binding to the acid labile subunit (Twigg and Baxter, 1998), the putative IGFBP-5 receptor 
(Andress 1998), and plasminogen activator inhibitor-I (Nam et al. 1997). It has even been 
postulated that this sequence has strong homology to nuclear localization signals (Schedlich et al. 
1998) and the DNA-binding domains of several transcription factors (Schedlich et al. 1998; 
Mitchell & Tjian 1989).
Heparin ligand analysis clearly demonstrates that the binding of mutants G203K, Q209A 
and Double for heparin is not compromised (Figure III. 14). However, as a control we also decided 
to study some of the flanking basic amino acids, mutation of which had been shown by others to 
affect heparin binding (Arai et al. 1996a), while not affecting IGF binding (Parker et al. 1998). This 
is confirmed with the results for our mutant Hep- (R201L, K202E, K206Q, R214A), which had a 
major reduction in binding heparin, but unimpaired binding to IGFs (Figure III.9, 10, 13, & 14). 
Therefore, it would appear that in the linear sequence, basic amino acids involved in heparin 
binding are interspersed with non-basic amino acids involved in IGF binding. A helical wheel 
prediction of the 201-218 region of IGFBP-5, places Gly203 adjacent to important ECM binding 
residues, while Gln209 is flanked by two further basic residues elsewhere in the wheel (Figure
III. 15). This demonstrates that there may be overlap between IGF and ECM binding sites in the C- 
terminus of IGFBP-5.
As Gly203 and Gln209 are conserved in all six binding proteins, whereas the C-terminal 
heparin binding sequence is only common to IGFBP-5 and -3 , this may mean that the IGF binding 
function of this region predates heparin binding. Therefore, the heparin/ECM binding sequences in 
IGFBP-5 and -3 may have evolved later to provide greater regulation of an increasingly complex 
IGF system. Whether this regulation serves to potentiate or inhibit the effects of IGFs is unresolved, 
although experiments from other laboratories clearly indicate that heparin/ECM bound IGFBP-5 
has between an 8- and 17-fold reduced affinity for binding IGF-I (Andress & Bimbaum 1992; Jones 
et al. 1993; Arai et al. 1994a). These reduced affinities may be crucial in obtaining the correct 
balance between soluble IGFs available for binding IGF receptors, and ECM bound IGFBP-IGF 
complexes.
Fig III. 15 Helical-wheel projection of the 201-218 region of rat IGFBP-5. 
The location of basic R and K residues believed to participate in heparin 
binding are indicated by grey shading, and the residues Gly203 and Gln209 
(mutated in this study) are shown in black, (adopted from Parker e t  a l , 1998)
One explanation offered for the reduced affinity of ECM bound IGFBP-5 for IGF-I is that heparin 
binding might induce a conformational change in IGFBP-5, which alters an IGF binding domain 
elsewhere in the protein (Arai et al. 1996a) (Figure III.16A). Based on the work reported here, 
where we indicate a potential overlap between heparin and IGF binding sites in the C-terminal 
domain of rat IGFBP-5, we propose an alternative more direct model whereby heparin or ECM 
binding to the basic amino acids in the 201-218 region of IGFBP-5 may physically interfere with 
the subsequent interaction with IGFs (Figure III.16B). It is possible however that this region of the 
IGFBP-5 protein does not exist as a helical structure and that there is a spatial separation of G203, 
Q209 and the important basic residues. Further advances in this area will be achieved by the careful 
structural and functional analysis of heparin-IGFBP5-IGF complexes.
120
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Fig III. 16 Schematic diagram outlining two models for the interaction of 
IGFBP-5 with components of the extracellular matrix and the subsequent 
lowering of affinity for IGF-IGFBP-5 interaction. In (A) binding of IGFBP to 
components of the ECM results in a conformational change in IGFBP structure 
such that the affinity of the binding protein for ligand is decreased. In (B ) , as 
supported by the data from the current study, there is overlap between the IGF 
and ECM binding domains in IGFBP-5, offering a more direct route by which 
interaction of IGFBP-5 with ECM may affect subsequent IGF binding.
Chapter IV. Binding o f chimeric IGFBP-2 and -5  proteins to IGFs
IV. 1 Introduction
As discussed in chapter 1.3.3, many researchers have performed experiments aimed at 
identifying the IGF binding motifs in the N- and C-terminal domains of IGFBPs (Hobba et al, 1996; 
Kalus et al, 1998; Imai et al, 2000; Song et al, 2000). Although, progress has been made in 
identifying the specific amino acids, that are involved in IGF binding, the exact contribution of the 
entire N- and C-terminal domains of IGFBPs in IGF binding is still controversial. For example, 
Kalus et al. (1998) have proposed that the primary IGF binding site is in the N-terminal domain and 
that the C-terminal domain merely serves to stabilise this primary binding event. It has been 
generally accepted that the two highly structured terminal domains are likely to be in simultaneous 
contact with the smaller IGF molecule, with the more flexible central domain connecting them, 
although this model will only be confirmed by the eventual determination of IGFBP-IGF structure 
through techniques such as X-ray crystallography.
In addition, ligand preferences of IGFBPs have been reported (reviewed by Jones and 
Clemmons, 1995; Clemmons, 1997). How this ligand preference operates at the level of the 
terminal domains is not known. One suggestion that this preference may operate in the C-terminal 
domain of IGFBP-2 came from the work of Forbes et al. (1998), where they found that the affinity 
for IGF-II was affected far more than that for IGF-I binding in C-terminally truncated mutants of 
this binding protein. Contrary to this, there are several reports from other laboratories that a 
proteolytic N-terminal IGFBP-5 fragment binds to IGF-II (Imai et al, 1997; Hakeda et al, 1996), 
whereas 13.3 and 13.5Kd C-terminal fragments retain significant IGF-I binding (Standker et al, 
1998).
In order to assess the contribution of the N- and C-terminal domains to IGF binding, we 
decided to make chimeric IGFBP proteins by switching domains between rat IGFBP-5 and rat 
IGFBP-2. In the context of IGF binding, these two binding proteins seemed the best choice from 
which to make chimeras, due to their very marked differences in IGF binding. IGFBP-2 and 
IGFBP-5 have been reported to have the lowest and highest affinities for binding IGFs respectively
among all six IGFBPs, although both have a preference for binding IGF-II over IGF-I (Kiefer et al., 
1992). In addition, IGFBP-5 and -2  differ greatly with respect to binding heparin/ECM and the cell 
surface and this will be dealt with in more detail in chapter V.
We have made four domain switched chimeric IGFBPs as described in chapter II, and 
have compared the IGF binding kinetics between wild type and chimeric IGFBPs. The chimeric 
IGFBPs are named BP552, BP522, BP255, and BP225 to reflect the domains that they contain 
(Figure IV. 1).
IV.2 Results
IV.2.1 Construction of BP552, BP522, BP255, and BP225 chimeric cDNAs
Four chimeric rat IGFBP cDNAs were constructed using mutagenesis to create a unique 
Xhol site at the junction between exonl and 2, and exon 2 and 3, in both rat IGFBP-5 and -2. 
Following digestion with Xhol, the domains were switched by “cutting and pasting” (described in 
more detail in chapter II). The introduced Xhol sites were designed carefully, so that the open 
reading frames would be maintained downstream following cutting and pasting. The rat IGFBP-2 
cDNA (977bp) consists of 65 bp 5’ and 3’ untranslated sequence (Figure III.3, see page 96), 393bp 
exonl, 210bp exon2, 148bp exon3, and 16lbp exon4. Exonl and 2 encode the N- and central- 
domains respectively, whereas exon3 and 4 encode the C-terminal domain. The rat IGFBP-5 (964 
bp) cDNA consists of 95bp 5’ and 3’ untranslated sequences (Figure III.3, see page 96), 390bp 
exonl, 228bp exon2, 120bp exon3, and 13lbp exon4. The exons encode the same domains 
described for the rat IGFBP-2 cDNA. Figureure IV.2 shows the results of Xhol restriction analyses 
of pFastBacl clones containing wild type IGFBP-5 and -2 and the initial Xhol containing IGFBP-5 
and -2 mutants termed BP5/XhoI and BP2/XhoI (Xhol site between exons 1 and 2 of IGFBP-5 and 
-2 respectively) and XhoI/BP5 and XhoI/BP2 (Xhol site between exons 2 and 3 of IGFBP-5 and -2 
respectively). Although there are no Xhol sites within the wild type rat IGFBP-5 and -2 cDNA 
sequences, there is one Xhol restriction site within the pFastBacl plasmid. Therefore, pFastBacl 
WTIGFBP-5 and WTIGFBP-2 are linearised following digestion with Xhol to create 5739 and 
5747 bp fragments respectively. After successful mutagenesis to create BP5/XhoI and XhoI/BP5, 
the new Xhol restriction sites within the IGFBP-5 sequence results in the release of 624 and 396 bp
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IGFBP-5 
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Fig IV.2 (A) Xhol digests of pFastBacl wtIGFBP-5 and mutant cDNAs, lane 
1: wild type IGFBP-5, lane2: BP5/XhoI, Lane3: XhoI/BP5. (B) Xhol digests of 
pFastBacl wtIGFBP-2 and mutant cDNAs, lane4: wild type IGFBP-2, lane5: 
BP2/XhoI, Lane6: XhoI/BP2. SM represents X-hindlll (A), X-Hindlll /(j>xl74 (B) 
DNA size markers, and arrows indicate newly created cleavage Bands.
fragments respectively (Figure IV.2A). Digestion of BP2/XhoI and XhoI/BP2 results in the release 
of 596 and 386 bp fragments respectively (Figure IV.2B). After "cutting and pasting" the various 
domains of rat IGFBP-2 and -5, the intermediate chimeric mutants still contain an Xhol site. 
Figure IV.3A shows the results of an Xhol restriction enzyme digestion of these clones, where 
BP552, BP225, BP522, BP255 release 386, 396, 596 and 624bp fragments respectively.
To restore the wild-type IGFBP-5 and -2  sequences at the various junctions in the 
chimeric cDNAs, and thereby remove the Xhol sites, a second round of mutagenesis was performed 
using the oligonucleotides described in chapter n. These final chimeric IGFBPs clones, containing 
completely wild type sequence, were also digested with Xhol. The results are shown in Figure 
IV.3B, where the BP552, BP225, BP522, BP255 are now only linearised at the Xhol site contained 
within the pFastBacl plasmid. To confirm this restriction analyses, all four chimeric cDNAs (10pg) 
were sequenced by MWG biotech (Milton Keynes, UK).
IV.2.2 Expression and primary analysis of non-purified chimeric proteins
The four chimeric proteins were expressed using the baculovirus expression system. To 
detect the presence of hybrid mutant proteins in the insect cell supernatants, equal volumes of the 
conditioned media were collected following an infection time-course and western immunoblotted. 
Three of the chimeric proteins were readily detected by either anti-IGFBP-5 and/or IGFBP-2 
antibody in the unconcentrated culture medium as a major band of approximately 30~34kDa (data 
not shown). However, BP225 was not detected in the culture medium in ten separate attempts to 
express this chimeric protein. Nevertheless, we decided to concentrate the culture medium from a 
BP225 infection ten-fold, along with the other three chimeras, using a centricon ultrafree-20 
column (Millipore, UK) as described previously.
Following concentration, the proteins were subject to electrophoresis on a 12.5% 
polyacrylamide protein gel under non-reducing conditions and the gel stained with coomasie blue in 
an attempt to determine the different ratios of protein concentrations relative to WTIGFBP-5 and -2 
(Figure IV.4). Western immunoblotting was not considered appropriate for determining these ratios, 
since the chimeric proteins will have varying immunogenic responses to the anti-IGFBP-5 and -2
126
Xhol containing
SM 552 225 522 255
B Wild type
SM 552 225 522 255
23130
9416
6557
2322
2027
564
Fig IV.3 (A) Xhol digests of Xhol containing pFastBacl IGFBP-5 and -2 
chimeric cDNAs. (B) Xhol digest of wild type chimeric IGFBP-5 and -2 cDNAs. 
SM represents a ^-Hindlll DNA size markers.
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antibodies. No protein species of the correct size (30~34kDa) could be detected in the concentrated 
BP225 culture medium (Figure IV.4). Densitometry was carried out on this gel to get an estimate of 
protein concentration for subsequent western ligand and immunoblot analysis. Based on this, an 
attempt was made to load equal amounts of WTIGFBP-5, WTIGFBP-2, BP552, BP522 and BP255 
protein, whereas the maximum well volume was loaded for BP225 (approx 25pi). The results of 
western ligand blotting and immunoblotting with these protein samples are shown in Figure IV.5 
(this experiment was repeated seven times with similar results in each instance). From the western 
immunoblot (IV.5B), the first point of note is that the anti-rat IGFBP-5 and anti-rat IGFBP-2 
antisera only recognise the binding protein to which they were raised and do not cross react with the 
other binding protein. It is also clear that the polyclonal anti-rat IGFBP-5 antisera has epitopes in 
the N-terminal domain of IGFBP-5, (as BP522 is recognised), and other epitopes elsewhere in the 
central and/or C-terminal domain (as BP255 is recognised). From our data we can only be sure that 
the anti-rat IGFBP-2 antisera has epitopes in the C-terminal domain of IGFBP-2 (as BP552 is 
recognised). For BP225 our data suggests very weak recognition by the IGFBP-2 antisera, although 
there is only a smear with the IGFBP-5 antisera. From the IGF ligand blots (IV.5B), it would appear 
that BP552 and BP522 are comparable to the wild type binding proteins in their binding affinities 
for both IGF-I and -II, whereas BP255 does not appear to bind IGF-I, and only binds IGF-II very 
weakly. The binding of BP225 to IGFs is inconclusive, as the evidence would strongly suggest that 
this protein is not properly expressed. Based on this evidence, BP225 was excluded from further 
analyses.
The IGF binding properties of the remaining three chimeric proteins were also analysed in 
125I-IGF-I or ,25I-IGF-II solution phase binding assays, and the results are shown in Figure IV.6. 
These results support the ligand blot data, where BP552 and BP522 have affinities for binding IGFs 
that are equivalent to the wild type proteins, whereas the affinity of BP255 for binding IGFs is 
greatly compromised. This experiment was repeated four times, with similar results in each 
instance.
Based on the above data from ligand blot and solution phase data, it was decided to purify 
BP552 and BP522 by IGF affinity chromatography, so that the IGF binding characteristics of these 
two chimeric proteins could also be analysed in the BiaCore system.
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IV.2,3 Analysis of purified chimeric proteins
Both BP552 and BP522 were applied to an IGF-II affinity column following the method 
described in chapter II. Subsequently, the concentration of the purified proteins was determined by 
Bradford assay (BP552 and BP522 were 45 and 26ug/ml respectively). The purified proteins were 
first analysed by western immuno blotting using the anti-IGFBP-2 and -5 antisera described above 
(Figure IV. 7) (these experiments were repeated three times, with similar results obtained on each 
occasion).
Solution phase IGF binding assays were also carried out on the purified BP552 and BP522 
chimeras and the data were applied to Scatchard transformation (Scatchard, 1949) to generate linear 
regression binding curves (Figure IV.8) (this experiment was repeated four times, with similar 
results in each instance). From this analyses, IGFBP-5, BP552, BP522, and IGFBP-2 proteins were 
calculated to have Kd values of 0.061, 0.62, 0.036 and 0.0.038nM respectively for binding to IGF-I 
(Figure IV.8.A), and 0.024, 0.034, 0.028 and 0.021nM respectively for binding to IGF-II (Figure
IV.8.B). Therefore, from this experiment it would appear that all four proteins have essentially the 
similar affinity whether IGF-I or IGF-II is used as ligand. However overall there appears to be an 
approximately 2-fold higher affinity for IGF-II.
Finally, a BiaCore analysis was undertaken to further investigate the IGF binding 
properties of BP552 and BP522 (Table IV. 1 and Figure IV.9). In Figure IV.9, the individual 
sensograms are presented for WTIGFBP-5, WTIGFBP-2, BP552 and BP522 binding to both human 
IGF-I and IGF-II immobilised on the surface of biosensor chips. The binding curves clearly indicate 
an interaction of all four proteins with both IGF-I and IGF-II. The data are summarised 
quantitatively in Table IV.1, where we demonstrate KD values for WTIGFBP-5 protein of 10'8 to 10' 
9 M. In this system, both BP552 and BP522 display wild type like binding for both IGFs, with their 
affinity constants comparable to that for WTIGFBP-2 and -5. Interestingly, the data for WTIGFBP- 
2 demonstrates that this binding protein not only has a 20-fold higher affinity than WTIGFBP-5 for 
binding IGF-I, but that it also has a 5-fold higher affinity for IGF-I than IGF-II.
132
0>
X
o
CL
0 3
H
£
03
0 3
•O)
Cl
CQ
0 3
i n
O h
CQ
'O
H
<
m
i
Oh
QQ
X
a
cd
L iI
C
<
<
t I t t
Q
x
r o
a
o
CO
Q
0 3
H
£
0 3
0 3
i n
CL
PQ
0 3
lO
•O
a .
CQ
» o
H
£
0 3i
CL
CQ
PLa
cd
LiI
»
c<
<d
L i -*—*
5  cd
t
3
o
ro
CQ
c/3
C
‘5
c
cd
l*
OO
L i
Ql ^
o ?
> 01 >  03
W  PL
<N a
CL ~  
CQ g  
Ph V
2  1
?  2  
__* cd
Id  c  
§  O ^ o  
03 >>
03 ^
JO CL 
CQ «*
L i
<D
<L>
03 
to
T^)
CL 
CQ •£
^  ’> m
H 1 -o
^  j s
w  o
lOI
CL
CQ
PL
O
Li
CL
<DLi
<D
£
£  O
<D c j 
X  X. n  -4—>
3  yCl C
i r  «*o C/3 
c/3 CD
£  W)
-—« (U
X  -o0
| !
1  u  Cfl
cd s—'
£  S 
CL 2
^  .22
t — cd
>  O <?
^  «  m  
S fS  £
E  1 2
CLi
<D+-»
C /3
CD
W
T5
; 
Kd
=0
.0
61
±0
.0
04
 
BP
55
2;
 K
d=
0.
06
2±
0.
00
3
133
* m
oo
CQ
<3
CO H HCtf r ' Ph
p . oA M C I 
O * -4
°  <!1/1 w '
^  o.p +->
73 00
<3 p
CO
Cd *»-hp ^
2 m
s> ph
£ oHH
<N P  
(N  O
co
<3 %  cd
CO >  
<3
P  ^
PO §
3
a
CO 
CO
CD
Sbjg 
a  p
u-i
P h
PQ
73
PO*tda
CO
<3 O
8 & § W
.a ^
JQ C '*-* is 
O 3
CO
a  -u
CM
Ph -3
• *-i
3  o
PQ
r iI
Ph
PQ
P h
O
3 r1 pCj Ph+■* o
*h  M(u z:CH ^3
*  iS
7 3  ' oj 
3  <D 
>  cd•J-* r—I
S3 §
8 °
£  1/3
COI
P hP > p
f t  2  °
2  *51-* S
?  g £
§ 8 
73
o3
O 'g b0
aoo
cd
P h CO
cds £ gLij • Vh
at—! %-t
C+H Wo
S*5co O
CO _ ,«* .a
w  7 3CO ^
cd
_  C<H 
Oh O
3Op
3
co
3*-iPh
<D-S  :5  -^  S £
c  £  o  <3 .ip 73J3
OC/3
00
>
CO H H
*  f i
1 *2CO ►“ P
rr* ^CO «n
bO 2  «  C ^
ea'-g SP  . JP_ J—i
f t  43 O
73
&
S CO<3
P
M  0
S  o
I  -a
w  -g # •
(3  >
(3  ; r i
*  ^  
« i
o £
. P  £  
*> *p^  £
PQ 2  
.23 |
? ..§--3 «h03 <3
a 9^cd XJ 
73 ^
is ^CO ^  
r P  Cdo
h—> cd
«  P h0  0)
C /) CO
r P  m
73 °
<3 CO
•I |H-> O
■o *s ”S
cd >  
T 3 ’ C  
<3
^  <3
J3 *-•*3) £p ^
S « 
^  5
5P > l-H
1 •-
T3 * £
Table IV.l BIA core analysis
Protein
IGF-I IGF-II
K 0 n (M s- ')  K q ff  ( s '1)  K d ( M '1)  K onC M s’1) K 0Ff  ( s '1)  K
IGFBP-5 6.58 X 104 5.06 X 10’3 7.68 X 10*8 4.53 X 105 2.93 X 10’3
BP552 1.03 X 105 1.18 X 10"3 1.14 X 1 0 8 6.30 X 104 6.04 X HT4
BP522 2.64 X 104 7.82 X 1 O'4 2.97 X 10 '8 1.84 X 104 1.42 X 10*3
IGFBP-2 1.11 X 105 4.09 X 10-4 3.69 X 10'9 1.74 X 104 3.19X 10-4
Biacore analysis of kinetic constants for WTIGFBP-5, BP552, BP522, and WTIGFBP-2 binding to 
immobilized IGF-I and -II. General curve fitting was performed for 8.75, 4.38, 2.19 and 1.04 nM of 
analyte -  using software provided by Biacore.
K d is derived as K 0f f  /  K 0n-
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IV. 3 Discussion
We have attempted to express four chimeric IGFBP proteins made from switching 
domains between rat IGFBP-5 and -2 in the baculovirus/insect cell system. While we are able to 
detect expression of three of these proteins, we were consistently unable to detect expression of one 
of the chimeras, BP225. One possible explanation for this is that this recombinant protein cannot 
be properly folded by the insect cells and, as a result, may be susceptible to proteolysis. In support 
of this, western immuno analysis using the anti-rat IGFBP-5 antiserum only detected a smear for 
BP225, which is suggestive o f proteolysis (FigureIV.5B). BP552, BP522 and BP255 were all 
detectable by both Coomassie blue staining and western immunoblotting. Our results indicate that 
the anti-rat IGFBP-5 and anti-rat IGFBP-2 antisera do not cross react with the other binding protein, 
so that the recognition of BP552 and BP522 by both antisera (Figures IV.5B and IV.7) confirms 
their identity as chimeric proteins made up from domains from both IGFBP-5 and -2. BP255, on the 
other hand, was only recognised by the anti-rat IGFBP-5, but this could be explained by the anti-rat 
IGFBP-2 antiserum lacking epitopes in the N-terminal domain of IGFBP-2.
As discussed earlier, IGFBP-5 normally appears as a doublet when expressed from insect 
cells, whereas IGFBP-2 is a single band. We have previously postulated that this may be the result 
of inefficient cleavage of the signal peptide from IGFBP-5. However, this does not explain our 
results for BP522, which appears as a single band in our Westerns, whereas BP552 still appears as a 
doublet (Figures IV.5B and IV.7). This strongly suggests that the double band is due to some effect 
of the central domain of IGFBP-5. Others have previously reported that IGFBP-5 undergoes post- 
translational modifcations (O-linked glycosylation and phosphorylation) specifically in the central 
domain (Conover & Kiefer 1993, Coverley & Baxter 1997). Therefore, one obvious explanation for 
the IGFBP-5 doublet is altered post-translational modification of the recombinant protein by the 
insect cells. Post-translational effects in the central domain could also explain why BP552 migrates 
at a slightly higher molecular weight than WTIGFBP-2 and BP522 (Figures IV.5B and IV.7), even 
though these three proteins have almost exactly the same number of amino acids in their sequence 
(BP552, WTIGFBP-2 and BP522 contain 269, 270 and 268 amino acids respectively, whereas 
WTIGFBP-5 has only 252). Finally, we also observe a greater number of proteolytic fragments 
from WTIGFBP-5 compared to BP552 using the anti-rat IGFBP-5 antiserum (Figure IV.7A). This
is initially surprising, as most of the proteolytic sites in IGFBP-5 are believed to be within the 
central domain (discussed in more detail in chapter V). However, the apparent greater number of 
fragments from the WTIGFBP-5 protein could also be explained by the antiserum detecting 
fragments containing sequences from the C-terminal domain of IGFBP-5.
Our solution phase IGF binding analyses for WTIGFBP-5 and -2 did not strictly agree 
with the results of Keifer et al,. (1992), in which they observed several fold higher affinities for 
IGFBP-5 binding to both IGF-I and -II, compared to IGFBP-2. In our work, we found that 
WTIGFBP-5 and -2 had very similar affinities irrespective of ligand, with both binding proteins 
having an approximately 2-fold higher affinity for IGF-II (Figure IV.8). These differences could 
possibly be explained by the fact that Kiefer et al., (1992) studied the interaction of human IGFBPs, 
either produced recombinantly or derived from human biological sources, with human IGFs, 
whereas we employed a heterologous system with rat IGFBPs and human IGFs. Furthermore, 
although our BiaCore study demonstrated KD values for WTIGFBP-5 and -2 of the same order of 
magnitude, IGFBP-2 appeared to show a higher affinity for IGF-I (5-fold) than IGF-II, whereas 
IGFBP-5 maintained a 10-fold greater affinity for IGF-II than IGF-I. Although the general 
consensus in the literature is that both IGFBP-5 and -2 exhibit a higher affinity for IGF-II than IGF- 
I, it is important to remember that almost all affinity studies reported to date have employed 
solution phase binding analyses. The BiaCore system is becoming increasingly recognised as 
providing more detailed information on molecular interactions, and it may be that our real time 
kinetics data for IGFBP-2 binding to IGFs reflects a more accurate picture of the ligand preference 
of this binding protein.
More important in the context of this study are the binding affinities for the chimeric 
proteins. First, BP225 had to be excluded from this analysis, as it would appear that the insect cells 
were unable to properly express this protein. As discussed above, this could be the result of 
improper folding of the recombinant protein, which, in turn, makes BP225 susceptible to 
proteolysis. On the other hand, although we were able to detect expression of BP255 by western 
immunoblot (Figure IV.5B), we were unable to detect any binding of this chimera to IGF-I by 
either solution phase assay (Figure IV.6), or ligand blotting (Figure IV.5A), and only very weak 
interaction with IGF-II. It is very difficult to draw any firm conclusions about the IGF binding
properties of BP255. One obvious, and potentially very interesting, conclusion would be that the N- 
terminal domain of IGFBP-2 is simply unable to co-operate with the C-terminal domain of IGFBP- 
5 in order to bind IGFs with high affinity. However, as with BP225, we cannot rule out the 
possibility that BP255 is incorrectly folded, (although it would not appear to be proteolysed as it 
retains immunogenicity for the anti-rat IGFBP-5 antiserum). The reasons why BP225 and BP255 
may be more susceptible to folding problems than BP552 and BP522 remain unclear. The N- and 
central domains of IGFBP-5 and -2 are very similar in size, although the C-terminal domain of 
IGFBP-2 is significantly larger. Moreover, others have identified the disulphide bonding pattern in 
the N-terminal domain of IGFBP-5 (Kalus et al, 1998; Neuman et al, 1999) and the C-terminal 
domain of IGFBP-2 (Forbes et al, 1998), and consequently have established that there are no inter­
domain disulphide bonds in either of these two binding proteins. Therefore, the IGFBP model of 
two highly structured terminal domains being held apart by a flexible central domain should also 
hold true for both IGFBP-5 and -2. Further elucidation of the IGF binding properties of BP255 
would require careful structural analysis, such as nuclear magnetic resonance (NMR) and/or 
circular dichroism (CD) spectroscopy.
The two remaining chimeric proteins, BP552 and BP522, have comparable affinities with 
the native IGFBP molecules from which they were derived for binding IGF-I and IGF-II, as 
measured by our solution phase and biosensor experiments. We conclude from this finding that 
these hybrid proteins do not have major structural alterations induced in their N- and C-terminal 
domains, as this would have been expected to cause a marked decrease in their affinity for ligands. 
Although the affinity constants of WTIGFBP-5, WTIGFBP-2, BP552 and BP522 were all similar in 
solution phase assay (Figure IV.8), the BiaCore analysis highlighted the differences in binding 
affinities. For IGF-I binding, KD values for the chimeric proteins fall within a range between the 
wild type proteins: WTIGFBP-2 > BP552 > BP522 > WTIGFBP-5, whereas for IGF-II the order 
was WTIGFBP-5 > BP552 > WTIGFBP-2 > BP522 (Table IV. 1). This demonstrates that the N- 
terminal domain of IGFBP-5 is able to co-operate with the C-terminal domain of IGFBP-2 to obtain 
high affinity IGF binding, irrespective of the central domain that is present.
Although the main objective of this study was to identify the particular contribution of the 
N- and C-terminal domains in binding IGFs, it is very difficult to say from the data above whether a
specific domain has a specific ligand binding preference. This is largely because we lack data for 
IGF binding to two of our chimeras (BP255 and BP225), but also that the affinities of the 
WTIGFBP proteins in our studies were markedly different from that previously reported in the 
literature. Based on previous proteolytic analysis o f IGFBP-5, where it was found that a 23kD N- 
terminal fragment is able to bind weakly to IGF-II (Imai et al, 1997; Standker et al, 1998), while a 
13.5kD C-terminal fragment binds IGF-I (Standker et al, 1998) it could simply be concluded that 
the sequences responsible for IGF-II and -I preference are contained within the N- and C-terminal 
domains respectively. Our data from the chimeric protein study can neither confirm or refute this 
hypothesis. In summary, we have made chimeric proteins containing domains from rat IGFBP-5 
and -2 and have shown that the N-terminal domain of IGFBP-5 can co-operate with the C-terminal 
domain of IGFBP-2 to obtain high affinity IGF binding, irrespective of which central domain is 
present, whereas preliminary evidence suggests that the N-terminal domain of IGFBP-2 cannot co­
operate with the C-terminal domain of IGFBP-5 for high affinity IGF binding.
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Chapter V. A cryptic heparin-binding site in the central domain of 
IGFBP-5
V.I. Introduction
As discussed in chapter 1.3.4, IGFBP-5 has three putative consensus heparin binding 
motifs, one in the basic region within the C-terminal domain, YKRKQCKP (205-212), and two 
overlapping in its central domain, VKKDRRKKL (132-140) (Hodgkinson et al. 1997). The central 
domain heparin binding motifs have previously been ruled out by others as functional heparin 
binding sites based on studies with the full-length IGFBP-5 protein. This included both competitive 
binding studies with synthetic peptides from these regions (Arai et al. 1994b) and amino acid 
substitutions at these putative heparin binding motifs (Arai et al. 1996a), neither which resulted in a 
change in IGFBP-5 heparin binding properties.
Domain switching to create chimeric IGFBP proteins has previously been adopted by other 
groups in order to ascertain which domains of IGFBP-3 and IGFBP-5 are involved in binding to a 
liver derived glycoprotein known as the acid-labile subunit (ALS) (Hashimoto et al. 1997, Twigg et 
al. 1998). Using this approach, it was demonstrated that the homologous stretch of basic amino 
acids in the C-terminal domains of IGFBP-3 (214-232) and IGFBP-5 (201-218) is necessary for 
ternary complex formation with ALS and IGFs. In addition, it was shown that at high 
concentrations, the GAGs heparin and heparan sulfate inhibited ALS binding to IGFBP-5 when it 
was bound to IGF, suggesting overlap of heparin and ALS binding sites in the C-terminal domain 
(Twigg et al. 1998). Further analysis of IGFBP-5/IGFBP-6 chimeric proteins with N-terminal and 
central domain swaps, and a C-terminally truncated mutant, IGFBP-51'169, has revealed the 
existence of a site in the central domain of IGFBP-5 that binds to ALS in the absence of the IGFBP- 
5 C-terminal domain (Twigg et al. 2000). Analogous to the overlap of heparin and ALS binding 
sites in the C-terminal basic region, these authors speculated that the ALS may bind somewhere 
within the two overlapping heparin binding sites at 132-140 in the central domain.
In order to assess the contribution of the C-terminal and central heparin binding sites to the 
function of IGFBP-5, we have employed two of our chimeric IGFBP proteins, BP552 and BP522,
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made by switching domains between rat IGFBP-5 and rat IGFBP-2 (discussed in detail in chapter 
IV; Figure IV. 1). Using biosensor real time analysis of binding kinetics, IGF binding properties 
were previously determined for WTIGFBP-5 and -2, BP552, BP522, the C-terminaly truncated 
BP550 and Hep- (chapter III and IV). In this chapter, Heparin ligand blotting was also used to 
investigate the heparin binding properties of the above proteins and three further IGFBP-5 mutants, 
Hep-2, Hep-3 and BP550Hep-, in which the mutations R136A:R137A were made in the central 
consensus heparin binding site of WTIGFBP-5, Hep- and BP550 respectively (Figure V.l). The 
implications of our findings for the function of IGFBP-5 with respect to proteolysis and interaction 
with heparin are discussed, and are published in Song et al, (2001).
V.2 Results
V.2.1 Construction of Hep-2, Hep-3, and BP550Hep-
To create Hep-2, Hep-3, and BP550Hep-, site-direct mutagenesis were performed on the 
wild type IGFBP-5, Hep-, and BP550 cDNAs respectively using the ‘Altered sites’ system 
(Promega) as explained in chapter II. The mutagenic oligonucleotide used for creating 
R136A:R137A also creates a restriction endonuclease cleavage site for Tsel. Figure V.2 shows the 
results of Tsel restriction digest of of WTIGFBP-5 and the various mutants. There are seven Tsel 
restriction sites within the IGFBP-5 cDNA sequence, and several more in the pFastBacl plasmid, 
which creates the complex restriction pattern shown in the WT track. However, succesful 
mutagenesis to create Hep-2, Hep-3 and BP550Hep-, inserts an extra Tsel site and this produces an 
extra 310bp restriction fragment (indicated with an arrow in Figure V.2). Based on this data, which 
initially identified our mutant cDNAs, we confirmed the prescence of the mutations by comercial 
automated sequencing (MWG biotec, Milton keynes, UK).
Hep-2, Hep-3, and BP550Hep- were expressed and purified as described in chapter II, and 
protein concentration was subsequently estimated by Bradford assay as described in chapter II.
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SM WT Hep-2 Hep-3 BP550Hep-
1353
1078
872
603
310
Fig V.2 1% agarose gel of wtIGFBP-5, Hep-2, Hep-3, and BP550Hep- 
cDNAs, inserted in pFastbacl plasmid, digested with Tsel. SM represents (J>x 
DNA size markers and the sizes are indicated. Arrow indicates newly created 
restriction fragment.
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V.2.2 Heparin-ligand blotting
Previously we have used heparin ligand blotting to study the heparin binding properties of 
Hep- and other IGFBP-5 mutants (Song et al. 2000). This clearly demonstrated that Hep- bound to 
heparin very poorly in comparison to WTIGFBP-5, and confirmed the identity o f some o f the 
important basic residues in the C-terminal domain that are required for heparin binding (Arai et al. 
1996a, Parker et al. 1998). Heparin ligand analysis was initially carried out on BP552, BP522, 
BP550 and Hep-, and the results are shown in Figure V.3. The great reduction in heparin binding 
displayed by Hep- again clearly demonstrates that full-length WTIGFBP-5 binds heparin 
predominantly through its C-terminal domain sequences. However, we found it intriguing that both 
BP552 and BP550 clearly bound to heparin with equivalent, or even greater, ability than 
WTIGFBP-5, whereas WTIGFBP-2 and BP522 failed to bind heparin. The absence of heparin 
binding with the BP522 chimera identifies that the central domain of IGFBP-5 as being involved in 
the heparin binding activity of BP552 and BP550. This experiment was repeated four times with 
similar results in each instance.
Based on these findings, we wanted to establish whether this central domain heparin 
binding activity is accounted for by the consensus GAG-binding sites between residues 132-140. 
Therefore, we mutated R136A:R137A in WTIGFBP-5, Hep- and BP550 to make the mutants Hep- 
2, Hep-3 and BP550Hep- respectively (Figure V.l). The effects of these mutations on heparin 
binding are shown in Figure V.4. It is clear that the R136A:R137A mutations have no appreciable 
effect in the full-length proteins, as Hep-2 and Hep-3 resemble WTIGFBP-5 and Hep- respectively 
with regard to heparin binding. However, BP550Hep- fails to bind heparin, which clearly 
demonstrates that R136 and R137 are essential for BP550 heparin binding. This experiment was 
repeated three times with similar results in each instance.
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V.3 Discussion
Our heparin ligand blots clearly demonstrate a major loss o f heparin binding for the Hep- 
mutant, which has four of the important C-terminal basic amino acids required for heparin binding 
mutated (Song et al. 2000). It is very interesting, therefore, that the removal of this entire basic C- 
terminal region, as is the case with the chimeric molecule BP552 or the truncated mutant BP550, 
should result in proteins with heparin binding affinities comparable to WTIGFBP-5. The heparin 
binding activity displayed by BP552 and BP550 must be contained within the central domain of 
IGFBP-5, as BP522 was unable to bind heparin. Furthermore, the work presented here suggests that 
heparin is prevented from interacting with these sites by the presence of the C-terminal domain of 
IGFBP-5.
The fact that our chimeric IGFBPs demonstrate similar affinities for binding IGFs 
(Chapter IV) would suggest that the N-terminal domain of IGFBP-5 is juxtaposed with the C- 
terminal domain of IGFBP-2 in these molecules in such a way as to simulate the spatial relationship 
between the N- and C-terminal domains of native IGFBP-5. However, the C-terminal domain of 
IGFBP-2 is unable to inhibit heparin binding to the central domain of IGFBP-5 in the BP552 
chimera. One obvious difference between the C-terminal domains of IGFBP-5 and -2 is the heparin 
binding site between 201-218 in IGFBP-5. This initially raises the interesting possibility that 
heparin binding to the C-terminal site in IGFBP-5 may itself inhibit subsequent heparin binding to 
the central site. In support of this, others have shown that heparin binding to the C-terminal domain 
of IGFBP-5 does in fact reduce the activity of an IGFBP-5 specific serine protease, which cleaves 
within the central GAG-binding consensus sites (Imai et al. 1997, Nam et al. 1994). However, we 
have shown with our Hep- mutant that prevention of heparin binding to the 201-218 region of 
IGFBP-5 does not facilitate heparin binding to the central domain.
In order to establish the important central domain sequences required for heparin binding, 
we set out to simultaneously disrupt both consensus GAG-binding sites (VKKDRRKKL at residue 
number 132-140) proposed by Hodgkinson et al, 1994, by mutating both arginines in the 
overlapping sequence to alanines (R136A:R137A). These mutations were carried out in WTIGFBP- 
5, Hep- and BP550 to create the mutants Hep-2, Hep-3 and BP550Hep- respectively (Figure V.l).
As expected, the ability of Hep-2 to bind heparin is comparable to WTIGFBP-5, since the heparin 
binding site in the C-terminal domain is still intactive. Conversely, Hep-3 binding to heparin 
resembles that of Hep- as the C-terminal site is mutated in both proteins. Overall, these results 
confirm that mutagenesis of the central domain heparin binding site has no appreciable effect in the 
presence of the C-terminal domain, which contains the major heparin binding site in the full-length 
protein. This would also explain why the previously reported K134A/R136A mutant of IGFBP-5 
performed as well as the native protein with respect to heparin binding (Arai et al. 1996a), since the 
effect of these mutations would again be masked by the C-terminus.
The failure of BP550Hep- to bind heparin confirms that R136 and R137 are essential for 
heparin binding in the absence of the C-terminal domain, and pinpoints this activity to the central 
consensus GAG-binding region. It seems likely that heparin binding to this region of IGFBP-5 will 
involve several, if not all of the six basic amino acids between 132-140, although the 
R136A:R137A mutations do not rule out the possibility that only one of the consensus sites is 
active. Future work will establish the individual contribution of the basic amino acids in this region 
to heparin binding, in a similar fashion to the detailed mutagenesis studies performed by others on 
the ten basic residues between 201-218 in the C-terminus (Arai et al. 1996a; Parker et al. 1998). 
Also, by analogy with the 201-218 region of IGFBP-5, which binds both heparin and the ALS 
(Twigg et al. 1998), it is conceivable that the central heparin-binding site identified in this paper 
will also account for the central ALS binding activity of IGFBP-5 described by Twigg et al, 2000.
The existence of a central heparin binding site, which only becomes functionally active 
after the removal of the C-terminal domain, is of major significance when considering the possible 
functions of IGFBP-5 in vivo. It is particularly relevant to the proteolytic cleavage of IGFBP-5, 
which has been the subject of many studies. Human fibroblasts and porcine smooth muscle cells 
have been shown to secrete a calcium-dependent serine protease that is specific for cleaving 
IGFBP-5 (Imai et al. 1997, Nam et al. 1994). Peptide sequencing of the proteolytic fragments 
suggested K138-K139 as the primary cleavage site (Figure V.5) and this was confirmed by the 
creation of a protease resistant mutant of IGFBP-5 by mutating these two residues (Imai et al. 
1997). Cleavage at this site could potentially produce an N-terminal fragment, which retains GAG- 
binding sites in the central domain, including R136 and R137. In addition, physiological
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concentrations of thrombin have been shown to cleave IGFBP-5 at three sites (Figure V.5), two of 
which are C-terminal to the central GAG-binding site (Zheng et al. 1998b), and metalloproteinases 
have been shown to degrade both IGFBP-5 and -3 (Thraikill et al. 1995a). This raises the 
interesting possibility that the central heparin binding site in IGFBP-5 is activated in vivo after 
removal of the C-terminal domain by proteolytic cleavage. This could produce a truncated IGFBP-5 
molecule that is able to bind GAGs in the ECM or on the cell surface, and which may have 
differential functions to the full-length protein. In support of this, it has been shown previously by 
others that a 23 kDa fragment of IGFBP-5, which has an identical N-terminus to the native protein, 
is able to stimulate osteoblast mitogenesis in the absence of IGFs (Andress & Bimbaum 1992). The 
ability of this fragment to bind heparin was not ascertained, but it could account for the 23 kDa 
fragment observed by Hodgkinson et al, (1994), when they eluted IGFBP complexes from a heparin 
affinity column.
In conclusion, we have demonstrated for the first time that there is a functional heparin 
binding site in the central domain of IGFBP-5 (Song et al, 2001). This site involves the amino acids 
R136 and R137, which lie within the consensus GAG-binding sites, and is active only in the 
absence of the C-terminal domain. Further understanding in this area will require the careful 
structural analysis of heparin-IGFBP-5 complexes combined with biological studies aimed at 
elucidating the function of IGFBP-5 proteolytic fragments.
Chapter VI. General discussion and Future study
The work undertaken in this study has provided many details relating to the molecular 
based interactions of IGFBP-5 with IGFs and/or ECM components (heparin). In this chapter, it is 
not our intention to repeat the discussion of the experimental results obtained in the thesis. Rather it 
is intended to discuss the possibility of using our mutant proteins to explore the role of IGFBP-5 in 
a biological context, particularly related to the pro-apoptotic model and IGF-independent biological 
actions of IGFBP-5 that were described in chapter I.
IGFBP-5 mutants
From this study, we have generated several extremely important mutants of IGFBP-5, 
which could now be used to test the function of this binding protein. This will first require the 
identification of a suitable cell culture assay, whereby the addition of IGFBP-5, either by 
transfection or adding recombinant protein to the culture medium, results in a measurable biological 
effect. When an appropriate assay is identified, it would then be possible to ask the question of 
whether IGF and/or ECM binding was essential for any IGFBP-5 effects by including our Double 
and Hep- mutants, which are non-IGF and non-ECM binders respectively. This is particularly 
relevant for the pro-apoptotic model for IGFBP-5 action discussed earlier, which is based upon the 
binding protein making contact with both ligand and ECM components simultaneously. 
Furthermore, proteolytic cleavage of IGFBP-5 into fragments with reduced affinity for IGFs is 
believed to be an additional mechanism to stimulate the activity of IGFs in biological fluids. Using 
the BP550 mutant, it should be possible to address the question of whether a truncated IGFBP-5, 
which may be representative of certain proteolytic fragments in vivo, has differential effects to the 
full-length protein. By inference, any such effects would have to be IGF-independent, and including 
BP550Hep- would also address the importance of ECM binding.
It is very difficult to imagine how any effects of our three chimeric mutants, BP552, 
BP522 and BP255, could easily be interpreted in a biological assay at this stage. This is because the 
loss of any IGFBP-5 sequences and /or functions in the chimeras may potentially be compensated 
for, or completely confused by, any gain of IGFBP-2 function. For example, the RGD sequence in 
the C-terminal domain of IGFBP-2 may enable BP552 and BP522 to bind cell surface integrin
receptors, thereby activating cellular responses that are completely different to those normally 
ascribed to IGFBP-5. Further studies of the ligand binding characteristics of these mutants may 
subsequently allow meaningful biological assessments of their activities.
There are several reports of in vitro biological systems used to identify the role of IGFBP- 
5, including assays in osteoblasts (Gabbitas and Canalis, 1998; Kanatani et al, 2000), chondrocytes 
(Sunic et al, 1998; Matsumoto et al, 2000), and fibroblasts (Parker et al, 1996; Nam et al, 1997; 
Zheng et al, 1998). As a start, we decided to test some of our IGFBP-5 mutants in culture systems 
that were being used by collaborators both within our institute and in other research organisations, 
and these are described below. Some progress was made towards these experiments within the 
period of this PhD project, although our biological experiments remain part of an ongoing study. 
These experiments are now discussed below.
Differentiation of C2 myoblasts
It has been shown previously by others that IGFBP-5 is the only IGFBP expressed by C2 
myoblasts (James et al., 1993), which makes these cells an attractive model for studying IGFBP-5 
function without potential interference from other IGFBPs. Furthermore, it was shown that the 
binding protein was secreted within 12h of the onset of terminal differentiation, suggesting a role 
for IGFBP-5 in this process (James et al, 1993). In support of this, it was subsequently shown that 
over expressing IGFBP-5 in these cells stimulates cell proliferation, thereby inhibiting cell 
differentiation, and it was shown that this effect was dependent upon the presence of IGFs (James et 
al, 1996). These authors postulated that IGFBP-5 in the ECM may function as a source of sustained 
low level growth factor release (James et al, 1996). This myoblast differentiation assay is being 
used successfully in the laboratory of Dr Claire Stewart at the University of Bristol, who has 
supplied us with untransfected C2 cells. We have clonally selected G418 resistant lines transfected 
with WTIGFBP-5, Double and Hep- constructs and sent these lines for analysis in Bristol. We 
would predict that the over expression of the Double mutant in these cells would have no effect on 
cell differentiation as the mutant is unable to bind IGFs. However, it is of interest to us to examine 
how the Hep- mutant will behave, as this will indicate whether IGFBP-5 must bind to the ECM in 
order to carry out its effects on differentiation. Our lines have indeed been shown to over express
the wild-type and mutant IGFBP-5 proteins, and preliminary data suggests that the Hep- mutant 
performs as well as WTIGFBP-5 in this assay, indicating that ECM binding may not be important 
(pers comm M. Grohmann).
Mammosphere tissue culture system
Work from other laboratories has shown that the culture of primary mammary epithelial 
cells on Engelbreth-Holm-Swarm (EHS) matrix, results in the formation of three-dimensional 
multi-cellular structures termed mammospheres, which contain a central luminal space into which 
milk proteins are secreted (Li et al, 1987; Barcellos-Hoff et al, 1989; Wilde et al, 1995; Roskelley 
et al, 1994). Formation of the luminal space in the mammospheres has been shown to involve 
programmed cell death of mammary epithelial cells, and consequently, it has been proposed that the 
mammosphere may provide a useful model for the apoptosis of mammary epithelial cells that 
occurs during involution of the mammmary gland (Blatchford et al, 1995 and 1999; Hurley et al, 
1994; Barcellos-Hoff et al, 1989; Streuli et al, 1991). Interestingly, from our point of view, it has 
also been observed that there is high levels of IGFBP-5 expression in the culture media during 
mammosphere formation (Blatchford et al, 1999), and preliminary immunocytochemistry 
experiments have shown the presence of IGFBP-5 protein in the luminal space, (pers. comm. D 
Flint), suggestive of a role for the binding protein in development of this structure. Therefore, we 
initially considered mammosphere culture as a potentially useful in vitro system in which to test the 
pro-apoptotic model for IGFBP-5 action.
A serious problem with this strategy is the reported very low transfection efficiencies (less 
than 0.3%) of both mouse and goat primary mammary epithelial using standard lipofectin based 
techniques (Wells., 2000). Therefore, as a prerequisite to expressing WTIGFBP-5 and various 
mutants in these cells prior to mammosphere differentiation, we had to devise an alternative 
strategy of delivering promoter-gene constructs into this system. We decided to use the baculovirus 
protein expression system, which is being used increasingly to express proteins in mammalian cells. 
Although the receptor for baculovirus on mammalian cells is not known, it is likely to be a 
glycosaminoglycan or other ubiquitous cellular component, given the wide range of cell types 
susceptible to infection. We have constructed a hybrid mammalian-baculovirus expression vector 
(Figure VI. 1; described in detail in chapter II), and have used this to generate a reporter virus,
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Fig VI. 1 pBacMaml. A baculovirus mammalian expression vector, which 
contains a multiple cloning site (MCS) down stream of the CMV-IE promoter. 
This cassette also contains the gene for G418 (Neo) and gentamycin (Gent) 
resistence and is flanked by transposable elements (Tn7L and Tn7R) which 
allow transposition into Bacmid DNA (see chapter II).
which expresses green fluorescence protein (GFP) from the cytomegalovirus (CMV) immediate 
early promoter (a powerful promoter in mammalian cells). The results of infection of both primary 
goat mammary epithelial cells and C2 myoblasts in culture with this virus at different multiplicities 
o f infection and time post infection are shown in Figure VI.2 and Figure VI.3 respectively, with 
GFP expression evident in both lines. From this we estimate an infection efficiency of the primary 
goat mammary epithelial cells as approximately 20%, which is much higher than that produced 
from traditional transfection techniques.
Based on this, we went ahead and produced BacMam virus with the potential to express 
WTIGFBP-5, Double and Hep- from the CMV promoter. However, the effects of infection of 
primary goat mammary epithelial cells with these viruses is the subject of future work. If 
endogenous IGFBP-5 is involved in the apoptosis of mammary epithelial cells that takes place 
during mammosphere lumen formation, we can hypothesise the possible effects of over- expression 
o f WTIGFBP-5, Double and Hep- in this system, based on the pro-apoptotic model, discussed 
before. Briefly, expression of exogenous WTIGFBP-5 may simply amplify the effects of the 
endogenous protein (Figure VI.4.A), although it is conceivable that this could affect the timing of 
lumen formation. However, we postulate that the expression of either Double or Hep- could 
possibly compete with the action of endogenous IGFBP-5 in this system, and consequently delay or 
inhibit lumen formation. Here the Double mutant protein could fill up available sites in the ECM, 
while unbound to IGFs, (Figure VI.4.B), while the Hep- mutant could still bind IGFs, but could not 
then sequester them to the ECM (Figure VI.4.C). Either way, IGFs may then become available for 
interaction with the type 1 receptor following proteolysis of the unprotected binding protein, and 
this, in turn, would interfere with the onset of apoptosis. These hypotheses require experimental 
validation, but are clearly testable.
Transeenics
Depending upon the effects of our IGFBP-5 mutants in appropriate in vitro systems, we 
would propose to test our IGFBP-5 mutants in vivo using transgenic mice. In collaboration with Dr 
Bruce Whitelaw at the Roslin Institute, our laboratory has already generated transgenic mice 
expressing wild type rat IGFBP-5 from the beta lactoglobulin (BLG) promoter, so that the 
transgene is specifically expressed in the mammary gland. It has been verified that transgenic mice
156
Negative field Fluorescence field
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M O I20 0
B.
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MOI 200
Fig VI.2 Transfection of primary goat mammary epithelial cells with 
pBacMaml GFP reporter baculovirus. Cells were observed under normal light 
(Negative) and fluorescence. (A.) shows a multiplicity of infection (MOI) of 200, 
4hr post infection. (B.) shows a MOI of 200, 18hr post infection.
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Fig VI.3 Transfection of C2 myoblasts with pBacMaml GFP reporter 
baculovirus. Cells were observed under normal light (Negative) and fluorescence. 
(A.) shows a multiplicity of infection (MOI) of 100, 12hr post infection. (B.) 
shows a MOI of 200, 18hr post infection.
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have high levels of IGFBP-5 expression in the mammary gland during lactation, whereas the 
binding protein is only expressed at the onset of involution in the wild type controls (pers. comm.
D. Flint). Based on the pro-apoptotic model it has been postulated that this aberrant expression of 
IGFBP-5 may result in premature involution of the gland. In support of this, we have found that the 
transgenic mice have impaired mammary gland development and produce less milk. Applying our 
model for a competitive effect of either the Double or Hep- mutant on endogenous IGFBP-5 action 
(Figure VIA), it is conceivable that expression of these mutants in transgenics in an analogous 
fashion to that described above for WTIGFBP-5, could have the opposite effect and result in 
extended lactation of the mammary gland.
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